Antibodies to stabilize TREM2
By specifically binding to TREM2 antibodies or antigen-binding fragments, TREM2 protein is stabilized, its shedding problem is solved, the signaling function of nerve cells is enhanced, and the treatment and prevention solutions for a variety of neurodegenerative diseases are provided.
Patent Information
- Application Number
- CN202411023066.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-27
- Filing Date
- 2019-10-15
- Publication Date
- 2024-11-08
AI Technical Summary
Existing antibodies are unable to effectively stabilize TREM2 protein, causing it to fall off on the cell surface, affecting the signaling function of nerve cells, and are thus related to a variety of neurodegenerative diseases.
An antibody or antigen-binding fragment of human TREM2 was developed to target the IgSF domain of TREM2, which can reduce or inhibit the ectodomain shedding of TREM2, stabilize the TREM2 protein on the cell surface, and promote its functional signaling.
By stabilizing TREM2 protein and enhancing its phagocytic and signaling function in macrophages and microglia, it provides potential methods for the treatment and prevention of neuroinflammatory and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease .
Smart Images

Figure CN118909116A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 201980067668.9 (International Application No. PCT / IB2019 / 058769), whose application date is October 15, 2019 and whose invention name is “Antibodies that Stabilize TREM2”.
[0002] Sequence Listing
[0003] This application contains a sequence listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy was created on September 16, 2019, named PAT058251_ST25, and is 147,551 bytes in size. Technical Field
[0004] The present invention provides antibodies that bind to and stabilize the human triggering receptor on myeloid cells 2 (TREM2) protein and methods of using these antibodies. Background Art
[0005] Triggering receptors on myeloid cells or "TREMs" are a group of transmembrane glycoproteins expressed on different types of bone marrow cells, such as macrophages, dendritic cells, osteoclasts, microglia, mast cells, monocytes, lung epithelial cells, skin Langerhans cells, Kupffer cells and neutrophils (Takaki, R. et al., Immunol. Rev. [Immunology Review], 2006, 214: 118-29). TREMs have an immunoglobulin (Ig) type fold in their extracellular domains and therefore belong to the immunoglobulin superfamily (IgSF). TREM receptors contain short intracellular domains, but lack docking motifs for signal transduction mediators and require adapter proteins such as DAP12 (DNAX activation protein of 12 kDa) for cell activation. Two TREM members have been reported: TREM1 and TREM2, both of which play important roles in immune and inflammatory responses. The gene encoding human TREM is located on chromosome 6p21.1, which carries a gene cluster encoding TREM1, TREM2, TREM3, TREM4 and TREM5, as well as TREM-like genes.
[0006] TREM2 is a glycoprotein of about 40kDa, which is reduced to 26kDa after N-deglycosylation. The entire TREM2 protein consists of a leading signal peptide (amino acid 1-18), a single V-type IgSF extracellular region (amino acid 19-132), a stem region (amino acid 133-172), a positively charged transmembrane domain (amino acid 173-197) and a cytoplasmic tail (amino acid 198-230) (Kober et al., Elife 5 (2016); Kober et al., J.Mol.Biol. [Journal of Molecular Biology] 429 (2017) 1607-1629.). The extracellular region encoded by exon 2 consists of a single type of V IgSF domain (which contains three potential N-glycosylation sites). The putative transmembrane region contains charged lysine residues. The cytoplasmic tail of TREM2 lacks a signal motif and is believed to signal through the signal transduction adapter molecule DAP12 / TRYROBP.
[0007] TREM2 physically associates with DAP12, which acts as a signaling adaptor protein for TREM2 and many other cell surface receptors. The cytoplasmic domain of DAP12 contains an immunoreceptor tyrosine activation motif (ITAM) (Wunderlich, J. Biol. Chem. 288, 33027–33036, 2013). Upon activation of the interacting receptor, DAP12 undergoes phosphorylation on the conserved ITAM tyrosine residues by Src kinase. The subsequent recruitment and activation of Syk protein kinase triggers downstream signaling pathways, including activation of mitogen-activated protein kinase (MAPK), PI3K, NFκB, and phospholipase Cγ (PLCγ).
[0008] TREM2 can be activated by: lipopolysaccharide (LPS), heat shock protein 60, neural debris, bacteria, apolipoprotein E and various anionic and zwitterionic lipids, such as phosphatidic acid (PA), phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylcholine (PC), cardiolipin and sphingomyelin. TREM2 activation increases the phagocytic capacity of microglia and macrophages, reduces the release of proinflammatory cytokines and limits TLR signaling. TREM2 maintains microglial survival by synergizing with CSF-1 receptor signaling. In addition, TREM2 interacts with the protein-A1 that regulates cell adhesion and motility. TREM2 is also enriched in those microglial surface areas that are in contact with Aβ plaques or neuronal debris (Yuan et al., Neuron 90 (2016) 724–739). Some ligands sensed by TREM2 in this setting have recently been identified, such as phospholipids and myelin (Poliani et al., J. Clin. Invest. [Journal of Clinical Research] 125 (2015): 2161-2170) and ApoE (Atagi et al., J. Biol. Chem. [Journal of Biological Chemistry] 290 (2015): 26043-26050; Bailey et al., J. Biol. Chem. [Journal of Biological Chemistry] 290 (2015): 26033-26042). Other ligands may be Aβ and plaque-associated neuronal debris, as TREM2 facilitates the uptake of Aβ into microglia (Xiang et al., EMBO Mol. Med. [Journal of European Molecular Biology Association] 8 (2016): 992-1004). TREM2 has also been shown to play a role in the clearance of apoptotic cells (Takahashi et al., J. Exp. Med. 201 (2005), 647-657), myelin debris (Poliani et al., J. Clin. Invest. [Journal of Clinical Research] 125 (2015): 2161-2170), and bacterial beads (Cen et al., Am. J. Respir. [American Journal of Respirology]. 188 (2013) 201-212). TREM2 signaling promotes the degradation of ingested captures and is critical for lipid metabolism, myelin uptake, and intracellular breakdown.
[0009] TREM2 undergoes sequential proteolytic processing by ectodomain shedding and intramembrane proteolysis (Wunderlich, J. Biol. Chem. 288, 33027–33036, 2013). During ectodomain shedding, the ectodomain of TREM2 is released by proteases such as members of the ADAM (proteins containing disintegrin and metalloproteinase domains) or BACE (β-site APP cleaving enzyme) family (Kleinberger, Sci. Transl. Med. 2014; 6(243): 243ra86).
[0010] After the ectodomain is removed, the remaining membrane-retained fragments are further processed by γ-secretase-mediated intramembrane proteolysis. Soluble fragments (sTREM2) of TREM2 produced by ectodomain shedding have been observed in the supernatant of dendritic cell cultures and in plasma and CSF (cerebrospinal fluid) samples from patients with non-inflammatory neurological diseases and multiple sclerosis (Kleinberger, 2014). The detached ectodomain of TREM2, i.e. sTREM2, in human CSF has been evaluated as a potential Alzheimer's disease (AD) biomarker and has been shown to increase in the general aging process (Suarez-Calvet, EMBO Mol. Med. [Journal of the European Molecular Biology Association, Molecular Medicine] 8, 466-476, 2016). Detailed analysis over the course of AD revealed that sTREM2 increases in early AD before clinical symptoms appear, peaks in MCI-AD, and remains elevated but at lower levels compared to the MCI-AD stage in AD dementia (Suarez-Calvet, 2016).
[0011] Increased TREM2 expression during the peak of disease drives resolution (e.g., peritonitis, wound healing) (Turnbull, 2006; Gawish, 2015). Under chronic inflammatory conditions such as neuroinflammation, TREM2 is continuously shed and unable to perform its signaling function in microglia and macrophages. Therefore, stabilizing and / or preventing TREM2 shedding on the cell surface will restore functional, signaling-capable TREM2 expression in microglia and macrophages.
[0012] Human genetic studies have shown that the absence of surface TREM2, rather than the lack of sTREM2, leads to disease risk. For example, a mutation of the amino acid at position 47 in the TREM2 protein from R to H (e.g., in SEQ ID NO: 1) results in a slight decrease in cell surface expression (Kleinberger 2014) and reduces the ligand binding ability of TREM2 (Wang 2015, Atagi 2015, Bailey 2015). The amino acid mutation T66M in TREM2 results in a lack of expression of TREM2 on the cell surface (Kleinberger 2014), and therefore no soluble TREM2 is produced. Mutations in the cleavage site of TREM2: H157Y enhance the expression of sTREM2 and reduce full-length membrane-bound TREM2, and are associated with an increased risk of AD (Thornton 2017, Schlepckow 2017). Therefore, these genetic studies show that stabilizing TREM2 on the cell surface is desirable for both reducing sTREM2 and increasing plasma membrane-bound TREM2.
[0013] Haass et al. (WO 18015573) produced antibodies that bind to a 10-amino acid peptide spanning amino acids 152-161 of the TREM2 stem region (AHVEHSISRS SEQ ID NO: 132) and inhibit TREM2 cleavage. Such antibodies prevent TREM2 cleavage by directly binding and thereby blocking the cleavage site. Schwabe et al. (WO 17062672) disclose antibodies that bind to TREM2. However, none of the disclosed antibodies showed a stabilizing effect. In contrast, for some antibodies described in WO 17062672, destabilization was reported (Example 15).
[0014] Therefore, there is a need to identify and develop hTREM2 antibodies that are capable of stabilizing TREM2 and activating and / or promoting or TREM2-related functions that have good developability characteristics and are suitable for treating patients with neurodegenerative diseases in which TREM2 stabilization is beneficial. Summary of the invention
[0015] Published documents have produced antibodies for the stem region of TREM2, and these antibodies stabilize TREM2 because the cleavage site of ADAM17 is located in the stem region. In fact, it is expected that macromolecules such as antibodies (or their binding fragments) will spatially hinder the entry of the shedding enzyme into the relatively small area of the stem (amino acid 133-172). Therefore, the efforts to produce stabilization antibodies for TREM2 previously have been for the stem region of TREM2 and are not surprising. The IgSF region of TREM2 (SEQ ID NO: 1, amino acid 19-132 of any one of 2 or 3) is located away from the cleavage site (H157) and is part of the extracellular domain. So far, the IgSF region has not been considered as a potential target for antibodies that stabilize TREM2, because it is expected that antibodies for the IgSF region of TREM2 will not spatially hinder the entry of the shedding enzyme into the TREM2 cleavage site.
[0016] Surprisingly, we found that the antibodies disclosed herein bind to the IgSF region and are able to effectively stabilize TREM2 on the cell surface. We also show that such antibodies can exhibit functional downstream effects, such as promoting TREM2-dependent phagocytosis in human M2A macrophages. In addition, such antibodies can also enhance TREM2-dependent functions in vivo, such as by increasing the phagocytic capacity of microglia or macrophages in the brain.
[0017] Therefore, antibodies or antigen-binding fragments thereof, such as monoclonal antibodies or antigen-binding fragments thereof, are provided herein, which specifically bind to the IgSF domain of human TREM2 (hTREM2) and stabilize the hTREM2 protein. Such antibodies are referred to herein as "hTREM2 antibodies or antigen-binding fragments thereof". These hTREM2 antibodies or antigen-binding fragments thereof can (i) reduce or inhibit the shedding of the TREM2 extracellular domain; (ii) stabilize the TREM2 protein on the cell surface; and / or (iii) maintain or increase TREM2 function, such as binding to its cognate ligand, intracellular signaling, increasing phagocytosis, promoting the degradation of engulfed substances, and promoting TREM2-dependent downstream regulatory functions. Because dysfunctional TREM2 or lack of surface TREM2 is associated with human neuroinflammatory and neurodegenerative pathologies, the hTREM2 antibodies or antigen-binding fragments thereof described herein can be used to treat, prevent, or diagnose neuroinflammatory or neurodegenerative diseases, such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage diseases, such as Niemann-Pick C and mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, Neuro-Behcet's disease ( Disease), neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen's encephalitis, Rett syndrome, stroke, transverse myelitis, traumatic brain injury, spinal cord injury, viral encephalitis, or bacterial meningitis. The hTREM2 antibodies or antigen-binding fragments thereof described herein are also suitable for treating, preventing, or diagnosing autoimmune disorders, inflammatory disorders, or malignant disorders mediated by or associated with extensive proteolytic cleavage of TREM2 or cells expressing abnormal or mutant variants of the TREM2 receptor. In some preferred embodiments, the hTREM2 antibodies or antigen-binding fragments thereof described herein can be used to treat, prevent, or diagnose a disease selected from Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, or Nasu-Hakora disease. Also provided herein are methods for diagnosing and / or treating TREM2-related diseases using the TREM2 binding antibodies or antigen-binding fragments disclosed herein.
[0018] In one aspect, provided herein is an antibody or an antigen binding fragment thereof, which specifically binds to the IgSF domain of a TREM2 protein and stabilizes the TREM2 protein. In some preferred embodiments, these antibodies or antigen binding fragments thereof stabilize TREM2 proteins on the cell surface of cells expressing TREM2 (e.g., macrophages, dendritic cells, osteoclasts, microglia, mast cells, monocytes, lung epithelial cells, Langerhans cells of the skin, Kupffer cells, neutrophils, or hepatoma cells). In some embodiments, these antibodies or antigen binding fragments thereof reduce the proteolytic shedding of the extracellular domain of the TREM2 protein.
[0019] In some embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to the IgSF domain of human TREM2. For example, such antibodies or antigen-binding fragments thereof bind to the IgSF domain of human TREM2, the IgSF domain comprising amino acid residues 19 to 132 of SEQ ID NO: 1, amino acid residues 19 to 132 of SEQ ID NO: 2, or amino acid residues 19 to 132 of SEQ ID NO: 3. In some embodiments, the TREM2 antibody is a human antibody or a humanized antibody. In some embodiments, the antigen-binding fragment is a Fab, F(ab') 2 , Fv fragment, scFv, minibody or diabody.
[0020] In some embodiments, the TREM2 antibody is a bispecific antibody. In some embodiments, the bispecific antibody specifically binds to human TREM2 and DAP12.
[0021] In some embodiments, the TREM2 antibody comprises an Fc region. In some embodiments, the Fc region is a modified IgG1 Fc region having one or more mutations compared to the parent antibody and having reduced antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. In some embodiments, the Fc region is selected from an IgG2 Fc region, an IgG4 Fc region, or an IgG2 / IgG4 hybrid Fc region.
[0022] In some embodiments, the hTREM2 antibody or antigen-binding fragment thereof is monoclonal. Provided herein are nucleic acids encoding such monoclonal antibodies or antigen-binding fragments thereof, as well as vectors and host cells comprising nucleic acids encoding such monoclonal antibodies or antigen-binding fragments thereof.
[0023] In another aspect, provided herein is a pharmaceutical composition comprising one or more TREM2 antibodies or antigen-binding fragments thereof described herein, or nucleic acids encoding such antibodies or antigen-binding fragments, or cells comprising such nucleic acids, and a pharmaceutically acceptable carrier.
[0024] On the other hand, provided herein is a method for treating a disease associated with loss of TREM2 function in a subject in need thereof by administering to the subject a therapeutically effective amount of any TREM2 antibody or antigen-binding fragment thereof described herein. These methods may include one or more of the following steps: (1) determining the level of cell surface TREM2 in a sample obtained from the subject; (2) selecting a subject whose cell surface TREM2 level is lower than a reference level, wherein the reference level is the level of cell surface TREM2 in a sample obtained from a healthy subject; and (3) administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to the IgSF domain of the TREM2 protein and stabilizes the TREM2 protein. In some embodiments, these methods further include administering a second agent to the subject. The level of cell surface TREM2 in the sample can be determined by an assay selected from the following: flow cytometry, immunohistochemistry, western blot, immunofluorescence assay, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), homogeneous time-resolved fluorescence (HTRF), or positron emission tomography (PET). In some embodiments, the sample comprises cerebrospinal fluid and its cellular components. In some embodiments, the disease associated with loss of TREM2 function is a neuroinflammatory or neurodegenerative disease, such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakora disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage diseases, such as Niemann-Pick disease (Niemann-Pick C) and mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, neurobehcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen's encephalitis (Rasmussen's In some preferred embodiments, the disease associated with loss of TREM2 function is a neurodegenerative disease selected from Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, or Nasu-Hakkara disease. In further preferred embodiments, the disease is Alzheimer's disease. In some embodiments, the TREM2 antibody or antigen-binding fragment thereof stabilizes the TREM2 protein on the cell surface of a cell expressing TREM2 selected from a macrophage, a dendritic cell, an osteoclast, a microglia, a mast cell, a monocyte, a lung epithelial cell, a skin Langerhans cell, a Kupffer cell, a neutrophil, or a hepatoma cell.In some embodiments, the TREM2 antibody or antigen-binding fragment thereof is administered to a subject by an oral, intravenous, intracranial, intrathecal, subcutaneous, or intranasal route.
[0025] On the other hand, provided herein are TREM2 antibodies or antigen-binding fragments thereof for treating diseases associated with loss of TREM2 function. In some preferred embodiments, these antibodies or antigen-binding fragments thereof specifically bind to the IgSF domain of the TREM2 protein (i.e., amino acid residues 19 to 132 of SEQ ID NO: 1, amino acid residues 19 to 132 of SEQ ID NO: 2, or amino acid residues 19 to 132 of SEQ ID NO: 3) and stabilize the TREM2 protein. In some preferred embodiments, these antibodies or antigen-binding fragments thereof stabilize the TREM2 protein on the cell surface of cells expressing TREM2 (selected from macrophages, dendritic cells, osteoclasts, microglia, mast cells, monocytes, lung epithelial cells, Langerhans cells of the skin, Kupffer cells, neutrophils, or hepatoma cells). In some embodiments, the disease associated with loss of TREM2 function is a neuroinflammatory or neurodegenerative disease, such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakora disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage diseases, such as Niemann-Pick disease (Niemann-Pick C) and mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, neurobehcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen's encephalitis (Rasmussen's In some preferred embodiments, the disease associated with loss of TREM2 function is a neurodegenerative disease selected from Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, or Nasu-Hakkara disease. In further preferred embodiments, the disease is Alzheimer's disease. In some embodiments, the TREM2 antibody or antigen-binding fragment thereof stabilizes the TREM2 protein on the cell surface of a cell expressing TREM2 selected from a macrophage, a dendritic cell, an osteoclast, a microglia, a mast cell, a monocyte, a lung epithelial cell, a skin Langerhans cell, a Kupffer cell, a neutrophil, or a hepatoma cell. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1AAn exemplary alignment of the amino acid sequences of human TREM2 isoform 1 (SEQ ID NO: 1), isoform 2 (SEQ ID NO: 2), and isoform 3 (SEQ ID NO: 3) is shown.
[0027] Figure 1B The structure of TREM2 and its interaction with the signaling adaptor protein DAP12 are illustrated. Mature TREM2 includes a single immunoglobulin (IgSF) domain, a stalk region, a transmembrane (TM) domain, and a cytoplasmic domain.
[0028] Figure 2 TREM2 was shown to be stabilized in CHO-hDAP12-hTREM2 cells by antibody treatment.
[0029] Figure 3 Shown is binding of TREM2 antibodies to human M2A macrophages before and after treatment with PMA.
[0030] Figure 4 shows the binding of antibodies to WT-TREM2 (4A) and TREM2-TREM1 chimeric proteins recombinantly expressed in CHO-hDAP12 cells (4B, C).
[0031] Figure 5 TREM2 antibodies were shown to stabilize TREM2 on the cell surface of hM2A.
[0032] Figure 6 (A, B) shows that antibodies that stabilize TREM2 on the cell surface also increase the phagocytic capacity of human M2A. Statistics were calculated using the Student's T test, *Pval<0.05, **Pval<0.01, ***Pval<0.001 compared to isotype controls.
[0033] Figure 7 (A, B) shows the determination of the lowest effective dose in the phagocytosis assay in hM2A. Statistics were calculated using Student's T-test, *Pval<0.05, **Pval<0.01, ***Pval<0.001 compared to isotype control.
[0034] Figure 8 Plate-bound TREM2 antibodies are shown to induce TREM2-dependent NFAT promoter-dependent gene transcription.
[0035] Figure 9 (A, B) shows that TREM2 antibodies increase Syk phosphorylation in human M2A macrophages. (B) shows the quantification of pSyk under different conditions relative to total Syk of the Western blot shown in (A).
[0036] Fig.10 Phagocytosis of S. aureus bioparticles by human M2A macrophages from 0-3 hours is shown.
[0037] Fig.11 Shown is the phagocytosis of SH-SY5Y cells by human M2A macrophages for 3-12 hours.
[0038] Fig.12 TREM2 antibodies were shown to promote chemotaxis of human M2A macrophages.
[0039] Fig.13 Shown that TREM2 antibody promotes phagocytosis of human iPS-derived microglia using apoptotic pHrodo-labeled SH-SY5Y cells and cumulative phagocytosis as readout.
[0040] Fig.14 TREM2 antibody was shown to promote chemotaxis of human iPS-derived microglia.
[0041] Figure 15(AE) shows the results of prophylactic / concomitant and therapeutic treatment with TREM2 antibodies in the cuprizone model.
[0042] Figure 16 shows the image analysis (A) results of the MPTP model in humanized TREM2 mice and representative microscopic photos of each group (B).
[0043] Figure 17 (AC) shows the results of cross-blocking experiments of Fabs MOR041877, MOR041895 and MOR042596 using whole IgGs MOR041877, MOR041895, MOR042596, MOR044698 and MOR03207 in CHO-hDAP12-hTREM2 cells.
[0044] Fig.18 Showing the increase in the phagocytic capacity of hM2A after treatment with MOR042596.
[0045] Fig.19 The TREM2 epitope bound by MOR042596 as determined by X-ray crystallography is shown. The protein backbone of TREM2 is shown in a cartoon diagram and the distance from the Fab The side chains of TREM2 residues within the distance are shown as sticks. The Fab heavy chain is shown as a dark grey surface, and the light chain is shown as a light grey surface.
[0046] Fig. 20 A close-up view showing the TREM2-Fab interface (see Fig.19 ), comparing MOR042596 (crystal structure) and MOR044698 (homology model). TREM2 residues within are shown as sticks, and residues proximal to LCDR3 (D39-K42) are labeled. LCDR1 and LCDR2 of the heavy chain (dark gray, upper right) and light chain (light gray, upper left) are identical for both Fabs. LCDR3 has several shared key residues (positions 90, 93, 95) that keep the main chain loop conformation of LCDR3 of the two Fabs the same. Positions 89, 91, 92, 94, 96 vary, and there is an additional insertion (S95a) in MOR044698. The entire epitope is conserved between MOR042596 and MOR044698.
[0047] Fig.21 The TREM2 epitope bound by MOR041877 as determined by X-ray crystallography is shown. The protein backbone of TREM2 is shown in a cartoon diagram and the distance from the Fab The side chains of TREM2 residues within the distance are shown as sticks. The Fab heavy chain is shown as a dark grey surface, and the light chain is shown as a light grey surface.
[0048] Figure 22 (A, B) shows the cerebral cortex of hTREM2-KI mice treated with cuprizone and MOR044698-mu or isotype control antibodies, as well as naive mice as controls (stained for TREM2 and Iba1 (A)). Quantitative analysis of the normalized area of hTREM2 positivity is provided (B). DETAILED DESCRIPTION
[0049] Provided herein are antibodies and antigen-binding fragments thereof that specifically bind to the extracellular domain of human TREM2 and stabilize the TREM2 protein. Those TREM2 antibodies and antigen-binding fragments thereof can reduce or inhibit the shedding of the TREM2 extracellular domain; can stabilize the TREM2 protein on the cell surface; and can optionally maintain or increase TREM2 function, such as binding to its cognate ligand, intracellular signaling, increasing phagocytosis, and promoting the degradation of engulfed substances. Because dysfunctional TREM2 or lack of surface TREM2 is associated with human neuroinflammatory and neurodegenerative pathologies, the antibodies and antigen-binding fragments thereof that stabilize TREM2 described herein can be used to treat, prevent, or diagnose neuroinflammatory or neurodegenerative diseases, such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakora disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage diseases (such as Niemann-Pick disease type C (Niemann-Pick disease) C)) and mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, neurobehcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen's encephalitis, Rett syndrome, stroke, transverse myelitis, traumatic brain injury, spinal cord injury, viral encephalitis, or bacterial meningitis. The TREM2 binding antibodies and antigen-binding fragments thereof described herein are also suitable for treating, preventing, or diagnosing autoimmune disorders, inflammatory disorders, or malignant disorders mediated by or associated with extensive proteolytic cleavage of TREM2 or cells expressing abnormal or mutant variants of the TREM2 receptor. In some preferred embodiments, the hTREM2 antibodies or antigen-binding fragments thereof described herein can be used to treat, prevent, or diagnose a disease selected from Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, or Nasu-Hakkara disease. Also provided herein are methods of diagnosing and / or treating TREM2-related diseases using the TREM2-binding antibodies and antigen-binding fragments thereof disclosed herein.
[0050] TREM2 mediates non-inflammatory phagocytosis of bacteria and dying cells and inhibits inflammatory responses. Homozygous loss of function of TREM2 leads to Nasu-Hakora disease (polycystic lipomembranous dysostosis with sclerosing leukoencephalopathy, "PLOSL"), or frontotemporal dementia (FTD)-like syndrome, a disease characterized by bone cysts, neuroinflammation, progressive neurodegeneration, and Alzheimer's disease. The heterozygous loss-of-function mutation R47H of TREM2 is also an important risk factor for late-onset Alzheimer's disease (AD), with an effect size similar to that of the apolipoprotein Eε4 allele. TREM2 is expressed in microglia found in the white matter, hippocampus, and neocortex, which is partially consistent with the pathological features reported in the AD brain, supporting that TREM2 may be involved in the pathogenesis of AD. In addition to AD, genetic screening has now identified heterozygous missense mutations in TREM2 as risk factors for Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) (Kleinberger, Sci Transl Med. 2014 Jul 2;6(243):243ra86). Therefore, functional TREM2 is required to prevent aging-associated neuroinflammation and neurodegenerative diseases that lead to severe cognitive impairment and dementia.
[0051] As a result of alternative splicing, three TREM2 isoforms exist in humans, with isoform 1 being the longest isoform. Figure 1A An alignment of the amino acid sequences of human TREM2 isoform 1 (SEQ ID NO: 1), human TREM2 isoform 2 (SEQ ID NO: 2), and human TREM2 isoform 3 (SEQ ID NO: 3) is shown in FIG. Figure 1B The structure of TREM2 and its interaction with the signaling adaptor protein DAP12 are illustrated.
[0052] definition
[0053] As used in the specification and claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a cell" includes a plurality of cells, including mixtures thereof.
[0054] All numerical designations, such as pH, temperature, time, concentration, and molecular weight (including ranges), are approximate and vary in increments of 0.1 (+) or (-). It should be understood that all numerical designations are preceded by the term "about", although not always explicitly stated. The term "about" in relation to a numerical value X means, for example, X ± 15%, including all values within the range. It should also be understood that the agents described herein are merely examples, and that equivalents thereof are known in the art, although not always explicitly stated.
[0055] Throughout the specification and the claims that follow, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising" are used herein in their open and non-limiting sense unless stated otherwise.
[0056] When used herein, "consisting of" excludes any elements, steps or ingredients not specified in the aspect, embodiment and / or claim section. When used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the aspect, embodiment and / or claim.
[0057] As used herein, "TREM2" (also referred to as "myeloid cell triggering receptor 2", TREM2, TREM2a, TREM2b or TREM2c) refers to a transmembrane glycoprotein belonging to the immunoglobulin superfamily (IgSF). The entire TREM2 protein (SEQ ID NO: 1) consists of a leader signal peptide (amino acids 1-18), a single V-type IgSF extracellular region (amino acids 19-132), a stem region (amino acids 133-172), a positively charged transmembrane domain (amino acids 173-197) and a cytoplasmic tail (amino acids 198-230) (Feuerbach et al., Neurosci. Lett. [Neuroscience Communications] 660 (2017): 109-114). The human TREM2 gene is mapped to chromosome position 6p21.1, and the genomic sequence of the TREM2 gene can be found in GenBank (Gene ID: 54209). Due to alternative splicing, there are three TREM2 isoforms in humans (protein sequences available in ENSEMBL with IDs ENSP00000362205, ENSP00000342651 and ENSP00000362214). The term "TREM2" is used to collectively refer to all isoforms of TREM2. The protein and mRNA sequences of the longest human TREM2 isoform are:
[0058] Triggering receptor 2 on myeloid cells precursor isoform 1 precursor [Homo sapiens] (NP_061838.1)
[0059] MEPLRLLILLFVTELSGAHNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRVVSTHNLWLLSFLRRWNGSTAITDDTLGGTLTITLRNLQPHDAGLYQCQSLHG SEADTLRKVLVEVLADPLDHRDAGDLWFPGESESFEDAHVEHSISRSLLEGEIPFPPTSILLLLACIFLIKILAASALWAAAWHGQKPGTHPPSELDCGHDPGYQLQTLPGLRDT
[0060] (SEQ ID NO:1)
[0061] Triggering receptor 2 on myeloid cells in Homo sapiens (TREM2), transcript variant 1, mRNA (NCBI Reference Sequence: NM_018965.3)
[0062]
[0063] (SEQ ID NO:133)
[0064] The amino acid sequences of human TREM2 isoform 2 (SEQ ID NO: 2) and isoform 3 (SEQ ID NO: 3) are shown in Figure 1A As used herein, human TREM2 protein also encompasses proteins having at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NO: 1, 2, or 3 over its full length, wherein such proteins still have ligand binding, intracellular signaling, promotion of phagocytosis and degradation of engulfed material, and other regulatory functions of TREM2. The sequences of murine, cynomolgus monkey (cyno), and other animal TREM2 proteins are known in the art (e.g., NP_112544.1 and NP_001259007.1 for murine TREM2 protein).
[0065] The term "extracellular domain" refers to a portion of a transmembrane protein that is exposed on the extracellular side of the lipid bilayer of a cell. Methods for determining the extracellular domain of a protein are known in the art (Singer (1990); High et al. (1993), and McVector software, Oxford Molecular). For example, the extracellular domain of a human TREM2 protein may include amino acid residues 19 to 172 of SEQ ID NO: 1.
[0066] The term "extracellular domain" of TREM2 refers to a portion of the extracellular domain of TREM2 that is released after shedding enzyme cleavage. It is reported that the cleavage site is located between amino acids H157 and S158 (Feuerbach et al., Neurosci. Lett. [Neuroscience Communications] 660 (2017): 109-114). Therefore, the extracellular domain of hTREM2 will consist of amino acids 19-157 of any one of SEQ ID NO: 1, 2 or 3.
[0067] The term "IgSF domain" refers to a portion of the extracellular domain of TREM2 that contains an immunoglobulin (Ig) type fold and therefore belongs to the immunoglobulin superfamily. For example, in humans, the IgSF domain consists of amino acid residues 19 to 132 of any one of SEQ ID NOs: 1, 2, and 3.
[0068] The term "stem region" of TREM2 refers to a portion of the extracellular domain of TREM2 that connects the V-type immunoglobulin (IgSF) domain and the transmembrane domain. For example, the stem region of a human TREM2 isoform 1 protein may include amino acids 133-172 of SEQ ID NO: 1.
[0069] The term "transmembrane domain" refers to the portion of a transmembrane protein that spans the lipid bilayer of a cell. Methods for determining the transmembrane domain of a protein are known in the art (Elofsson et al., Annu. Rev. Biochem. [Annual Review of Biochemistry] 76 (2007): 125-140; Bernsel et al., Protein Science [Protein Science] 14 (2005): 1723-1728).
[0070] The terms "cytoplasmic domain" and "cytoplasmic tail" are used interchangeably and refer to the portion of a transmembrane protein that is located on the cytoplasmic side of the lipid bilayer of a cell. Methods for determining the cytoplasmic tail of a protein are known in the art (Elofsson et al. (2007) and Bernsel et al. (2005)).
[0071] As used herein, the term "stabilize" refers to maintaining, restoring or increasing the TREM2 cell surface level in cells expressing TREM2, for example, to the TREM2 level in cells expressing TREM2 corresponding to healthy subjects without inflammation or neurodegenerative diseases. This can be achieved by, for example, reducing or inhibiting the shedding of the TREM2 extracellular domain, or by increasing the cell surface expression of TREM2. TREM2 cell surface levels can be assessed by flow cytometry / FACS or by TREM2 cell surface immunoprecipitation or by a decrease in soluble TREM2 over time. TREM2 cell surface expression can also be detected by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), bioassay (e.g., increased phagocytosis), western blot assay, flow cytometry, immunohistochemistry, immunofluorescence assay, homogeneous time-resolved fluorescence (HTRF), or positron emission tomography (PET).
[0072] The term "activation" herein refers to the initiation or maintenance of downstream signaling of TREM2 expressed on the cell surface, such as in cells expressing TREM2 in healthy subjects or individuals with inflammatory or neurodegenerative diseases (where appropriate TREM2-dependent activity is impaired). This can be achieved, but is not limited to, phosphorylation of TREM2-related DAP12 or DAP10, which leads to enhanced Syk phosphorylation, phagocytosis, enhanced targeted cell motility (chemotaxis), increased cell survival, regulation of cytokine or chemokine release of cells expressing TREM2, increased degradation of intracellular phagocytic material, or changes in gene expression. Increased TREM2-dependent DAP12 or Syk phosphorylation can be assessed by Western blotting, ELISA, or flow cytometry / FACS. Directed motility of cells, such as chemotaxis, can be assessed by bioassays. Regulation of cytokine release can be assessed by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or flow cytometry / FACS. Changes in gene expression can be assessed by quantitative RT-PCR at the mRNA level or by western blotting or flow cytometry at the protein level.
[0073] The term "promote" herein refers to the enhancement or restoration of a TREM2-dependent activity that is impaired by the disease. These activities may include phagocytosis, increased motility (chemotaxis) of targeted cells, increased cell survival, modulation of cytokine or chemokine release from cells expressing TREM2, increased degradation of intracellular phagocytic material, modulation of cellular responses of neighboring cells (astrocytes / neurons), or changes in gene expression.
[0074] As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies can be polyclonal or monoclonal, multi-chain or single-chain, or complete immunoglobulins, and can be derived from natural sources or from recombinant sources. Naturally occurring "antibodies" are glycoproteins comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region comprises one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conservative regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The antibody can be a monoclonal antibody, a human antibody, a humanized antibody, a camelid antibody, or a chimeric antibody. These antibodies can have any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), category (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. Throughout the document, unless otherwise indicated in the context, the term "antibody" or "antibody molecule" also includes any fragment thereof and any derivative thereof.
[0075] The term "antibody fragment" or "antigen-binding fragment" refers to at least a portion of an antibody that retains the ability to specifically interact with an antigenic epitope (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution). Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments, scFv antibody fragments, disulfide-linked Fv (sdFv), Fd fragments consisting of VH and CH1 domains, linear antibodies, single domain antibodies such as sdAb (VL or VH), Camelidae VHH domains, multispecific antibodies formed from antibody fragments (e.g., a bivalent fragment comprising two Fab fragments linked by a disulfide bond at the hinge region), and isolated CDRs, or other epitope-binding fragments of antibodies. Antigen binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23: 1126-1136, 2005). Antigen binding fragments can also be grafted into scaffolds based on polypeptides such as fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide minibodies). The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region are continuously connected, for example, by a synthetic linker (e.g., a short flexible polypeptide linker) and can be expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise indicated, as used herein, a scFv may have VL and VH variable regions in any order, for example relative to the N-terminus and C-terminus of the polypeptide, and may comprise VL-linker-VH or may comprise VH-linker-VL.
[0076] As used herein, the term "complementarity determining region" or "CDR" refers to the sequence of amino acids within the variable region of an antibody that confers antigen specificity and binding affinity. For example, in general, there are three CDRs (e.g., HCDR1, HCDR2, and HCDR3) in each heavy chain variable region, and three CDRs (LCDR1, LCDR2, and LCDR3) in each light chain variable region. The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th ed., National Institutes of Health, Public Health Service, Bethesda, Maryland ("Kabat" numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme), or a combination thereof, and ImMunoGenTics (IMGT) numbering (Lefranc, M.-P., The Immunology Bulletin, 1996). Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003); Lefranc et al., (2015) Nucleic Acids Res. 43, D413-422) ("IMGT" numbering scheme). In a combined Kabat and Josiah numbering scheme for a given CDR region (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, or LCDR3), in some embodiments, these CDRs correspond to amino acid residues defined as part of a Kabat CDR, and amino acid residues defined as part of a Josiah CDR. As used herein, CDRs defined according to the "Josiah" numbering scheme are sometimes also referred to as "hypervariable loops". Under IMGT, the CDR regions of an antibody can be determined using the program IMGT / DomainGap Align. In general, unless otherwise indicated, the antibody molecule may include any combination of one or more Kabat CDRs and / or Josiah CDRs.
[0077] The term "epitope" includes any protein determinant that is capable of specifically binding to an immunoglobulin or otherwise interacting with a molecule. Epitope determinants are typically composed of chemically active surface groups of molecules, such as amino acids or carbohydrate or sugar side chains, and may have specific three-dimensional structural characteristics as well as specific charge characteristics. Epitopes may be "linear" or "conformational". Conformational epitopes differ from linear epitopes, for example, in that binding to conformational epitopes (but not non-conformational epitopes) is lost in the presence of denaturing solvents.
[0078] An antibody, antibody fragment, or other antigen binding portion that "binds to the same epitope as..." binds to a specific antigen and binds to the same epitope as the exemplary antibody (when the antibodies are compared using the same epitope mapping technique). Epitope mapping techniques can be used to determine the epitopes of the exemplary antibodies and other antibodies. Epitope mapping techniques are well known in the art. For example, conformational epitopes can be readily identified by determining the spatial conformation of amino acids, such as by hydrogen / deuterium exchange, X-ray crystallography, and two-dimensional nuclear magnetic resonance.
[0079] In another embodiment, the disclosure relates to antibodies or antibody fragments that cross-compete with the antibodies described in Table 1.
[0080] In one embodiment, the disclosure relates to an antibody or antibody fragment, wherein the antibody or antibody fragment cross-competes with an antibody or antibody fragment comprising six CDRs defined by the Kabat, Josiah, IMGT or combined Kabat / Josiah methods of one or more antibodies in Table 1.
[0081] In another embodiment, the disclosure relates to an antibody or antibody fragment that binds to (eg, by binding to and / or stabilizing) the same epitope as one of the antibodies in Table 1.
[0082] In another embodiment, the antibody or antigen-binding fragment thereof binds (e.g., by binding and / or stabilizing) an epitope that overlaps with an epitope of an antibody or antibody fragment comprising six CDRs defined by any of the Kabat, Josiah, IMGT, or Kabat / Josiah combination methods for any of the antibodies in Table 1.
[0083] The term "monovalent antibody" as used herein refers to an antibody that binds to a single epitope on a target molecule.
[0084] The term "bivalent antibody" as used herein refers to an antibody that binds to two epitopes on at least two identical target molecules. A bivalent antibody can also cross-link target molecules to each other. A "bivalent antibody" also refers to an antibody that binds to two different epitopes on at least two identical target molecules.
[0085] The term "multivalent antibody" refers to a single binding molecule with more than one valency, where "valency" is described as the number of antigen binding moieties present per molecule of the antibody construct. Thus, a single binding molecule can bind to more than one binding site on a target molecule. Examples of multivalent antibodies include, but are not limited to, bivalent antibodies, trivalent antibodies, tetravalent antibodies, pentavalent antibodies, etc., as well as bispecific antibodies and biparatopic antibodies. For example, for TREM2, a multivalent antibody (e.g., a TREM2 biparatopic antibody) has binding moieties for two domains of TREM2, respectively.
[0086] The term "multivalent antibody" also refers to a single binding molecule that has more than one antigen binding moiety for two separate target molecules. For example, an antibody that binds TREM2 and a second target molecule that is not TREM2. In one embodiment, the multivalent antibody is a tetravalent antibody with four epitope binding domains. The tetravalent molecule can be bispecific and bivalent for each binding site on the target molecule.
[0087] The term "bispecific antibody" as used herein refers to an antibody that binds to two or more different epitopes. In some embodiments, a bispecific antibody binds to two different targets. In some embodiments, a bispecific antibody binds to two different epitopes on a single target molecule. An antibody that binds to two different epitopes on a single target molecule is also referred to as a "biparatopic antibody."
[0088] As used herein, the phrase "monoclonal antibody" or "monoclonal antibody composition" refers to polypeptides (including antibodies, bispecific antibodies, etc.) having substantially the same amino acid sequence or derived from the same genetic source. This term also includes preparations of antibody molecules having a single molecular composition. A monoclonal antibody composition exhibits a single binding specificity and affinity for a particular epitope.
[0089] As used herein, the phrase "human antibody" includes antibodies having variable regions in which both the framework and CDR regions are derived from sequences of human origin. The constant region is also derived from human sequences, such as human germline sequences or mutant forms of human germline sequences, or antibodies containing consensus framework sequences derived from human framework sequence analysis, e.g., as described in Knappik et al. (2000. J Mol Biol [Molecular Biology Journal] 296, 57-86). The structure and position of immunoglobulin variable domains (e.g., CDRs) can be defined using well-known numbering schemes, for example, the Kabat numbering scheme, the Jossian numbering scheme, or a combination of Kabat and Jossian, and the ImMunoGenTics (IMGT) numbering (see, e.g., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1991), ed. Kabat et al.; Al Lazikani et al., (1997) J. Mol. Bio. 273:927 948; Kabat et al., (1991) Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication No. 91-3242, U.S. Department of Health and Human Services. Services); Chothia et al., (1987) J. Mol. Biol. [Journal of Molecular Biology] 196:901-917; Chothia et al., (1989) Nature [Nature] 342:877-883; and Al-Lazikani et al., (1997) J. Mal. Biol. [Journal of Molecular Biology] 273:927-948; Lefranc, M.-P., The Immunologist [Immunologist], 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol. [Developmental and Comparative Immunology], 27, 55-77 (2003); Lefranc et al., (2015) Nucleic Acids Res. [Nucleic Acids Research] 43, D413-422.
[0090] The human antibodies of the present invention may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro, or by somatic mutation in vivo, or conservative substitutions to promote stability or production). However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species (such as a mouse) have been grafted into human framework sequences.
[0091] As used herein, the phrase "recombinant human antibody" includes all human antibodies prepared, expressed, produced or isolated by recombinant means, such as antibodies isolated from animals (e.g., mice) (the animals are transgenic or transchromosomal for human immunoglobulins) or hybridomas prepared therefrom; antibodies isolated from host cells transformed to express human antibodies (e.g., from transfectomas); antibodies isolated from recombinant, combinatorial human antibody libraries; and antibodies prepared, expressed, produced or isolated by any other means (involving splicing of all or part of human immunoglobulin genes, sequences to other DNA sequences). Such recombinant human antibodies have variable regions, wherein the framework regions and CDR regions are derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies may be subjected to in vitro mutagenesis (or, when using animals of transgenic human Ig sequences, in vivo somatic cell mutagenesis), and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are derived from human germline VH and VL sequences and sequences related thereto, which may not naturally exist in the human antibody germline library in vivo.
[0092] As used herein, the term "Fc region" refers to a polypeptide comprising at least a portion of the CH3, CH2 and hinge regions of the constant domains of an antibody. Optionally, the Fc region may include a CH4 domain present in some antibody species. The Fc region may include the entire hinge region of the antibody constant region. In one embodiment, the present invention includes the Fc region and CH1 region of an antibody. In one embodiment, the present invention includes the Fc region and CH3 region of an antibody. In another embodiment, the present invention includes the Fc region, the CH1 region and the Cκ / λ region from the constant domain of an antibody. In one embodiment, the binding molecule of the present invention includes a constant region, such as a heavy chain constant region. In one embodiment, such constant regions are modified compared to the wild-type constant region. That is, the polypeptide of the present invention disclosed herein may include changes or modifications to one or more of the three heavy chain constant domains (CH1, CH2 or CH3) and / or to the light chain constant region domain (CL). Example modifications include adding, deleting or replacing one or more amino acids in one or more domains. Such changes may be included to optimize effector functions, half-life, etc.
[0093] As used herein, the term "affinity" refers to the strength of the interaction between an antibody and an antigen at a single antigenic site. Within each antigenic site, the variable region of an antibody interacts with the antigen at many sites through weak non-covalent forces; the more interactions, the stronger the affinity. As used herein, the term "high affinity" for an IgG antibody or a fragment thereof (e.g., a Fab fragment) refers to an antibody that has 10 -8 M or smaller, 10 -9 M or smaller, or 10 -10 M, or 10 -11 M or smaller, or 10 -12 M or smaller, or 10 -13 However, for other antibody isotypes, "high affinity" binding may vary. For example, "high affinity" binding for an IgM isotype means an antibody with an affinity of 10 -7 M or lower or 10 -8 M or lower affinity.
[0094] As used herein, the term "Kassoc", "Ka" or "K on " is intended to refer to the association rate of a particular antibody-antigen interaction, while the terms "Kdis", "Kd" or "K off " is intended to refer to the dissociation rate of a particular antibody-antigen interaction. In one embodiment, as used herein, the term "KD" (or "K D ”) is intended to refer to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e., Kd / Ka) and expressed as a molar concentration (M). The KD value of an antibody can be determined using methods established in the art. Methods for determining the KD of an antibody are by using surface plasmon resonance, or using a biosensor system, such as system.
[0095] As used herein, the term "avidity" refers to an informative measure of the overall stability or strength of an antibody-antigen complex. It is controlled by three main factors: antibody epitope affinity; the valency of both the antigen and the antibody; and the structural arrangement of the interacting parts. Ultimately, these factors determine the specificity of the antibody, i.e., the likelihood that a particular antibody will bind to a precise antigen epitope.
[0096] As used herein, the term "binding specificity" or "specific binding" refers to the ability of a single antibody binding site to react with one antigenic determinant and not with a different antigenic determinant. The binding site of an antibody is located in the Fab portion of the molecule and is constructed from the hypervariable regions of the heavy and light chains. The binding affinity of an antibody is the strength of the reaction between a single antigenic determinant and a single binding site on the antibody. It is the sum of the attractive and repulsive forces operating between the antigenic determinant and the binding site of the antibody.
[0097] The terms "treat" and "treatment" refer to therapeutic treatment, wherein the purpose is to slow down an undesirable physiological change or disorder. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in extent of disease, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or alleviation of the disease state, and remission (whether partial or complete), whether detectable or undetectable. "Treatment" may also mean prolonged survival compared to expected survival if not receiving treatment.
[0098] The terms "prevention," "prevent," and "preventing," with respect to any particular disease or disorder, refer to prophylactic or preventive measures, such as administering a compound of the invention to a subject before any symptoms of the disease or disorder appear.
[0099] The term "subject" refers to an animal, human, or non-human to whom the treatment according to the method of the present invention is provided. Veterinary applications and non-veterinary applications are contemplated. The term includes, but is not limited to, mammals, such as humans, other primates, pigs, rodents such as mice and rats, rabbits, guinea pigs, hamsters, cattle, horses, cats, dogs, sheep and goats. Typical subjects include humans, farm animals and domestic pets, such as cats and dogs. In some preferred embodiments, the subject is a human.
[0100] "Effective amount" refers to an amount sufficient to produce a beneficial or desired result. For example, a therapeutic amount is an amount that achieves the desired therapeutic effect. The amount may be the same or different from a prophylactically effective amount, which is the amount required to prevent the onset of a disease or disease symptom. An effective amount may be administered in one or more administrations or applications or administrations. The "therapeutically effective amount" (i.e., effective dose) of a therapeutic compound depends on the selected therapeutic compound. The composition can be administered once or more per day to once or more per week; including once every other day. The skilled person will understand that certain factors may affect the dose and schedule required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatment, the general health and / or age of the subject, and other diseases present. In addition, treatment of a subject with a therapeutically effective amount of a therapeutic compound described herein may include a single treatment or a series of treatments.
[0101] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless otherwise specified, the term encompasses nucleic acids containing known natural nucleotide analogs that have binding properties similar to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a specific nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs and complementary sequences as well as sequences explicitly specified. Specifically, degenerate codon substitutions can be obtained by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0102] The terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to compounds comprising amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that can constitute a protein or peptide sequence. Polypeptides include any peptide or protein comprising two or more amino acids linked to each other by peptide bonds. As used herein, the term refers to short chains, such as those also commonly referred to in the art as peptides, oligopeptides, and oligomers; and also to longer chains, which are commonly referred to in the art as proteins, and there are many types of proteins. "Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, and the like. Polypeptides include natural peptides, recombinant peptides, or a combination thereof.
[0103] The term "conservative sequence modification" refers to an amino acid modification that does not significantly affect or change the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the antibody or antibody fragment of the present invention by standard techniques known in the art (such as site-directed mutagenesis and PCR-mediated mutagenesis). Conservative amino acid substitutions are substitutions in which amino acid residues are replaced by amino acid residues with similar side chains. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within an antibody or antigen-binding fragment thereof of the invention can be replaced with other amino acid residues from the same side chain family, and the altered antibody or antigen-binding fragment can be tested using the functional assays described herein.
[0104] The term "homologous" or "identical" refers to the subunit sequence identity between two polymeric molecules, such as two nucleic acid molecules (such as two DNA molecules or two RNA molecules) or between two polypeptide molecules. When the subunit position in the two molecules is occupied by the same monomer subunit; for example, if the position in each of the two DNA molecules is occupied by adenine, they are homologous or identical at that position. The homology between two sequences is a direct function of the number of matching positions or homologous positions; for example, if half of the positions in the two sequences (e.g., five positions in a polymer of ten subunits in length) are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 out of 10) are matched or homologous, the two sequences are 90% homologous. The percentage of "sequence identity" can be determined by comparing two optimally aligned sequences over a comparison window, wherein a fragment of the amino acid sequence in the comparison window may contain additions or deletions (e.g., gaps or overhangs) compared to a reference sequence (which does not contain additions or deletions) to optimally align the two sequences. This percentage can be calculated by determining the number of positions at which the identical amino acid residue occurs in the two sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to yield the percent sequence identity. The output is the percent identity of the subject sequence with respect to the query sequence.
[0105] The term "isolated" means changed or removed from the natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated", but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated". An isolated nucleic acid or protein can exist in a substantially purified form, or can exist in a non-natural environment (such as, for example, a host cell). An "isolated antibody" is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds to TREM2 is substantially free of antibodies that specifically bind to antigens other than TREM2). However, an isolated antibody that specifically binds to a target molecule may have cross-reactivity with the same antigen from other species, for example, an isolated antibody that specifically binds to TREM2 may bind to TREM2 molecules from other species. The isolated antibody may be a monoclonal antibody. The isolated antibody may be a recombinant monoclonal antibody. In addition, the isolated antibody may be substantially free of other cellular materials and / or chemicals.
[0106] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification including the definitions shall prevail. In addition, materials, methods and examples are illustrative only and are not intended to be limiting.
[0107] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
[0108] Antibodies that stabilize functional TREM2
[0109] Provided herein are antibodies and antigen-binding fragments thereof that stabilize TREM2 on the cell surface. These antibodies or antigen-binding fragments thereof can achieve stabilization of TREM2 by interfering with the proteolytic cleavage of TREM2 and / or reducing the shedding of the extracellular domain of the TREM2 protein. In some preferred embodiments, those antibodies or antigen-binding fragments thereof specifically bind to the IgSF domain of human TREM2, such as amino acid residues 19 to 132 of any one of SEQ ID NO: 1, 2 or 3.
[0110] Since reduction or absence of cell surface TREM2 is associated with human neuroinflammatory and neurodegenerative pathologies, the antibodies or antigen-binding fragments thereof that stabilize TREM2 described herein can be used to treat, prevent or diagnose neuroinflammatory and neurodegenerative diseases, such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakora disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage diseases, such as Niemann-Pick disease (Niemann-Pick C) and mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, neurobehcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen's encephalitis, Rett syndrome, stroke, transverse myelitis, traumatic brain injury, spinal cord injury, viral encephalitis or bacterial meningitis. In some preferred embodiments, the hTREM2 antibodies or antigen-binding fragments thereof described herein can be used to treat, prevent or diagnose a disease selected from Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis or Nasu-Hakkara disease.
[0111] Due to their pharmacological characteristics, the hTREM2 antibodies or antigen-binding fragments thereof described herein can be used to treat a variety of diseases or conditions, such as CNS-related diseases, PNS-related diseases, systemic inflammation, and other diseases associated with inflammation, pain, and withdrawal symptoms caused by abused chemicals. Diseases or disorders associated with the CNS include generalized anxiety disorder, cognitive impairment, learning and memory deficits and dysfunctions, Alzheimer's disease (mild, moderate and severe), attention deficit and hyperactivity disorder, Parkinson's disease, Parkinson's disease dementia, Huntington's disease, ALS, chronic neurodegenerative disorders such as Creutzfeld-Jacob disease and Kuru disease, Tourette syndrome, psychosis, depression and depressive disorders, mania, manic-depressive disorder, schizophrenia, cognitive deficits in schizophrenia, obsessive-compulsive disorder, panic disorder, eating disorders, narcolepsy, nociception, AIDS-dementia, Alzheimer's disease, age-related mild cognitive impairment (MCI), age-related memory impairment, autism, dyslexia, tardive dyskinesia, epilepsy, and convulsive disorders, post-traumatic stress disorder, transient hypoxia, pseudodementia, premenstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome and jet lag.
[0112] The hTREM2 antibodies or antigen-binding fragments thereof described herein are particularly useful for treating, preventing or diagnosing autoimmune disorders, inflammatory disorders or malignant disorders mediated by or associated with extensive proteolytic cleavage of TREM2 or cells expressing abnormal or mutant variants of the TREM2 receptor. Examples of autoimmune diseases include, but are not limited to, arthritis (e.g., rheumatoid arthritis, chronic arthritis and deforming arthritis) and rheumatic diseases, including inflammatory conditions and rheumatic diseases involving bone loss, inflammatory pain, spondylitis (including ankylosing spondylitis), Reiter's syndrome, reactive arthritis, psoriatic arthritis and enterophathic arthritis, hypersensitivity reactions (including airway hypersensitivity reactions and skin hypersensitivity reactions) and allergies. Autoimmune diseases include autoimmune blood disorders (including, for example, hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), systemic lupus erythematosus, inflammatory muscle disorders, polychondritis, scleroma, Wegener's granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven Johnson syndrome, idiopathic sprue, endocrine eye diseases, Graves' disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis chondroitinib, leukemia, leukoderma, leukoplakia, chondroitinib, leukoderma lucidum, leukoderma necrosis, leukoderma sclerosing ...necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma necrosis, leukoderma necrosis, leukoderma necrosis
[0113] The hTREM2 antibodies or antigen-binding fragments thereof described herein can also be used to treat, prevent or ameliorate asthma, bronchitis, pneumoconiosis, emphysema and other obstructive or inflammatory diseases of the airways, including idiopathic pulmonary fibrosis or COPD.
[0114] The hTREM2 antibodies or antigen-binding fragments thereof described herein can be used to treat hematopoietic or hepatocellular malignancies, such as acute myeloid leukemia, chronic myeloid leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, paroxysmal nocturnal hemoglobinuria, fanconi anemi, thalassemia major, Wiskott-Aldrich syndrome, and erythrophagocytic lymphohistiocytosis.
[0115] The hTREM2 antibodies or antigen-binding fragments thereof described herein can be used to treat any disease or disorder directly or indirectly associated with aberrant TREM2 activity and / or expression. TREM2-related disorders include: immune disorders, particularly those involving inflammatory disorders (such as bacterial infections, fungal infections, viral infections, protozoan or other parasitic infections, psoriasis, sepsis, cerebral malaria, inflammatory bowel disease, arthritis, such as rheumatoid arthritis, folliculitis, impetigo, granulomas, lipoid pneumonia, vasculitis, and osteoarthritis), autoimmune disorders (such as rheumatoid arthritis, thyroiditis, such as Hashimoto's thyroiditis and Graves' disease), insulin-resistant diabetes, pernicious anemia, Addison's disease, pemphigus, vitiligo, ulcerative colitis, enteritis, systemic lupus erythematosus (SLE), Sjögren's syndrome, multiple sclerosis, dermatomyositis, mixed connective tissue disease, scleroderma, polymyositis, transplant rejection (such as allogeneic transplant rejection), T-cell disorders (such as AIDS), allergic inflammatory disorders (such as skin and / or mucosal allergies, such as allergic rhinitis, asthma, psoriasis), nervous system disorders, eye disorders, embryonic disorders, or any other disorder directly or indirectly related to aberrant activity and / or expression of TREM2 (such as tumors, cancer, leukemia, myeloid diseases, and trauma).
[0116] In some embodiments, the TREM2-associated disorder is selected from asthma, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthritis, arthritis, inflammatory osteolysis, or chronic inflammation caused by chronic viral or bacterial infection.
[0117] In some embodiments, the TREM2-associated disorder is selected from dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tauopathy, Nasu-Hakkara disease, stroke, acute trauma, chronic trauma, lupus, acute and chronic colitis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, essential tremor, central nervous system lupus, Behcet's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, multiple system atrophy syndrome (Shy-Drager syndrome), progressive supranuclear palsy, corticobasal ganglionic degeneration, acute disseminated encephalomyelitis, granulomatous diseases, sarcoidosis, diseases of aging, epileptic seizures, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, respiratory tract infection, sepsis, eye infection, systemic infection, lupus, arthritis, multiple sclerosis, low bone density, osteoporosis, osteogenesis, osteopetrotic disease, Paget's disease of bone, and cancer. In some preferred embodiments, the TREM2-associated disorder is selected from the list consisting of Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, or Nasu-Hakkara disease.
[0118] In some preferred embodiments, the TREM2-associated disorder is selected from dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakkara disease, and multiple sclerosis. In some preferred embodiments, the TREM2-associated disorder is dementia, such as frontotemporal dementia, Alzheimer's disease, vascular dementia, semantic dementia, or dementia with Lewy bodies. In a more preferred embodiment, the TREM2-associated disorder is Alzheimer's disease. In another preferred embodiment, the disorder is Parkinson's disease.
[0119] Antibodies and antigen-binding fragments that specifically bind to human TREM2
[0120] In one aspect, provided herein are antibodies or antigen-binding fragments thereof, such as monoclonal antibodies or antigen-binding fragments thereof, that specifically bind to the IgSF domain of a human TREM2 protein ("hTREM2 antibody or antigen-binding fragment thereof"). Those antibodies or antigen-binding fragments can stabilize the TREM2 protein on the cell surface and / or reduce the shedding of the extracellular domain of the TREM2 protein.
[0121] In some embodiments, the hTREM2 antibodies or antigen-binding fragments thereof provided herein include heavy chain CDR1 (HCDR1), heavy chain CDR2 (HCDR2), heavy chain CDR3 (HCDR3) and light chain CDR1 (LCDR1), light chain CDR2 (LCDR2) and light chain CDR3 (LCDR3). In some embodiments, the hTREM2 antibodies or antigen-binding fragments provided herein include a heavy chain variable region (VH) comprising CDR1, CDR2 and CDR3 and a light chain variable region (VL) comprising CDR1, CDR2 and CDR3. In some embodiments, the hTREM2 antibodies or antigen-binding fragments provided herein include a full-length heavy chain sequence (HC) and a full-length light chain sequence (LC).
[0122] Table 1 lists the sequences of exemplary TREM2 antibodies or antigen-binding fragments that specifically bind to human TREM2 proteins. Throughout this application, if there is a discrepancy between the specification text (e.g., Table 1) and the sequence listing, the specification text shall prevail.
[0123] Table 1. Sequences of exemplary monoclonal antibodies that bind to human TREM2.
[0124]
[0125]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147]
[0148]
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159] In some embodiments, the hTREM2 antibody or antigen-binding fragment thereof comprises a VH domain having an amino acid sequence of any VH domain described in Table 1. Other suitable hTREM2 antibodies or antigen-binding fragments thereof may include amino acids that have been mutated, but have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity in the VH domain to the VH region depicted in the sequence described in Table 1. In certain embodiments, the disclosure also provides antibodies or antigen-binding fragments thereof that specifically bind to human TREM2, wherein the antibody or antibody fragment (e.g., antigen-binding fragment) comprises a VH CDR having an amino acid sequence of any one of the HCDRs listed in Table 1. In specific embodiments, the present invention provides antibodies or antibody fragments (e.g., antigen-binding fragments) that specifically bind to human TREM2, comprising (or alternatively consisting of) one, two, three, four, five or more VH CDRs having an amino acid sequence of any one of the HCDRs listed in Table 1.
[0160] In some embodiments, the hTREM2 antibody or antibody fragment (e.g., antigen binding fragment) comprises a VL domain having an amino acid sequence of any VL domain described in Table 1. Other suitable anti-human TREM2 antibodies or antibody fragments (e.g., antigen binding fragments) may include amino acids that have been mutated but have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity in the VL domain to the VL region depicted in the sequence described in Table 1. The present disclosure also provides antibodies or antibody fragments (e.g., antigen binding fragments) that specifically bind to human TREM2, which antibodies or antibody fragments (e.g., antigen binding fragments) comprise VL CDRs having an amino acid sequence of any one of the LCDRs listed in Table 1. In particular, the present invention provides antibodies or antibody fragments (e.g., antigen binding fragments) that specifically bind to human TREM2, which antibodies or antibody fragments comprise (or alternatively consist of) one, two, three or more VL CDRs having an amino acid sequence of any one of the LCDRs listed in Table 1.
[0161] Other anti-human TREM2 antibodies or antibody fragments (e.g., antigen-binding fragments) disclosed herein include amino acids that have been mutated but have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity in the CDR regions to the CDR regions depicted in the sequences described in Table 1. In some embodiments, they include mutant amino acid sequences wherein no more than 1, 2, 3, 4, or 5 amino acids in the CDR regions have been mutated when compared to the CDR regions depicted in the sequences described in Table 1.
[0162] Also provided herein are nucleic acid sequences encoding VH, VL, full-length heavy chains, and full-length light chains of antibodies and antigen-binding fragments thereof that specifically bind to human TREM2 (e.g., nucleic acid sequences in Table 1). Such nucleic acid sequences can be optimized for expression in intended host cells, such as mammalian cells.
[0163] Other anti-human TREM2 antibodies disclosed herein include those in which the amino acids or nucleic acids encoding the amino acids have been mutated but have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the sequences described in Table 1. In some embodiments, the antibodies or antigen-binding fragments thereof comprise mutant amino acid sequences in which no more than 1, 2, 3, 4, or 5 amino acids have been mutated in the variable region when compared to the variable region depicted in the sequences described in Table 1, while retaining substantially the same therapeutic activity.
[0164] Since each provided antibody binds to human TREM2, VH, VL, full-length light chain, and full-length heavy chain sequences (amino acid sequences and nucleotide sequences encoding the amino acid sequences) can be "mixed and matched" to produce other TREM2 binding antibodies disclosed herein. Such "mixed and matched" TREM2 binding antibodies can be tested using binding assays known in the art (e.g., ELISA, assays described in the Examples). When chains are mixed and matched, the VH sequence from a specific VH / VL pairing should be replaced with a structurally similar VH sequence. The full-length heavy chain sequence from a specific full-length heavy chain / full-length light chain pairing should be replaced with a structurally similar full-length heavy chain sequence. The VL sequence from a specific VH / VL pairing should be replaced with a structurally similar VL sequence. The full-length light chain sequence from a specific full-length heavy chain / full-length light chain pairing should be replaced with a structurally similar full-length light chain sequence.
[0165] Therefore, in one embodiment, the present invention provides an isolated monoclonal antibody or an antigen-binding fragment thereof, which has: a heavy chain variable region (VH) comprising an amino acid sequence selected from any one of SEQ ID NOs: 13 and 50; and a light chain variable region (VL) comprising an amino acid sequence selected from any one of SEQ ID NOs: 24 and 61; wherein the antibody specifically binds to human TREM2.
[0166] In another embodiment, the present invention provides (i) an isolated monoclonal antibody having: a full-length heavy chain (HC) comprising an amino acid sequence selected from any one of SEQ ID NOs: 15, 29, 33, 35, 37, 39, 52, 66, 70, 72, 74, 76; and a full-length light chain (LC) comprising an amino acid sequence selected from any one of SEQ ID NOs: 26 and 63; or (ii) a functional protein comprising an antigen binding portion thereof.
[0167] In another embodiment, the present disclosure provides a human TREM2 binding antibody or an antibody fragment thereof, comprising a heavy chain CDR1, CDR2 and CDR3 and a light chain CDR1, CDR2 and CDR3 as described in Table 1, or a combination thereof. The amino acid sequence of the HCDR1 of the antibody is shown in SEQ ID NO: 4, 7, 8, 10, 41, 44, 45, 47. The amino acid sequence of the HCDR2 of the antibody is shown in SEQ ID NO: 5, 9, 11, 42, 46, 48. The amino acid sequence of the HCDR3 of the antibody is shown in SEQ ID NO: 6, 12, 43, 49. The amino acid sequence of the LCDR1 of the antibody is shown in SEQ ID NO: 17, 20, 23, 54, 57, 60. The amino acid sequence of the LCDR2 of the antibody is shown in SEQ ID NO: 18, 21, 55, 58. The amino acid sequence of the LCDR3 of the antibody is shown in SEQ ID NO: 19, 22, 56, 59, 56.
[0168] Given that each of these antibodies can bind to TREM2 and that antigen binding specificity is primarily provided by the CDR1, CDR2, and CDR3 regions, the VH CDR1, CDR2, and CDR3 sequences and the VL CDR1, CDR2, and CDR3 sequences can be "mixed and matched" (i.e., CDRs from different antibodies can be mixed and matched), but each antibody must contain VH CDR1, CDR2, and CDR3 and VL CDR1, CDR2, and CDR3 to produce other TREM2 binding molecules disclosed herein. Such "mixed and matched" TREM2 binding antibodies can be tested using binding assays known in the art and those described in the Examples (e.g., ELISA). When mixing and matching VH CDR sequences, the CDR1, CDR2, and / or CDR3 sequences from a particular VH sequence should be replaced with one or more structurally similar CDR sequences. Similarly, when mixing and matching VL CDR sequences, the CDR1, CDR2, and / or CDR3 sequences from a particular VL sequence should be replaced with one or more structurally similar CDR sequences. It will be readily apparent to one of ordinary skill that novel VH and VL sequences can be generated by replacing one or more VH and / or VL CDR region sequences with structurally similar sequences from the CDR sequences set forth herein for the monoclonal antibodies of the invention.
[0169] Accordingly, the present disclosure provides an isolated monoclonal antibody or antigen-binding region thereof, comprising: a heavy chain CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 7, 8, 10, 41, 44, 45, 47; a heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 9, 11, 42, 46 and 48; a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 12, 43, 49; a light chain CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 17, 20, 23, 54, 57, 60; a light chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18, 21, 55, 58; and a light chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 22, 56, 59, 56; wherein the antibody specifically binds to human TREM2.
[0170] In certain embodiments, the antibody that specifically binds to human TREM2 is an antibody or antibody fragment (e.g., antigen binding fragment) described in Table 1. In some embodiments, the antibody or antigen binding region thereof that specifically binds to human TREM2 comprises: a heavy chain complementary determining region 1 (HCDR1) comprising an amino acid sequence of SEQ ID NO: 4, 7, 8, or 10; a heavy chain complementary determining region 2 (HCDR2) comprising an amino acid sequence of SEQ ID NO: 5, 9, or 11; a heavy chain complementary determining region 3 (HCDR3) comprising an amino acid sequence of SEQ ID NO: 6 or 12; a light chain complementary determining region 1 (LCDR1) comprising an amino acid sequence of SEQ ID NO: 17, 20, or 23; a light chain complementary determining region 2 (LCDR2) comprising an amino acid sequence of SEQ ID NO: 18 or 21; and a light chain complementary determining region 3 (LCDR3) comprising an amino acid sequence of SEQ ID NO: 19 or 22.
[0171] In some embodiments, an antibody or antigen-binding region thereof that specifically binds to human TREM2 comprises: a HCDR1 comprising an amino acid sequence of SEQ ID NO: 41, 44, 45 or 47; a HCDR2 comprising an amino acid sequence of SEQ ID NO: 42, 46 or 48; a HCDR3 comprising an amino acid sequence of SEQ ID NO: 43 or 49; a LCDR1 comprising an amino acid sequence of SEQ ID NO: 54, 57 or 60; a LCDR2 comprising an amino acid sequence of SEQ ID NO: 55 or 58; and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 56 or 59.
[0172] In some embodiments, the antibody or antigen binding region thereof that specifically binds to human TREM2 comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 13 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 24 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0173] In some embodiments, the antibody or antigen binding region thereof that specifically binds to human TREM2 comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 50 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 61 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0174] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 15 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO: 26 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0175] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:29 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:26 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0176] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:33 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:26 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0177] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:35 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:26 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0178] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:37 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:26 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0179] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:39 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:26 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0180] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:52 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:63 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0181] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:66 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:63 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0182] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:70 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:63 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0183] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:72 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:63 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0184] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:74 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:63 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0185] In some embodiments, an antibody that specifically binds to human TREM2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:76 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof), and a light chain comprising the amino acid sequence of SEQ ID NO:63 (or a sequence having at least about 90%, 95%, 99% or more identity thereof, and / or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications thereof).
[0186] In some embodiments, the present invention provides an antibody or antigen-binding fragment thereof that binds to the IgSF domain of a TREM2 protein with a dissociation constant (K) of: D ) Binding: less than 200 pM, for example, K D Less than 150 pM, less than 120 pM, less than 100 pM, less than 90 pM, less than 70 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, or less than 10 pM. In some preferred embodiments, the antibodies or antigen-binding fragments provided herein bind to the IgSF domain of the TREM2 protein with a dissociation constant (K) of less than 50 pM. D In some preferred embodiments, the antibodies or antigen-binding fragments provided herein bind to the IgSF domain of the TREM2 protein with a dissociation constant (K) of less than 5 pM. D )combined.
[0187] Once the desired epitope on the antigen is determined, it is possible, for example, to generate antibodies against the epitope using the technology described in the present invention. Alternatively, in the discovery process, the generation and characterization of antibodies can clarify information about the desired epitope. Based on this information, antibodies can then be competitively screened to bind to the same epitope. The method for achieving this purpose is to conduct cross-competition studies to find antibodies that competitively bind to each other, such as antibodies competing to bind to antigens. In International Patent Application No. WO 2003 / 48731, a high-throughput method for "binning" these antibodies based on the cross-competition of antibodies is described. The epitope may include those residues that the antibody binds to.
[0188] Generally, an antibody specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of proteins and / or macromolecules.
[0189] Any number of epitope mapping techniques known in the art can be used to identify regions of a given polypeptide that contain epitopes. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Volume 66 (Glenn E. Morris, ed., 1996, Humana Press, Totowa, NJ). For example, linear epitopes can be determined, for example, by simultaneously synthesizing a large number of peptides on a solid support that correspond to portions of a protein molecule and to which the peptides react with antibodies while the peptides remain attached to the support. These techniques are known in the art and are described, for example, in U.S. Pat. No. 4,708,871; Geysen et al., (1984) Proc. Natl. Acad. Sci. USA 8:3998-4002; Geysen et al., (1985) Proc. Natl. Acad. Sci. USA 82:78-182; Geysen et al., (1986) Mol. Immunol. 23:709-715. Similarly, conformational epitopes can be readily identified by determining the spatial conformation of amino acids, such as by X-ray crystallography and two-dimensional nuclear magnetic resonance. See, for example, Epitope Mapping Protocols, supra. Antigenic regions of proteins can also be identified using standard antigenicity and hydrophilicity plots, such as those calculated using, for example, the Omiga version 1.0 software program available from the Oxford Molecular Group. This computer program employs the Hopp / Woods method (Hopp et al., (1981) Proc. Natl. Acad. Sci USA [Proceedings of the National Academy of Sciences of the United States] 78:3824-3828) for determining antigenicity curves and the Kyte-Doolittle technique (Kyte et al., (1982) J. Mol. Biol. [Journal of Molecular Biology] 157:105-132) for hydrophilicity plots. In some embodiments, an anti-TREM2 antibody specifically binds to an epitope in the IgSF domain of human TREM2. For example, an anti-TREM2 antibody can specifically bind to an epitope within amino acid residues 19 to 132 of any one of SEQ ID NO: 1, 2, or 3.
[0190] The antibody molecule may be polyclonal or monoclonal. Monoclonal antibodies may be prepared by hybridoma technology or by other methods such as phage display or combinatorial methods.
[0191] Phage display and combinatorial methods for generating antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. International Publication No. WO 92 / 18619; Dower et al. International Publication No. WO 91 / 17271; Winter et al. International Publication No. WO 92 / 20791; Markland et al. International Publication No. WO 92 / 15679; Breitling et al. International Publication No. WO 93 / 01288; McCafferty et al. International Publication No. WO 92 / 01047; Garrard et al. International Publication No. WO 92 / 09690; Ladner et al. International Publication No. WO 90 / 02809; Fuchs et al. (1991) Bio / Technology 9:1370-1372; Hay et al. (1992) Hum Antibodies). Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio / Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res [Nucleic Acids Research] 19:4133-4137; and Barbas et al. (1991) PNAS [Proceedings of the National Academy of Sciences of the United States of America] 88:7978-7982).
[0192] In one embodiment, the antibody is a human antibody (e.g., an antibody prepared in a transgenic mouse that has been genetically engineered to produce antibodies from human immunoglobulin sequences), or a non-human antibody, such as a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody.
[0193] Chimeric and / or humanized antibodies can be engineered to minimize the immune response of human patients to antibodies produced in non-human subjects or antibodies derived from non-human antibody gene expression.Chimeric antibodies include non-human animal antibody variable regions and human antibody constant regions.Such antibodies retain the epitope binding specificity of the original monoclonal antibody, but may have lower immunogenicity when applied to people, and are therefore more likely to be tolerated by patients.For example, one or all (for example, one, two or three) of the variable regions of one or more light chains of a mouse antibody (for example, a mouse monoclonal antibody) and / or one or all (for example, one, two or three) of the variable regions of one or more heavy chains can each be connected to a human constant region, such as, but not limited to, IgG1 human constant region.Chimeric monoclonal antibodies can be produced by recombinant DNA techniques known in the art. For example, the gene encoding the constant region of a non-human antibody molecule can be replaced with a gene encoding a human constant region (see Robinson et al., PCT patent application PCT / US86 / 02269; Akira et al., European patent application 184,187; or Taniguchi, M., European patent application 171,496). In addition, other suitable techniques that can be used to produce chimeric antibodies are described in, for example, U.S. Patent Nos. 4,816,567, 4,978,775; 4,975,369; and 4,816,397.
[0194] Chimeric antibodies can be further "humanized" by replacing portions of the variable regions that are not involved in antigen binding with equivalent portions from human variable regions. Humanized antibodies comprise one or more human framework regions in the variable regions and non-human (e.g., mouse, rat, or hamster) complementarity determining regions (CDRs) of the heavy and / or light chains. In some embodiments, the humanized antibody comprises a fully human sequence except for the CDR regions. Relative to non-humanized antibodies, humanized antibodies are generally less immunogenic to humans, and therefore provide therapeutic benefits in some cases. Humanized TREM2 antibodies can be produced using methods known in the art. See, e.g., Hwang et al., Methods 36:35, 2005; Queen et al., Proc. Natl. Acad. Sci. USA 86:10029-10033, 1989; Jones et al., Nature 321:522-25, 1986; Riechmann et al., Nature 332:323-27, 1988; Ve Rhoeyen et al., Science 239:1534-36, 1988; Orlandi et al., Proc. Natl. Acad. Sci. USA 86:3833-3837, 1989; U.S. Patent Nos. 5,225,539; 5,530,101; 5,585,089; 5,693,761; 5,693,762; and 6,180,370; and WO 90 / 07861.
[0195] Human TREM2 antibodies can be generated using methods known in the art. For example, human engineering techniques are used to convert non-human antibodies into engineered human antibodies. U.S. Patent Publication No. 20050008625 describes an in vivo method for replacing non-human antibody variable regions with human variable regions in antibodies while maintaining the same binding characteristics relative to non-human antibodies or providing better binding characteristics. The method relies on epitope-guided replacement of the variable regions of non-human reference antibodies with fully human antibodies. The obtained human antibodies are generally structurally unrelated to the reference non-human antibodies, but bind to the same epitope on the same antigen as the reference antibody. In short, in the presence of a reporter system that responds to the binding of the test antibody to the antigen, a continuous epitope-guided complementary substitution method is achieved by establishing competition between a library of multiple hybrids of a "competitor" and a reference antibody ("test antibody") in a cell for binding to a limited amount of antigen. The competitor can be a reference antibody or a derivative thereof, such as a single-chain Fv fragment. The competitor can also be a natural or artificial ligand of an antigen that binds to the same epitope as the reference antibody. The only requirement for the competitor is that it binds to the same epitope as the reference antibody and that it competes with the reference antibody for antigen binding. The test antibody has a common antigen-binding V region from the non-human reference antibody and another V region randomly selected from a variety of sources (such as a library of human antibodies). The common V region from the reference antibody is used as a guide to position the test antibody on the same epitope on the antigen and in the same orientation, so that the selection is biased towards the highest antigen binding fidelity to the reference antibody.
[0196] Many types of reporter systems can be used to detect the required interaction between test antibodies and antigens. For example, complementary report fragments can be connected to antigens and test antibodies respectively, so that the reporter gene activation by fragment complementation occurs only when the test antibody is combined with the antigen. When test antibody and antigen report fragment fusions are co-expressed with competitors, reporter gene activation becomes dependent on the ability of test antibodies to compete with competitors, and this ability is directly proportional to the affinity of test antibodies to antigens. Other reporter systems that can be used include the reporter gene reactivation system (RAIR) disclosed in the autoinhibition disclosed in U.S. Patent Application No. 10 / 208,730 (Publication No. 20030198971) or the reactivator of the competitive activation system disclosed in U.S. Patent Application No. 10 / 076,845 (Publication No. 20030157579).
[0197] Utilize the complementary substitution system guided by continuous epitopes, select to identify cells expressing single test antibodies and competitors, antigens and reporter components. In these cells, each test antibody competes with competitors one-to-one to bind a limited amount of antigen. The activity of the reporter gene is directly proportional to the amount of the antigen bound to the test antibody, and the amount of the antigen bound to the test antibody is proportional to the affinity of the test antibody to the antigen and the stability of the test antibody. When expressed as a test antibody, the test antibody is initially selected based on its activity relative to the reference antibody. The result of the first round of selection is a group of "hybrid" antibodies, wherein each antibody is composed of the same non-human V region from the reference antibody and the people's V region from the library, and each antibody is combined with the same antigenic epitope as the reference antibody. One or more hybrid antibodies selected in the first round have an affinity to the antigen comparable to or higher than the reference antibody.
[0198] In the second V region replacement step, the human V region selected in the first step is used as a guide to select the remaining non-human reference antibody V regions for human replacement of a diverse homologous human V region library. The hybrid antibody selected in the first round can also be used as a competitor for the second round of selection. The result of the second round of selection is a group of fully human antibodies that are structurally different from the reference antibody, but compete with the reference antibody for binding to the same antigen. Some selected human antibodies bind to the same epitope on the same antigen as the reference antibody. Among these selected human antibodies, one or more bind to the same epitope with an affinity equivalent to or higher than that of the reference antibody.
[0199] In some embodiments, the present invention provides an antibody or antigen-binding fragment thereof that binds to a human TREM2 protein and promotes a TREM2-dependent physiological activity, for example, enhancing phagocytosis (e.g., in hM2A macrophages or human iPS-derived microglia-like cells, or in microglia / macrophages of the brain), enhancing the chemotaxis of human iPS-derived microglia-like cells, increasing NFAT-driven reporter gene activity in a human monocytic cell line, or increasing Syk phosphorylation in hM2A macrophages. This promotion and / or enhancement can be, for example, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0200] Engineered and modified antibodies
[0201] The antibodies of the invention can be prepared using antibodies having one or more of the VH and / or VL sequences described in Table 1 as starting materials to engineer modified antibodies that may have altered properties compared to the starting antibody. Antibodies can be engineered by modifying one or more residues within one or both variable regions (i.e., VH and / or VL), for example, within one or more CDR regions and / or within one or more framework regions. Additionally or alternatively, antibodies can be engineered by modifying residues within one or more constant regions, for example, to alter one or more effector functions of the antibody.
[0202] One type of variable region engineering that can be performed is CDR transplantation. Antibodies interact with target antigens primarily through amino acid residues located in the six heavy and light chain complementary determining regions (CDRs). Therefore, the amino acid sequences within the CDRs are more diverse between individual antibodies than the sequences outside the CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, recombinant antibodies that mimic the properties of a specific naturally occurring antibody can be expressed by constructing an expression vector comprising the CDR sequences from the specific naturally occurring antibody grafted onto framework sequences from a different antibody with different properties (see, e.g., Riechmann, L. et al., 1998 Nature 332:323-327; Jones, P. et al., 1986 Nature 321:522-525; Queen, C. et al., 1989 Proc. Natl. Acad., USA 86:10029-10033; U.S. Pat. No. 5,225,539 to Winter and U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762 and 6,180,370 to Queen et al.).
[0203] Such framework sequences can be obtained from public DNA databases or public references containing germline antibody gene sequences or rearranged antibody sequences. For example, germline DNA sequences of human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database (available on the Internet at www.mrc-cpe.cam.ac.uk / vbase), as well as in Kabat, EA, et al., 1991 Sequences of Proteins of Immunological Interest [immunology-related protein sequences], Fifth Edition, U.S. Department of Health and Human Services (USDepartment of Health and Human Services), NIH Publication No. 91-3242; Tomlinson, IM, et al., 1992 J. fol. Biol. 227: 776-798; and Cox, JPL et al., 1994 Eur. J Immunol. [European Journal of Immunology] 24: 827-836; the contents of each of which are expressly incorporated herein by reference. For example, germline DNA sequences of human heavy and light chain variable region genes and rearranged antibody sequences can be found in the "IMGT" database (available on the Internet at www.imgt.org; see Lefranc, MP et al., 1999 Nucleic Acids Res. 27:209-212); the contents of each of which are expressly incorporated herein by reference).
[0204] Examples of framework sequences for antibodies and antigen-binding fragments thereof of the present invention are those sequences that are structurally similar to the framework sequences used by the selected antibodies and antigen-binding fragments thereof of the present invention, for example, consensus sequences and / or framework sequences used by the monoclonal antibodies of the present invention. The VH CDR1, 2 and 3 sequences and the VL CDR1, 2 and 3 sequences can be transplanted onto framework regions having sequences identical to those found in germline immunoglobulin genes from which the framework sequences are derived, or the CDR sequences can be transplanted onto framework regions containing one or more mutations compared to the germline sequences. For example, it has been found that in some cases it is beneficial to mutate residues within the framework regions to maintain or enhance the antigen-binding ability of the antibody (see, for example, U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762 and 6,180,370 to Queen et al.).
[0205] Another type of variable region modification is to mutate amino acid residues within the VH and / or VL CDR1, CDR2 and / or CDR3 regions to improve one or more binding properties (e.g., affinity) of the antibody of interest, referred to as "affinity maturation". Site-directed mutagenesis or PCR-mediated mutagenesis can be performed to introduce one or more mutations, and the effect on antibody binding or other functional properties of interest can be assessed in in vitro or in vivo assays as described herein and provided in the Examples. Conservative modifications (as discussed above) can be introduced. The mutations can be amino acid substitutions, additions or deletions. In addition, typically no more than one, two, three, four or five residues are changed within the CDR regions.
[0206] A variety of antibody / immunoglobulin frameworks or scaffolds can be used, so long as the resulting polypeptide comprises at least one binding region that specifically binds TREM2. Such frameworks or scaffolds include human immunoglobulins of the five major idiotypes, antigen-binding fragments thereof, and immunoglobulins of other animal species, preferably with humanized features. In this regard, single heavy chain antibodies such as those identified in camelids are of particular interest. Those skilled in the art will continue to discover and develop new frameworks, scaffolds, and fragments.
[0207] In one aspect, the invention relates to methods for generating non-immunoglobulin-based antibodies using non-immunoglobulin scaffolds on which the CDRs of the invention can be grafted. Known or future non-immunoglobulin frameworks and scaffolds can be used as long as they contain binding regions specific for the target TREM2 protein. Known non-immunoglobulin frameworks or scaffolds include, but are not limited to, fibronectin (Compound Therapeutics, Inc., Waltham, Mass.), ankyrin (Molecular Partners AG, Zurich, Switzerland), domain antibodies (Domantis, Ltd., Cambridge, Mass., and Ablynx nv, Zwijnaarde, Belgium), lipocalin (Pieris Proteolab AG, Freising, Germany), small modular immunotherapeutics (Trubion Pharmaceuticals Inc., Seattle, Wash.), maxybodies (Avidia, Inc., Mountain View, Calif.), protein A (Affibody AG, Sweden), and affilin (γ-crystallin or ubiquitin) (SciI Proteins GmbH, Halle, Germany).
[0208] Fibronectin scaffolds are based on fibronectin type III domains (e.g., the tenth module of type III fibronectin (10Fn3 domain)). Fibronectin type III domains have 7 or 8 β chains distributed between two β sheets, which themselves wrap around each other to form the core of the protein and also contain loops (similar to CDRs) that connect the β chains to each other and are exposed to the solvent. There are at least three such loops at each edge of the β sheet sandwich, wherein the edge is the boundary of the protein perpendicular to the direction of the β chain (see U.S. Patent No. 6,818,418). These scaffolds based on fibronectin are not immunoglobulins, but the overall folding is closely related to the folding of the minimum functional antibody fragment (heavy chain variable region), which contains the complete antigen recognition unit in camel and llama IgG. Due to this structure, non-immunoglobulin antibodies mimic antigen binding properties, which are similar to those antigen binding properties of antibodies in properties and affinity. These scaffolds can be used for in vitro loop randomization and reorganization strategies, which are similar to the process of antibody affinity maturation in vivo. These fibronectin-based molecules can be used as scaffolds in which the loop regions of the molecule can be replaced with the CDRs of the invention using standard cloning techniques.
[0209] Camelid Antibodies
[0210] Antibody proteins obtained from members of the camel and dromedary (Camelus bactrianus and Calelus dromaderius) family, including New World members such as llama species (Lama paccos, Alpaca and Camelus truncatus), have been characterized with respect to size, structural complexity, and antigenicity to human subjects. Certain IgG antibodies from this family of mammals found in nature lack light chains and are therefore structurally distinct from the typical four-chain quaternary structure of antibodies from other animals, having two heavy chains and two light chains. See PCT / EP93 / 02214 (WO 94 / 04678 published March 3, 1994).
[0211] Low molecular weight antibody-derived proteins called "camelid nanobodies" are produced by genetically engineering regions of camelid antibodies, which are small single variable domains identified as VHHs, to produce small proteins with high affinity for targets. See U.S. Pat. No. 5,759,808, filed June 2, 1998; see also Stijlemans, B. et al., 2004 J Biol Chem 279:1256-1261; Dumoulin, M. et al., 2003 Nature 424:783-788; Pleschberger, M. et al., 2003 Bioconjugate Chem 14:440-448; Cortez-Retamozo, V. et al., 2002 Int J Cancer 89:456-62; and Lauwereys, M. et al., 1998 EMBO J 17:3512-3520. Engineered libraries of camelid antibodies and antibody fragments are commercially available, for example, from Ablynx, Ghent, Belgium. As with other antibodies and antigen-binding fragments thereof of non-human origin, the amino acid sequence of a camelid antibody can be recombinantly altered to obtain a sequence that more closely resembles a human sequence, i.e. a Nanobody can be "humanized". Thus, the naturally low antigenicity of camelid antibodies to humans can be further reduced.
[0212] The molecular weight of camelid nanobodies is about one-tenth that of human IgG molecules, and the physical diameter of the protein is only a few nanometers. One consequence of the small size is the ability of camelid nanobodies to bind antigenic sites that are functionally invisible to larger antibody proteins, i.e., camelid nanobodies can be used as reagents for detecting antigens that are hidden using classical immunological techniques, and can be used as possible therapeutic agents. Therefore, another consequence of the small size is that camelid nanobodies can inhibit due to binding to specific sites in grooves or narrow clefts of target proteins, and therefore can have the ability to function more closely similar to classical low molecular weight drugs than classical antibodies.
[0213] Low molecular weight and compact size also cause camelid nanobodies to be extremely heat-stable, stable to extreme pH and proteolytic digestion, and poor antigenicity. Another result is that camelid nanobodies are easily moved from the circulatory system to tissues, even through the blood-brain barrier and can treat obstacles affecting neural tissue. Nanobodies can also promote drug transport across the blood-brain barrier. Referring to U.S. Patent Application 20040161738, disclosed on August 19, 2004. These features are combined with low antigenicity to people and show huge therapeutic potential. In addition, these molecules can be fully expressed in prokaryotic cells such as Escherichia coli, and are expressed as fusion proteins with phage and are functional.
[0214] Thus, the invention features camelid antibodies or nanobodies with high affinity for TREM2. In one embodiment herein, the camelid antibody or nanobody is naturally produced in camelids, i.e., produced by camelids after immunization with TREM2 or a peptide fragment thereof using the techniques described herein for other antibodies. Alternatively, the camelid nanobody that binds to TREM2 is engineered, i.e., produced by selecting from a phage library of camelid nanobody proteins exhibiting appropriate mutagenesis using a panning procedure with TREM2 as a target as described in the examples herein. The engineered nanobodies can be further customized by genetic engineering to have a half-life of 45 minutes to two weeks in a recipient subject. In a specific embodiment, the camel antibody or nanobody is obtained by transplanting the CDR sequence of the heavy or light chain of a human antibody of the present invention into a nanobody or single domain antibody framework sequence, as described, for example, in PCT / EP 93 / 02214.
[0215] Bispecific molecules and multivalent antibodies
[0216] On the other hand, the present invention features a bispecific or multispecific molecule comprising a TREM2 binding antibody or fragment thereof of the present invention. The antibody of the present invention or its antigen binding region can be derivatized or connected to another functional molecule, such as another peptide or protein (e.g., another antibody or a ligand of a receptor), to generate a bispecific molecule that binds at least two different binding sites or target molecules. In fact, the antibody of the present invention can be derivatized or connected to more than one other functional molecule to generate a multispecific molecule that binds more than two different binding sites and / or target molecules; such multispecific molecules are also intended to be covered by the term "bispecific molecule" as used herein. In order to produce the bispecific molecules of the present invention, the antibodies of the present invention can be functionally connected (e.g., by chemical coupling, genetic fusion, non-covalent association or other means) to one or more other binding molecules, such as another antibody, antibody fragment, peptide or binding mimetic, thereby producing a bispecific molecule.
[0217] Thus, the present invention includes bispecific molecules comprising at least one first binding specificity for TREM2 and a second binding specificity for a second target epitope. For example, the second target epitope is another epitope of TREM2 that is different from the first target epitope.
[0218] Additionally, for inventions where the bispecific molecule is multispecific, the molecule may comprise a third binding specificity in addition to the first and second target epitopes.
[0219] In one embodiment, the bispecific molecules of the invention comprise at least one binding specificity of an antibody or antibody fragment thereof, including, for example, Fab, Fab', F(ab')2, Fv or single-chain Fv. The antibody may also be a light chain or heavy chain dimer or any minimal fragment thereof, such as the Fv or single-chain construct described in U.S. Pat. No. 4,946,778 to Ladner et al.
[0220] Diabodies are bivalent bispecific molecules in which the VH and VL domains are expressed on a single polypeptide chain, connected by a linker that is too short to allow pairing between the two domains on the same chain. The VH and VL domains are paired with the complementary domains of another chain, thereby producing two antigen binding sites (see, e.g., Holliger et al., 1993 Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 90: 6444-6448; Poijak et al., 1994 Structure [Structure] 2: 1121-1123). Diabodies can be produced by expressing two polypeptide chains with the structures VHA-VLB and VHB-VLA (VH-VL configuration) or VLA-VHB and VLB-VHA (VL-VH configuration) in the same cell. Most of them can be expressed in soluble form in bacteria. Single-chain diabodies (scDb) are produced by connecting two diabody-forming polypeptide chains with a linker of about 15 amino acid residues (see Holliger and Winter, 1997 Cancer Immunol. Immunother., 45(3-4): 128-30; Wu et al., 1996 Immunotechnology, 2(1): 21-36). scDb can be expressed in bacteria as a soluble, active monomer (see Holliger and Winter, 1997 Cancer Immunol. Immunother., 45(34):128-30; Wu et al., 1996 Immunotechnology, 2(1):21-36; Pluckthun and Pack, 1997 Immunotechnology, 3(2):83-105; Ridgway et al., 1996 Protein Eng., 9(7):617-21). Diabodies can be fused to Fc to generate "di-diabodies" (see Lu et al., 2004 J. Biol. Chem., 279(4):2856-65).
[0221] Other antibodies that can be used in the bispecific molecules of the invention are murine chimeric and humanized monoclonal antibodies.
[0222] The bispecific molecules of the present invention can be prepared by conjugating the component binding specificities using methods known in the art. For example, each binding specificity of the bispecific molecule can be generated separately and then conjugated to each other. When the binding specificity is a protein or peptide, a variety of coupling agents or cross-linking agents can be used for covalent conjugation. Examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-5-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) (see, e.g., Karpovsky et al., 1984 J. Exp. Med. [Journal of Experimental Medicine] 160:1686; Liu, MA et al., 1985 Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 82:8648). Other methods include those described in Paulus, 1985 Behring Ins. Mitt. 78, 118-132; Brennan et al., 1985 Science 229: 81-83) and Glennie et al., 1987 J. Immunol. 139: 2367-2375). The conjugating agents were SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL).
[0223] When the binding specificities are antibodies, they can be conjugated via sulfhydryl bonding of the C-terminal hinge regions of the two heavy chains. In specific embodiments, the hinge region is modified, for example, to contain an odd number of sulfhydryl residues prior to conjugation.
[0224] Alternatively, the two binding specificities can be encoded in the same vector and expressed and assembled in the same host cell. This method is particularly useful when the bispecific molecule is a mAb×mAb, mAb×Fab, Fab×F(ab')2, or ligand×Fab fusion protein. The bispecific molecule of the present invention can be a single-chain molecule comprising a single-chain antibody and a binding determinant, or a single-chain bispecific molecule comprising two binding determinants. The bispecific molecule may comprise at least two single-chain molecules. Methods for preparing bispecific molecules are described in, for example, U.S. Patent No. 5,260,203; U.S. Patent No. 5,455,030; U.S. Patent No. 4,881,175; U.S. Patent No. 5,132,405; U.S. Patent No. 5,091,513; U.S. Patent No. 5,476,786; U.S. Patent No. 5,013,653; U.S. Patent No. 5,258,498; and U.S. Patent No. 5,482,858.
[0225] Binding of the bispecific molecule to its specific target can be confirmed by, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (REA), FACS analysis, bioassay (e.g., growth inhibition), or Western blot assay. Each of these assays typically detects the presence of a protein-antibody complex of particular interest by using a labeled reagent (e.g., antibody) specific for the complex of interest.
[0226] On the other hand, the present invention provides multivalent compounds comprising at least two identical or different antigen binding portions of the antibodies and antigen binding fragments thereof of the present invention that bind to TREM2. The antigen binding portions can be linked together via protein fusion or covalent or non-covalent linkage. Alternatively, methods for linking bispecific molecules have been described. A tetravalent compound can be obtained, for example, by cross-linking an antibody or antigen binding fragment thereof of the present invention with an antibody or antigen binding fragment that binds to a constant region (e.g., Fc or hinge region) of an antibody and antigen binding fragment thereof of the present invention.
[0227] Trimerization domains are described, for example, in patent EP 1 012 280 B1. Pentamerization modules are described, for example, in PCT / EP 97 / 05897.
[0228] In some embodiments, the TREM2 binding molecule is a bispecific antibody that binds TREM2 and DAP12. In some embodiments, the TREM2 binding molecule is a bispecific antibody that recognizes a first antigen and a second antigen. In some embodiments, the first antigen is human TREM2 or a naturally occurring variant thereof. In some embodiments, the second antigen is human DAP12 or a naturally occurring variant thereof. In some embodiments, the second antigen is human DAP10 or Siglec (sialic acid-binding immunoglobulin-type lectin). In some embodiments, the second antigen is a pathogenic protein selected from the group consisting of amyloid beta or a fragment thereof, Tau, IAPP, alpha-synuclein, TDP-43, FUS protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, Lewy body, atrial natriuretic factor, islet amylin, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, beta 2 microglobulin, gelsolin, corneal epithelial protein, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation product, dipeptide repeat (DPR) peptide, glycine-alanine (GA) repeat peptide, glycine-proline (GP) repeat peptide, glycine-arginine (GR) repeat peptide, proline-alanine (PA) repeat peptide, and proline-arginine (PR) repeat peptide. In some embodiments, the second antigen is a blood-brain barrier targeting protein selected from transferrin receptor, insulin receptor, insulin-like growth factor receptor, LRP-1 and LRP1; or a ligand and / or protein expressed on an immune cell, wherein these ligands and / or proteins are selected from the group consisting of CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, BTLA, KIR, GAL9, TIM3, A2AR, LAG and phosphatidylserine. Alternatively, the second antigen may be a protein expressed on one or more tumor cells.
[0229] Antibodies with extended half-lives
[0230] The present invention provides antibodies that specifically bind to TREM2 and have a prolonged half-life in vivo.
[0231] Many factors may affect the half-life of proteins in vivo. For example, renal filtration, liver metabolism, proteolytic enzyme (protease) degradation and immunogenic response (e.g., neutralization of proteins by antibodies and uptake by macrophages and dendritic cells). A variety of strategies can be used to extend the half-life of the antibodies and antigen-binding fragments thereof of the present invention. For example, by chemical connection with polyethylene glycol (PEG), reCODE PEG, antibody scaffolds, polysialic acid (PSA), hydroxyethyl starch (HES), albumin binding ligands and carbohydrate shielding; by genetic fusion and transfer of proteins that bind serum proteins (such as albumin, IgG, FcRn); by coupling (genetically or chemically) with other binding moieties that bind serum proteins (such as nanobodies, Fab, DARPin, avimer, affibody and anticalin); by genetic fusion with rPEG, albumin, albumin domains, albumin binding proteins and Fc; or by incorporation into nanocarriers, sustained-release formulations or medical devices.
[0232] In order to extend the serum circulation of antibodies in vivo, inert polymer molecules (such as high molecular weight PEG) can be attached to antibodies or fragments thereof with or without multifunctional joints by site-specific conjugation of PEG to the N-terminal or C-terminal of the antibody or via the ε-amino groups present on lysine residues. In order to PEGylate the antibody, the antibody, its antigen-binding fragment and polyethylene glycol (PEG) (such as reactive esters or aldehyde derivatives of PEG) are usually reacted under the condition that one or more PEG groups are attached to the antibody or antibody fragment. Pegylation can be carried out by acylation or alkylation using reactive PEG molecules (or similar reactive water-soluble polymers). As used herein, the term "polyethylene glycol" is intended to cover any form of PEG that has been used to derivatize other proteins, such as single (C1-C10) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. In one embodiment, the antibody to be pegylated is a non-glycosylated antibody. A linear or branched polymer derivatization resulting in minimal loss of biological activity will be used. The degree of conjugation can be closely monitored by SDS-PAGE and mass spectrometry to ensure the proper conjugation of the PEG molecule to the antibody. Unreacted PEG can be separated from the antibody-PEG conjugate by size exclusion or by ion exchange chromatography. The binding activity and in vivo efficacy of the PEG-derivatized antibody can be tested using methods well known to those skilled in the art, such as by immunoassays as described herein. Methods for pegylated proteins are known in the art and can be applied to the antibodies and antigen-binding fragments thereof of the present invention. See, for example, EP 0 154 316 of Nishimura et al. and EP 0 401 384 of Ishikawa et al.
[0233] Other improved PEGylation technologies include Reconstruction Chemical Orthogonal Directed Engineering (ReCODE PEG), which incorporates chemically specified side chains into biosynthetic proteins via a reconstructed system comprising tRNA synthetase and tRNA. This technology is capable of incorporating more than 30 new amino acids into biosynthetic proteins in E. coli, yeast, and mammalian cells. tRNA incorporates canonical amino acids at any position where the amber codon is located, thereby converting the amber from a stop codon to a codon that signals the incorporation of a chemically specified amino acid.
[0234] Recombinant PEGylation technology (rPEG) can also be used to extend serum half-life. The technology generally includes fusion of 300-600 amino acid unstructured protein tails with existing drug protein genes. Because the apparent molecular weight of this unstructured protein chain is about 15 times greater than its actual molecular weight, the serum half-life of the protein is greatly increased. Contrary to the traditional PEGylation that requires chemical conjugation and repurification, the preparation process is greatly simplified and the product is uniform.
[0235] Polysialylation is another technology that utilizes the natural polymer polysialic acid (PSA) to extend the active life and improve the stability of therapeutic peptides and proteins. PSA is a polymer of sialic acid (a sugar). When used for protein and therapeutic peptide drug delivery, polysialic acid provides a protective microenvironment when conjugated. This increases the active life of the therapeutic protein in the circulation and prevents it from being recognized by the immune system. The PSA polymer occurs naturally in the human body. It is adopted by certain bacteria that have evolved over millions of years to coat their cell walls with it. These naturally polysialylated bacteria are then able to thwart the body's defense system by virtue of molecular mimicry. PSA - nature's ultimate secret technology, can be easily produced in large quantities from this bacterium and has predetermined physical characteristics. Even when coupled to proteins, bacterial PSA is completely non-immunogenic because it is chemically identical to PSA in the human body.
[0236] Another technique involves the use of hydroxyethyl starch ("HES") derivatives linked to antibodies. HES is a modified natural polymer derived from waxy corn starch and can be metabolized by the body's enzymes. HES solutions are often administered to replace deficient blood volume and improve the rheological properties of blood. Hesylation of antibodies can extend the circulation half-life by increasing the stability of the molecule and by reducing renal clearance, leading to increased biological activity. A variety of HES antibody conjugates can be customized by varying different parameters such as the molecular weight of HES.
[0237] Antibodies with increased in vivo half-life can also be generated by introducing one or more amino acid modifications (i.e., substitutions, insertions or deletions) into an IgG constant domain or an FcRn binding fragment thereof (preferably an Fc or hinge Fc domain fragment). See, e.g., International Publication No. WO 98 / 23289; International Publication No. WO 97 / 34631; and U.S. Pat. No. 6,277,375.
[0238] In addition, the antibody can be conjugated to albumin to make the antibody or antibody fragment more stable in vivo or have a longer half-life in vivo. These techniques are well known in the art, see, for example, International Publication Nos. WO 93 / 15199, WO 93 / 15200 and WO 01 / 77137; and European Patent No. EP 413,622.
[0239] The strategy of increasing half-life is particularly useful for nanobodies, fibronectin-based binders, and other antibodies or proteins for which increased in vivo half-life is desired.
[0240] Antibody conjugates
[0241] The present invention provides antibodies or antigen-binding fragments thereof, which specifically bind to the IgSF domain of human TREM2 recombinantly fused or chemically conjugated (including covalent and non-covalent conjugation) with a heterologous protein or polypeptide (or an antigen-binding fragment thereof, preferably with a polypeptide of at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 amino acids) to generate a fusion protein. In particular, the present invention provides a fusion protein comprising an antigen-binding fragment of an antibody described herein (e.g., a Fab fragment, a Fd fragment, a Fv fragment, a F(ab) fragment, or a polypeptide of at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 amino acids). 2The invention relates to antibodies or antibody fragments (VH domains, VH CDRs, VL domains or VL CDRs) and heterologous proteins, polypeptides or peptides. Methods for fusing or conjugating proteins, polypeptides or peptides to antibodies or antibody fragments are known in the art. See, e.g., U.S. Pat. Nos. 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, and 5,112,946; European Patent Nos. EP 307,434 and EP 367,166; International Publication Nos. WO 96 / 04388 and WO 91 / 06570; Ashkenazi et al., 1991, Proc. Natl. Acad. Sci. USA 88:10535-10539; Zheng et al., 1995, J. Immunol. 154:5590-5600; and Vil et al., 1992, Proc. Natl. Acad. Sci. USA 89:11337-11341.
[0242] Additional fusion proteins can be generated by the techniques of gene shuffling, motif shuffling, exon shuffling and / or codon shuffling (collectively referred to as "DNA shuffling"). DNA shuffling can be used to alter the activity of the antibodies and antigen-binding fragments thereof of the invention (e.g., antibodies and antigen-binding fragments thereof with higher affinity and lower dissociation rates). See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458; Patten et al., 1997, Curr. Opinion Biotechnol. 8:724-33; Harayama, 1998, Trends Biotechnol. 16(2):76-82; Hansson, et al., 1999, J. Mol. Biol. 287:265-76; and Lorenzo and Blasco, 1998 Biotechniques 24(2):308-313 (each of these patents and publications is hereby incorporated by reference in its entirety). Antibodies and antigen-binding fragments thereof, or encoded antibodies and antigen-binding fragments thereof, can be altered by random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. Polynucleotides encoding antibodies or antigen-binding fragments thereof that specifically bind to the IgSF region of TREM2 can be recombined with one or more components, motifs, segments, parts, domains, fragments, etc. of one or more heterologous molecules.
[0243] In addition, antibodies and Fabs thereof can be fused with marker sequences such as peptides to facilitate purification. In one embodiment, the marker amino acid sequence is a hexa-histidine peptide, such as a tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, California, 91311), etc., many of which are commercially available. As described in Gentz et al., 1989 Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 86: 821-824, for example, hexa-histidine facilitates purification of fusion proteins. Other peptide tags that can be used for purification include, but are not limited to, hemagglutinin ("HA") tags corresponding to epitopes derived from influenza hemagglutinin proteins (Wilson et al., 1984 Cell [Cell] 37: 767) and "FLAG" tags (Hopp et al., Bio / Technology [Biological / Technology] 6 (1988): 1204-1210).
[0244] In one embodiment, the antibodies and antigen-binding fragments thereof of the invention are conjugated to a diagnostic or detectable agent. Such antibodies can be used to monitor or prognose the onset, development, progression and / or severity of a disease or condition as part of a clinical trial procedure (e.g., to determine the efficacy of a particular therapy). Such diagnosis and detection can be achieved by coupling the antibody to a detectable substance, which includes but is not limited to various enzymes, such as but not limited to horseradish peroxidase, alkaline phosphatase, β-galactosidase or acetylcholinesterase; prosthetic groups, such as but not limited to streptavidin / biotin and avidin / biotin; fluorescent materials, such as but not limited to umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent materials, such as but not limited to luminol; bioluminescent materials, such as but not limited to luciferase, luciferin and aequorin; radioactive materials, such as but not limited to iodine (131I, 125I, 123I and 121I), carbon (14C), sulfur (35S), tritium (3H), indium (115In, 1 13In, 112In and 111In), technetium (99Tc), thallium (201Ti), gallium (68Ga, 67Ga), palladium (103Pd), molybdenum (99Mo), xenon (133Xe), fluorine (18F), 153Sm, 177Lu, 159Gd, 149Pm, 140La, 175Yb, 166Ho, 90Y, 47Sc, 186Re, 188Re, 142Pr, 105Rh, 97Ru, 68Ge, 57Co, 65Zn, 85Sr, 32P, 153Gd, 169Yb, 51Cr, 54Mn, 75Se, 113Sn and 117Tin; as well as positron-emitting metals and non-radioactive paramagnetic metal ions using a variety of positron emission tomography.
[0245] In addition, the antibody or its antigen-binding fragment can be conjugated with a therapeutic moiety or a drug moiety. The therapeutic moiety or drug moiety should not be construed as being limited to classical chemotherapeutic agents. For example, the drug moiety can be a protein, peptide or polypeptide having a desired biological activity. Such proteins may include, for example, toxins such as abrin, ricin A, Pseudomonas exotoxin, cholera toxin or diphtheria toxin; proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet-derived growth factor, tissue plasminogen activator, apoptotic agents, anti-angiogenic agents; or biological response modifiers such as lymphokines.
[0246] In addition, the antibody can be conjugated with a therapeutic moiety such as a radioactive metal ion (e.g., an α-emitter such as 213Bi) or a macrocyclic chelator for conjugating radioactive metal ions (including but not limited to 131In, 131LU, 131Y, 131Ho, 131Sm) to a polypeptide. In one embodiment, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), which can be attached to the antibody via a linker molecule. Such linker molecules are well known in the art and are described in Denardo et al., 1998, Clin Cancer Res. 4(10):2483-90; Peterson et al., 1999, Bioconjug. Chem. 10(4):553-7; and Zimmerman et al., 1999, Nucl. Med. Biol. 26(8):943-50, each of which is incorporated by reference in its entirety.
[0247] Techniques for conjugating therapeutic moieties to antibodies are well known, see, e.g., Amon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy," In Monoclonal Antibodies And Cancer Therapy, Reisfeld et al., (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery," In Controlled Drug Delivery (2nd ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: Thorpe," Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies 84: Biological And Clinical Applications, Pinchera et al. (eds.), 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), 303-16 (Academic Press 1985) and Thorpe et al., 1982, Immunol. Rev. 62: 119-58.
[0248] Antibodies can also be attached to solid supports, which are particularly useful for immunoassays or purification of target antigens. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
[0249] Nucleic acid encoding the antibody
[0250] Also provided herein are nucleic acids encoding antibodies or antigen-binding fragments thereof described herein. Such nucleic acids may encode polypeptides comprising segments or domains of hTREM2 antibodies or antigen-binding fragments thereof described herein. Such nucleic acids or polynucleotides may encode at least one CDR region, and generally encode all three CDR regions of the heavy chain or light chain from the hTREM2 antibodies described herein. Such nucleic acids or polynucleotides may also encode all or substantially all of the variable region sequences of the heavy chain and / or light chain of the hTREM2 antibodies described herein. Such nucleic acids or polynucleotides may also encode the variable and constant regions of antibodies. Due to the degeneracy of the genetic code, a variety of nucleic acid sequences will encode each of the immunoglobulin amino acid sequences. For example, the present invention is characterized in that the first and second nucleic acids encoding the heavy and light chain variable regions of the hTREM2 antibodies or antigen-binding fragments thereof selected from one or more antibodies disclosed herein, respectively. The nucleic acid may comprise a nucleotide sequence as listed in Table 1 or a sequence substantially identical thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto, or a sequence that differs by no more than 3, 6, 15, 30, or 45 nucleotides from a sequence shown in Table 1). The nucleic acid may comprise more than one nucleotide sequence as listed in Table 1 (e.g., a light chain variable domain sequence and a heavy chain variable domain sequence, or, for example, a light chain sequence or a heavy chain sequence) or a sequence substantially identical thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto, or a sequence that differs by no more than 3, 6, 15, 30, or 45 nucleotides from a sequence shown in Table 1).
[0251] In certain embodiments, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having an amino acid sequence as listed in Table 1, or a sequence substantially homologous thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto, and / or a sequence having one or more substitutions, e.g., conservative substitutions). In other embodiments, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having an amino acid sequence as listed in Table 1, or a sequence substantially homologous thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto, and / or a sequence having one or more substitutions, e.g., conservative substitutions). In yet another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having an amino acid sequence as listed in Table 1, or a sequence substantially homologous thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto, and / or a sequence having one or more substitutions, e.g., conservative substitutions).
[0252] In certain embodiments, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having a nucleotide sequence as listed in Table 1, or a sequence substantially homologous thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto). In another embodiment, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having a nucleotide sequence as listed in Table 1, or a sequence substantially homologous thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto). In certain embodiments, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, three, four, five or six CDRs or hypervariable loops from a heavy chain and a light chain variable region having a nucleotide sequence as listed in Table 1, or a sequence substantially homologous thereto (e.g., a sequence having at least about 85%, 90%, 95%, or 99% sequence identity thereto).
[0253] The polynucleotide sequence can be generated by de novo synthesis (e.g., solid phase DNA synthesis) or by PCR mutagenesis of an existing sequence encoding an hTREM2 antibody or antigen-binding fragment thereof. Direct chemical synthesis of nucleic acids can be accomplished by methods known in the art, such as Narang et al., 1979, Meth. Enzymol. [Methods in Enzymology] 68:90); Brown et al., Meth. Enzymol. [Methods in Enzymology] 68:109, 1979, the phosphodiester method; Beaucage et al., Tetra. Lett. [Tetrahedron Letters], 22:1859, 1981, the diethylphosphoramidite method; and the solid support method of U.S. Pat. No. 4,458,066. Introduction of mutations into a polynucleotide sequence by PCR can be performed as described, for example, in PCR Technology: Principles and Applications for DNA Amplification, HA Erlich (ed.), Freeman Press, NY, NY, 1992; PCR Protocols: A Guide to Methods and Applications, Innis et al., (eds.), Academic Press, San Diego, Calif., 1990; Mattila et al., Nucleic Acids Res. 19:967, 1991; and Eckert et al., PCR Methods and Applications 1:17, 1991.
[0254] Also provided herein is a vector (e.g., an expression vector) comprising a polynucleotide encoding a polypeptide comprising a segment or domain of an hTREM2 antibody or antigen-binding fragment thereof as described herein. Such vectors can be used to express and / or produce or affect the expression of hTREM2 antibodies or antigen-binding fragments (e.g., as described herein), for example, in vitro intracellular or in vivo intracellular expression, such as in one or more target tissues in an organism. Various expression vectors can be used to express polynucleotides encoding hTREM2 antibodies or binding fragments thereof. Both viral-based and non-viral expression vectors can be used to produce antibodies or fragments thereof in cells such as mammalian cells. Non-viral vectors and systems include plasmids, episomal vectors (typically with expression cassettes for expressing proteins or RNA), and human artificial chromosomes (see, e.g., Harrington et al., Nat Genet. [Natural Genetics] 15: 345, 1997). These non-viral vectors can be delivered to target cells using transfection or transduction methods known in the art (e.g., using lipids (e.g., liposome transfection), electroporation, mechanical cell membrane deformation, etc.). The term "expression vector" refers to a vector nucleic acid molecule into which a desired coding sequence can be inserted for introduction into a cell in which it can be expressed. A vector can be a DNA vector, an RNA vector, a plasmid, a cosmid, or a viral vector, or an artificial chromosome (see, e.g., Harrington et al., Nat Genet [Natural Genetics] 15:345, 1997). For example, non-viral vectors for expressing hTREM2 antibodies or antigen-binding fragments thereof in mammalian (e.g., human) cells include pThioHis A, B, and C; pcDNA3.1 / His; pEBVHis A, B, and C (Invitrogen, San Diego, Calif.); MPSV vectors; and many other vectors known in the art for expressing proteins. For example, one class of vectors utilizes DNA elements derived from animal viruses, such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retrovirus (Rous sarcoma virus, MMTV or MOMLV), or SV40 virus. Another class of vectors utilizes RNA elements derived from RNA viruses, such as Semliki Forest virus, Eastern Equine Encephalitis virus, and Flaviviruses.Useful viral vectors include vectors based on any of the following viruses: retroviruses (e.g., lentiviruses), lentiviruses, adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex virus (HSV)), SV40-based vectors, papillomaviruses, Epstein-Barr virus, vaccinia virus, Sinbis virus, influenza virus, reovirus, Newcastle disease virus (NDV), measles virus, vesicular stomatitis virus (VSV), parvovirus, poliovirus, poxvirus, Seneca Valley virus, coxsackie virus, enterovirus, myxoma virus, maraba virus, or Semliki Forest virus (SFV). See, Brent et al., supra; Smith, Annu. Rev. Microbiol. [Annual Review of Microbiology] 49:807, 1995; and Rosenfeld et al., Cell [Cell] 68:143, 1992.
[0255] In some embodiments, the vector is a retroviral vector. In some embodiments, the vector is a lentiviral vector. Vectors derived from retroviruses such as lentiviruses are suitable tools for achieving long-term gene transfer because they allow long-term stable integration of transgenics and their propagation in daughter cells. Lentivirus vectors have additional advantages relative to vectors derived from tumor retroviruses such as murine leukemia viruses because they can transduce non-proliferative cells, such as hepatocytes. They also have the additional advantage of low immunogenicity. Retroviral vectors can also be, for example, γ-retroviral vectors. γ-retroviral vectors can include, for example, promoters, packaging signals (ψ), primer binding sites (PBS), one or more (eg, two) long terminal repeat (LTR) sequences, and transgenics of interest (eg, genes encoding CAR). γ-retroviral vectors may lack viral structural genes (eg, gag, pol, and env). Exemplary γ-retroviral vectors include murine leukemia virus (MLV), spleen lesion virus (SFFV), and myeloproliferative sarcoma virus (MPSV), as well as vectors derived therefrom. Other gammaretroviral vectors are described, for example, in Tobias Maetzig et al., “Gammaretroviral Vectors: Biology, Technology and Application,” Viruses. 2011 Jun; 3(6): 677-713).
[0256] In some embodiments, the vector is an adeno-associated virus (AAV) vector, e.g., a recombinant AAV (rAAV) vector. "AAV" is an abbreviation for adeno-associated virus and can be used to refer to the virus itself or its derivatives. The term encompasses all subtypes and naturally occurring and recombinant forms unless otherwise required. The abbreviation "rAAV" refers to a recombinant adeno-associated virus, also referred to as a recombinant AAV vector (or "rAAV vector"). The term "AAV" includes, for example, AAV type 1 (AAV1), AAV type 2 (AAV2), AAV type 3 (AAV3), AAV type 4 (AAV4), AAV type 5 (AAV5), AAV type 6 (AAV6), AAV type 7 (AAV7), AAV type 8 (AAV8), AAV type 9 (AAV9), AAV type 10 (AAV10, including AAVrh10), AAV type 12 (AAV12), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV. "Primate AAV" refers to AAV that infects primates, "non-primate AAV" refers to AAV that infects non-primate mammals, "bovine AAV" refers to AAV that infects bovine mammals, etc.
[0257] The genomic sequences of various serotypes of AAV, as well as the sequences of the natural inverted terminal repeats (ITRs), the Rep proteins and the capsid subunits are known in the art. Such sequences can be found in the literature or in public databases such as GenBank. See, for example, GenBank accession numbers NC-002077 (AAV1), AF063497 (AAV1), NC-001401 (AAV2), AF043303 (AAV2), NC-001729 (AAV3), NC-001829 (AAV4), U89790 (AAV4), NC-006152 (AAV5), AF513851 (AAV7), AF513852 (AAV8), and NC-006261 (AAV8); or in publications such as WO 2005033321 (AAV1-9), the disclosures of which are incorporated herein by reference. See also, e.g., Srivistava et al., (1983) J. Virology 45:555; Chiorini et al., (1998) J. Virology 71:6823; Chiorini et al., (1999) J. Virology 73:1309; Bantel-Schaal et al., (1999) J. Virology 73:939; Xiao et al., (1999) J. Virology 73:943. irology [Journal of Virology] 73:3994; Muramatsu et al., (1996) Virology [Virology] 221:208; Shade et al., (1986) J. Virol. [Virology] 58:921; Gao et al., (2002) Proc. Nat. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 99:11854; Moris et al., (2004) Virology [Virology] 33:375-383; International Patent Publications WO 00 / 28061, WO99 / 61601, WO 98 / 11244; and U.S. Patent No. 6,156,303.
[0258] As used herein, "rAAV vector" refers to an AAV vector comprising a polynucleotide sequence from a non-AAV source (i.e., a polynucleotide heterologous to AAV), which is generally a sequence of interest for genetic transformation of cells. In some embodiments, the heterologous polynucleotide may be flanked by at least one (sometimes two) AAV reverse terminal repeat (ITR) sequence. The term rAAV vector includes rAAV vector particles and rAAV vector plasmids. The rAAV vector may be a single-stranded (ssAAV) or a self-complementary sequence (scAAV). "AAV virus" or "AAV virus particle" or "rAAV vector particle" refers to a virus particle composed of at least one AAV capsid protein (usually composed of all capsid proteins of one or more wild-type AAVs or capsid proteins derived from one or more wild-type AAVs) and an encapsulated polynucleotide rAAV vector. If the particle contains a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome, such as a transgene to be delivered to a mammalian cell), it is generally referred to as "rAAV vector particle" or simply "rAAV vector". Therefore, the production of rAAV particles necessarily includes the production of rAAV vectors, since such vectors are contained within the rAAV particles.
[0259] In some embodiments, the vector can be a recombinant DNA molecule comprising a nucleic acid encoding an hTREM2 antibody or an antigen-binding fragment thereof, for example as described herein. "Recombinant" as used herein means that the vector, polynucleotide, polypeptide, or cell is a clone; a restriction or ligation step; and / or the product of various combinations of other processes that result in a construct different from the product found in nature (e.g., involving a polynucleotide or polypeptide contained therein). A recombinant virus or vector is a viral particle comprising a recombinant polynucleotide. The term includes replication of the original polynucleotide construct and duplication of the original viral construct, respectively.
[0260] The recombinant vector generally includes one or more regulatory sequences operably linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include sequences that direct constitutive expression of nucleotide sequences, as well as tissue-specific regulatory and / or inducing sequences. The expression vector may also include elements designed to optimize messenger RNA stability and translatability in host cells, and / or drug selection markers for establishing permanent stable cell clones expressing hTREM2 antibodies or their antigen binding (e.g., as described herein). The design of the expression vector may depend on factors such as the following: the selection of host cells to be transformed, the expression level of the desired protein, etc. General methods for generating such recombinant expression vectors can be found in the following documents: Sambrook and Russell, ed. (2001) Molecular Cloning: A Laboratory Manual [Molecular Cloning: Laboratory Manual], 3rd edition; Ausubel et al., edited series (updated from 2007 to 2010) Current Protocols in Molecular Biology [Contemporary Molecular Biology Experiment Guide], and other methods known in the art.
[0261] Specific start signals may also be required for efficient translation of the coding sequence. These signals include the ATG start codon or adjacent sequences. It may be necessary to provide exogenous translation control signals, including the ATG start codon. One of ordinary skill in the art will be able to easily determine this and provide the necessary signals. It is well known that the start codon must be "in-frame" with the reading frame of the desired coding sequence in order to ensure translation of the entire insert. Exogenous translation control signals and start codons can be natural or synthetic. Expression efficiency can be improved by including suitable transcription enhancer elements.
[0262] Expression can use any suitable host cell known in the art, for example, mammalian host cells, bacterial host cells, yeast host cells, insect host cells, etc. Prokaryotic and eukaryotic expression systems are widely available. In certain embodiments, the expression system is mammalian cell expression, such as CHO cell expression system. In certain embodiments, nucleic acid can be codon optimized to promote expression in desired host cells. It is important to use promoters and / or enhancers that effectively guide the expression of DNA segments in cell types, organelles, and organisms selected for expression. Technicians in the field of molecular biology generally know the uses of promoters, enhancers, and cell type combinations for protein expression, for example, referring to Sambrook et al., (2001).
[0263] Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcript. Vectors containing genomic eukaryotic sequences may require donor and / or acceptor splice sites to ensure correct processing of transcripts for protein expression (see Chandler et al., 1997, Proc. Natl. Acad. Sci. USA, 94(8):3596-601).
[0264] The vector or construct of the present disclosure generally comprises at least one termination signal." termination signal " or " terminator " is comprised of the DNA sequence that participates in RNA polymerase specific termination RNA transcript. Therefore, in certain embodiments, the termination signal that terminates RNA transcript generation is considered. In vivo, terminator may be needed to reach required information level. In eukaryotic systems, terminator region can also comprise specific DNA sequence, and this sequence allows site-specific cutting of new transcript, thereby exposing polyadenylation site. This represents that specialized endogenous polymerase adds a section of about 200A residues (poly A) at the 3 ' end of transcript. RNA molecules modified with this poly A tail seem to be more stable and more effectively translated. Therefore, in other embodiments relating to eukaryotic organisms, preferably terminator comprises the signal for cutting RNA, and more preferably terminator signal promotes the polyadenylation of information. Terminator and / or polyadenylation site element can be used to enhance information level and / or minimize the reading from box to other sequences. Terminators contemplated for use in the present disclosure include any known transcription terminators described herein or known to those of ordinary skill in the art, including, but not limited to, for example, termination sequences of genes (e.g., such as bovine growth hormone terminators) or viral terminators (e.g., SV40 terminators). In certain embodiments, the termination signal may be a lack of a transcribable or translatable sequence, such as due to sequence truncation.
[0265] In expression, particularly eukaryotic expression, a polyadenylation signal will generally be included to achieve proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be critical to the successful practice of the present disclosure, and / or any such sequence may be employed. Preferred embodiments include the SV40 polyadenylation signal and / or the bovine growth hormone polyadenylation signal, which are convenient and / or known to work well in a variety of target cells. Polyadenylation may increase the stability of the transcript or may promote cytoplasmic transport.
[0266] In order to propagate the vector in the host cell, it may contain one or more replication site origins (commonly referred to as "ori"), which are specific nucleic acid sequences at which replication is initiated. Alternatively, if the host cell is yeast, an autonomous replication sequence (ARS) may be used.
[0267] In certain embodiments of the present disclosure, cells containing nucleic acid constructs of the present disclosure can be identified in vitro or in vivo by including a marker in an expression vector. Such markers will confer identifiable changes to the cells, thereby allowing cells containing the expression vector to be easily identified. Typically, a selectable marker is a marker that confers a property that allows selection. A positive selectable marker is a marker in which the presence of the marker allows its selection, while a negative selectable marker is a marker in which the presence of the marker prevents its selection. An example of a positive selectable marker is a drug resistance marker.
[0268] Typically, comprising a drug selection marker helps to clone and identify transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, bleomycin and histidinol are useful selection markers. In addition to conferring markers that allow the phenotype of transformants to be distinguished based on conditional implementation, other types of markers are also contemplated, including screenable markers (e.g., GFP), which are based on colorimetric analysis. Alternatively, screenable enzymes such as thymidine kinase (HSV-tk) or chloramphenicol acetyltransferase (CAT) of herpes simplex virus can be used. Those skilled in the art will also know how to use immune markers in conjunction with FACS analysis. The marker used is not considered important as long as it can be expressed simultaneously with the nucleic acid encoding the gene product. Other examples of selectable and screenable markers are well known to those skilled in the art.
[0269] The choice of expression vector depends on the intended cell in which one or more components of the vector are to be expressed. Typically, the vector contains one or more regulatory sequences, such as a promoter and other regulatory sequences (e.g., enhancers), which are operably linked to a polynucleotide encoding an hTREM2 antibody or antigen-binding fragment thereof.
[0270] A "promoter" is a control sequence that is a region of a nucleic acid sequence that controls the initiation and rate of transcription. It may contain genetic elements on which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases "operably positioned," "operably linked," "controlled," and "under transcriptional control" mean that the promoter is in the correct functional position and / or orientation relative to the nucleic acid sequence to control the initiation of transcription and / or the expression of the sequence. The promoter may be used in conjunction with or without an "enhancer," which refers to a cis-acting regulatory sequence that participates in the transcriptional activation of a nucleic acid sequence.
[0271] The promoter can be a promoter naturally associated with a gene or sequence, such as can be obtained by isolating a 5' non-coding sequence located upstream of a coding segment and / or exon. Such a promoter can be referred to as "endogenous". Similarly, an enhancer can be an enhancer naturally associated with a nucleic acid sequence, located downstream or upstream of the sequence. Alternatively, certain advantages will be obtained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not usually associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer also refers to an enhancer that is not usually associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers can include promoters or enhancers of other genes, as well as promoters or enhancers isolated from any other prokaryotic, viral or eukaryotic cells, and non-"naturally occurring" promoters or enhancers, i.e., different elements containing different transcriptional regulatory regions and / or mutations that change expression. In addition to synthetically producing nucleic acid sequences of promoters and enhancers, sequences can be produced using recombinant cloning and / or nucleic acid amplification techniques (e.g., PCR) in conjunction with compositions disclosed herein (see US 4683202, US 5928906). In addition, it is contemplated that control sequences for directing transcription and / or sequence expression in non-nuclear organelles (e.g., mitochondria, chloroplasts, etc.) can also be used.
[0272] The promoter used may be constitutive, inducible, synthetic, tissue or cell specific, and / or useful under appropriate conditions to direct high-level expression of the introduced DNA segment, for example, to facilitate large-scale production of recombinant proteins and / or peptides. In addition, other regulatory elements may be incorporated to improve expression of nucleic acids encoding antibodies that bind to human TREM2 protein (i.e., hTREM2), such as enhancers, ribosome binding sites, transcription termination sequences, and the like.
[0273] In some embodiments, a constitutive promoter is used to provide constant expression of the hTREM2 antibody or antigen-binding fragment thereof. Examples of constitutive promoters include, but are not limited to, immediate early cytomegalovirus (CMV) promoter, simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV) promoter, human immunodeficiency virus (HIV) long terminal repeat (LTR) sequence promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, elongation factor-1α promoter, hemoglobin promoter, and creatine kinase promoter.
[0274] In one embodiment, in addition to the inducing conditions, an inducible promoter is used to prevent the expression of the inserted sequence. The use of an inducible promoter provides a molecular switch that can turn on the expression of the polynucleotide sequence to which the promoter is operably linked when such expression is desired, or turn off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to, metallothionein promoters, a.
[0275] Inducible promoters include, but are not limited to, for example, an arabinose promoter, a lacZ promoter, a tetracycline promoter, a metallothionein promoter, a glucocorticoid promoter, a progesterone promoter, or a heat shock promoter.
[0276] In addition to the promoter, other regulatory elements may be required or desired to effectively express the hTREM2 antibody or its antigen-binding fragment. These elements include the ATG start codon and adjacent ribosome binding sites or other sequences. In addition, the expression efficiency can be improved by including an enhancer suitable for the cell system in use (see, for example, Scharf et al., Results Probl. Cell Differ. [Results and Problems in Cell Differentiation] 20: 125, 1994; and Bittner et al., Meth. Enzymol. [Enzymology Methods], 153: 516, 1987). For example, the SV40 enhancer or the CMV enhancer can be used to increase expression in mammalian host cells.
[0277] In some embodiments, tissue or cell-specific promoters are used to provide expression of hTREM2 antibodies or antigen-binding fragments thereof only in specific tissues or cells. The properties of tissue or cell-specific promoters or elements and assays to characterize their activity are well known to those skilled in the art. Examples include human LIMK2 gene (Nomoto et al., 1999, Gene, 236(2):259-271), somatostatin receptor 2 gene (Kraus et al., 1998, FEES Lett. [FEES Express], 428(3):165-170), murine epididymal retinoic acid-binding gene (Lareyre et al., 1999, J. Biol. Chem. [Journal of Biological Chemistry], 274(12):8282-8290), human CD4 (Zhao-Emonet et al., 1998, Biochirn. Biophys. Acta [Journal of Biochemistry and Biophysics], 1442(2-3):109-119), mouse α2(XI) collagen (Tsumaki, et al., 1998, J. Biol. Chem. [Journal of Biological Chemistry], 273(36):22861-2286 4), D1A dopamine receptor gene (Lee, et al., 1997, J. Auton. Nerv. Syst., 74(2-3):86-90), insulin-like growth factor II (Wu et al., 1997, Biochem. Biophys. Res. Commun., 233(1):221-226), human platelet endothelial cell adhesion molecule-1 (Almendro et al., 1996, J. Immunol., 157(12):5411-5421), muscle creatine kinase (MCK) promoter (Wang et al., Gene Ther. 2008 Nov;15(22):1489-99).
[0278] In some embodiments, synthetic promoters are used to provide expression of hTREM2 antibodies or antigen-binding fragments thereof. Synthetic promoters can significantly exceed the transcriptional efficiency of natural promoters. For example, synthetic promoters that are not shut down or reduced in activity by endogenous cellular machinery or factors can be selected. Other elements (including trans-acting factor binding sites and enhancers) can be inserted into synthetic promoters to improve transcription efficiency. Synthetic promoters can be rationally designed and chemically synthesized to combine the best features of synthetic and biological promoters. The synthetic oligonucleotides are annealed and connected through several processes to produce a full-length chemically synthesized promoter. Synthetic promoters can be inducible or cell-type specific promoters.
[0279] In preferred embodiments, the vector is an adeno-associated vector (AAV). In embodiments, the AAV vector comprises a polynucleotide encoding an hTREM2 antibody or an antigen-binding fragment thereof (e.g., as described herein). In typical embodiments, the AAV vector comprises a polynucleotide encoding an hTREM2 antibody or an antigen-binding fragment thereof, which is flanked on one or both sides by an inverted terminal repeat (ITR) sequence. The polynucleotide may additionally comprise one or more additional elements, such as a promoter, an enhancer, one or more intron sequences, poly (A) sequences, and combinations thereof. In some embodiments, the vector comprises a polynucleotide AAV vector plasmid comprising a polynucleotide encoding an hTREM2 antibody or an antigen-binding fragment thereof (e.g., as described herein) encapsulated in an AAV capsid.
[0280] In some embodiments, the vector comprises a polynucleotide encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein) operably linked to a regulatory sequence (e.g., a promoter) that is compatible with at least one target cell.
[0281] In some embodiments, the ITRs in the AAV vectors are derived from the same AAV serotype. In some embodiments, the ITRs in the AAV vectors are derived from different AAV serotypes. In some embodiments, the ITRs in the AAV particles are the same. In embodiments, the ITRs in the AAV particles are different.
[0282] In some embodiments, the ITRs in the AAV vector are derived from the same AAV serotype as the AAV capsid. In embodiments, the ITRs in the AAV vector are derived from a serotype different from the serotype of the AAV capsid. In one embodiment, the ITRs are derived from AAV2, and the AAV capsid is derived from a serotype other than AAV2, such as AAV9.
[0283] The expression vector can also provide a secretion signal sequence position to form a fusion protein with the polypeptide encoded by the inserted hTREM2 antibody or its antigen-binding fragment sequence. More commonly, the inserted hTREM2 antibody or its antigen-binding fragment sequence is connected to the signal sequence before being included in the vector. The vector used to receive the sequence encoding the hTREM2 antibody light chain and heavy chain variable domains sometimes also encodes the constant region or part thereof. Such a vector allows the variable region to be expressed as a fusion protein with a constant region, thereby resulting in the production of a complete antibody and its antigen-binding fragment. Typically, such constant regions are human.
[0284] Expression vectors can be produced using vectors containing a multiple cloning site (MCS), which is a region of nucleic acid containing multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant techniques to digest the vector. See Carbonelli et al., 1999, Levenson et al., 1998, and Cocea, 1997. "Restriction endonuclease digestion" refers to the catalytic cleavage of a nucleic acid molecule with an enzyme that acts only at a specific position in a nucleic acid molecule. Many of these restriction endonucleases are commercially available. The use of these enzymes is widely understood by those skilled in the art. Typically, a restriction endonuclease that cuts within the MCS is used to linearize or fragment a vector so that an exogenous sequence is connected to the vector. "Connection" refers to the process of forming a phosphodiester bond between two nucleic acid fragments that may or may not be adjacent to each other. Techniques involving restriction endonucleases and ligation reactions are well known to those skilled in the art of recombinant technology.
[0285] The method for introducing the expression vector containing the target polynucleotide sequence varies according to the type of cell host.For example, calcium chloride transfection is generally used for prokaryotic cells, and calcium phosphate treatment or electroporation can be used for other cell hosts (generally referring to Sambrook et al., the same).Other methods include, for example, electroporation, calcium phosphate treatment, liposome-mediated conversion, injection and microinjection, impact method / gene gun, virion, immunoliposome, polycation: nucleic acid conjugate, naked DNA, artificial virion, fusion with herpes virus structural protein VP22, DNA uptake enhanced by medicament, in vitro transduction, protoplast fusion, reverse transcription transduction, viral transfection, transfection based on lipid or other conventional techniques.In the case of protoplast fusion, cells are grown in culture medium and screened for appropriate activity.For the long-term high-yield production of recombinant proteins, stable expression is generally desired.For example, expression vectors containing viral replication origin or endogenous expression elements and selectable marker genes can be used to prepare cell lines for stably expressing polypeptides.After introducing the vector, cells can be grown in enriched medium for 1-2 days, and then they are converted to selective medium. The purpose of the selective marker is to confer resistance to selection, and its presence allows the growth of cells that successfully express the introduced sequence in a selective medium. Tissue culture techniques appropriate to the cell type can be used to propagate resistant, stably transfected cells. Methods and conditions for culturing the resulting transfected cells and recovering the produced antibodies are known to those skilled in the art and can be altered or optimized based on the specific expression vectors and mammalian host cells used in this specification.
[0286] Also provided herein are cells comprising any of the expression vectors described herein. In certain embodiments, the disclosure is characterized in that the host cells comprise the nucleic acid molecules described herein. These cells can be host cells or therapeutic cells. The terms "host cell" and "recombinant host cell" are used interchangeably herein to refer not only to specific subject cells, but also to the offspring or potential offspring of such cells. Because some changes may occur in offspring due to mutations or environmental influences, such offspring may in fact be different from the parental cell, but are still included within the scope of the term as used herein.
[0287] In one embodiment, the host cells are genetically engineered to contain a nucleic acid encoding an hTREM2 antibody or antigen-binding fragment thereof. In one embodiment, the host cells are genetically engineered by using an expression cassette. The phrase "expression cassette" refers to a nucleotide sequence that is capable of affecting the expression of a gene in a host that is compatible with such a sequence. Such a cassette may include a promoter, an open reading frame with or without introns, and a termination signal. Other factors that are necessary or helpful in achieving expression, such as an inducible promoter, may also be used.
[0288] Host cells for containing and expressing the chains of hTREM2 antibodies or antigen-binding fragments thereof may be, but are not limited to, eukaryotic cells or prokaryotic cells, such as bacterial cells, insect cells, or human cells. Escherichia coli is a prokaryotic host that can be used to clone and express the polynucleotides of the present invention. Other microbial hosts suitable for use include Bacillus (such as Bacillus subtilis) and other Enterobacteriaceae (such as Salmonella, Serratia) and various species of Pseudomonas. In these prokaryotic hosts, expression vectors can also be prepared, which generally contain expression control sequences (e.g., origins of replication) that are compatible with the host cells. In addition, there will be any number of various well-known promoters, such as lactose promoter systems, tryptophan (trp) promoter systems, beta-lactamase promoter systems, or promoter systems from bacteriophage lambda. Promoters typically optionally use an operator sequence to control expression, and have a ribosome binding site sequence, etc., for initiating and completing transcription and translation. Other microorganisms such as yeast can also be used to express the hTREM2 antibodies or antigen-binding fragments thereof of the present invention. Insect cells in combination with baculovirus vectors can also be used. Suitable insect cells include, but are not limited to Sf9 cells.
[0289] In one embodiment, mammalian host cells are used to express and produce the hTREM2 antibodies or antigen-binding fragments thereof of the present invention. For example, they can be hybridoma cell lines expressing endogenous immunoglobulin genes (e.g., 1D6.C9 myeloma hybridoma cells) or mammalian cell lines containing exogenous expression vectors (e.g., SP2 / 0 myeloma cells). These include any normal mortal or normal or abnormal immortal animal or human cells. For example, many suitable host cell lines capable of secreting complete immunoglobulins have been developed, including CHO cell lines, various Cos cell lines, HeLa cells, myeloma cell lines, transformed B cells and hybridomas. The use of mammalian tissue cell culture to express polypeptides is generally discussed in, for example, Winnacker, FROM GENES TO CLONES [from genes to clones], VCH Publishers, New York, New York, 1987. Expression vectors for mammalian host cells may include expression control sequences such as origins of replication, promoters and enhancers (see, e.g., Queen, et al., Immunol. Rev. [Immunology Review] 89: 49-68, 1986) and necessary processing information sites such as ribosome binding sites, RNA splicing sites, polyadenylation sites and transcription terminator sequences. These expression vectors typically contain promoters derived from mammalian genes or derived from mammalian viruses. Suitable promoters may be constitutive, cell type specific, stage specific and / or regulatable or adjustable. Useful promoters include, but are not limited to, metallothionein promoters, constitutive adenovirus major late promoters, dexamethasone-inducible MMTV promoters, SV40 promoters, MRP pol III promoters, constitutive MPSV promoters, tetracycline-inducible CMV promoters (e.g., human early CMV promoters), constitutive CMV promoters and promoter-enhancer combinations known in the art.
[0290] Host cells can be used to produce or express antibodies that bind to human TREM2 protein (i.e., hTREM2). Therefore, the present disclosure is also characterized by a method for producing hTREM2 antibodies or antigen-binding fragments thereof using host cells. In one embodiment, the method includes culturing host cells (in which a recombinant expression vector encoding an antibody has been introduced) in a suitable culture medium to produce hTREM2 antibodies or antigen-binding fragments thereof. In another embodiment, the method further includes isolating antibodies from the culture medium or host cells. Suitable eukaryotic cells include, but are not limited to, Vero cells, HeLa cells, COS cells, CHO cells, HEK293 cells, BHK cells, and MDCKII cells. The method for introducing an expression vector containing a polynucleotide sequence of interest varies depending on the type of cell host. For example, calcium chloride transfection is commonly used for prokaryotic cells, while calcium phosphate treatment or electroporation can be used for other cell hosts. (See generally Sambrook et al., supra). Other methods include, for example, electroporation, calcium phosphate treatment, liposome-mediated transformation, injection and microinjection, impact methods, virosomes, immunoliposomes, polycationic nucleic acid conjugates, naked DNA, artificial virus particles, fusions with herpes virus structural protein VP22 (Elliot and O'Hare, Cell [Cell] 88: 223, 1997), agent-enhanced DNA uptake and in vitro transduction. For long-term, high-yield production of recombinant proteins, stable expression is generally desired. For example, expression vectors of the present invention containing viral origins of replication or endogenous expression elements and selective marker genes can be used to prepare cell lines that stably express hTREM2 antibody chains or antigen-binding fragments. After the introduction of the vector, the cells can be grown in an enriched medium for 1-2 days and then switched to a selective medium. The purpose of the selective marker is to confer resistance to selection, and its presence allows the growth of cells that successfully express the introduced sequence in a selective medium. Resistant, stably transfected cells can be proliferated using tissue culture techniques appropriate to the cell type.
[0291] Adjustment sequence
[0292] One skilled in the art will recognize that expression of one or more components of the vector in a target cell may require regulatory sequences.
[0293] In one embodiment, the AAV vector plasmid comprises regulatory sequences effective for expressing an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein).
[0294] In one embodiment, the AAV vector plasmid comprises regulatory sequences effective to drive expression in the targeted cells.
[0295] In one embodiment, the AAV vector plasmid comprises a regulatory sequence, such as, but not limited to, a promoter. As non-limiting examples, the promoter can be (1) a CMV promoter, (2) a CBA promoter, (3) a FRDA or FXN promoter, (4) a UBC promoter, (5) a GUSB promoter, (6) a NSE promoter, (7) a synapsin promoter, (8) a MeCP2 promoter, (9) a GFAP promoter, (10) a HI promoter, (11) a U6 promoter, (12) a NFL promoter, (13) a NFH promoter, (14) a SCN8A promoter, or (15) a PGK promoter.
[0296] Promoter
[0297] One skilled in the art will recognize that expression of hTREM2 antibodies or antigen-binding fragments thereof (e.g., as described herein) in target cells may require specific promoters, including but not limited to species-specific promoters, inducible promoters, tissue-specific promoters, or cell cycle-specific promoters (Parr et al., Nat. Med. 3: 1145-9 (1997); the contents of which are incorporated herein by reference in their entirety).
[0298] In one embodiment, the AAV vector plasmid comprises a promoter effective for expressing an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein).
[0299] In one embodiment, the AAV vector plasmid comprises a promoter effective to drive expression in the targeted cells.
[0300] In one embodiment, the promoter provides for expression of an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein) in a target tissue (e.g., but not limited to, nervous system tissue) for a period of time. Expression of a hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein) can be sustained for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 3 weeks, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months , 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 2 1 year, 22 years, 23 years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years, 30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36 years, 37 years, 38 years, 39 years, 40 years, 41 years, 42 years, 43 years, 44 years, 45 years, 46 years, 47 years, 48 years, 49 years, 50 years, 55 years, 60 years, 65 years, or more than 65 years. Expression of the hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein) can persist for 1-5 hours, 1-12 hours, 1-2 days, 1-5 days, 1-2 weeks, 1-3 weeks, 1-4 weeks, 1-2 months, 1-4 months, 1-6 months, 2-6 months, 3-6 months, 3-9 months, 4-8 months, 6-12 months, 1-2 years, 1-5 years, 2-5 years, 3-6 years, 3-8 years, 4-8 years, or 5-10 years or 10-15 years, or 15-20 years, or 20-25 years, or 25-30 years, or 30-35 years, or 35-40 years, or 40-45 years, or 45-50 years, or 50-55 years, or 55-60 years, or 60-65 years.
[0301] In one embodiment, the AAV vector plasmid comprises a region approximately 5 kb upstream of the first exon of an encoded hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein); more specifically, there is a 17-bp region approximately 4.9 kb upstream of the first exon of the encoded frataxin gene to allow expression with the FRDA promoter (see, e.g., Puspasari et al. Long Range Regulation of Human FXN Gene Expression, PLOS ONE, 2011; the contents of which are incorporated herein by reference in their entirety).
[0302] In one embodiment, the promoter is less than 1 kb. The promoter may have 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, , 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 or a length greater than 800. The promoter may have a length of between 200-300, 200-400, 200-500, 200-600, 200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800, or 700-800.
[0303] In one embodiment, the promoter can be a combination of two or more components, regions or sequences of the same or different promoters (such as but not limited to CMV and CBA). Each component can have 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 701 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 or more in length. Each component can have a length of between 200-300, 200-400, 200-500, 200-600, 200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800, or 700-800.
[0304] In one embodiment, the promoter is a combination of a CMV enhancer sequence (e.g., an immediate / early CMV enhancer sequence (e.g., a 382-nucleotide CMV-enhancer sequence)) and a chicken β-actin (CBA)-promoter sequence (e.g., a 260-nucleotide CBA promoter sequence).
[0305] In one embodiment, the promoter is a combination of a 280-nucleotide fragment of the CMV enhancer sequence and a 266-nucleotide fragment of the chicken β-actin (CBA)-promoter sequence. In some embodiments, the CMV enhancer sequence comprises, for example, consists of: cgttacat aacttacggt aaatggcccg cctggctgac cgcccaacgacccccgcccattgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggactttccattgacgtcaatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagtgtatcatatgccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgcctggcattatgcccagtacatgacct tatgggactt tcctacttgg cagtacatct ac
[0306] (SEQ ID NO:134)
[0307] In some embodiments, the CBA promoter sequence comprises, e.g., consists of, cc acgttctgcttcactctccc catctccccc ccctccccac ccccaatttt gtatttatttatttttttaat tattttgtgcagcgatgggg gcgggggggg ggggggggcg cgcgccaggcggggcggggc ggggcgaggg gcggggcggggcgaggcgga gaggtgcggc ggcagccaatcagagcggcg cgctccgaaa gtttcctttt atggcgaggcggcggcggcg gcggccctataaaaagcgaa gcgcgcggcg ggcg
[0308] (SEQ ID NO:135)
[0309] In one embodiment, the AAV vector comprises a hybrid CMV enhancer / chicken β-actin promoter comprising, e.g., consisting of:
[0310] cgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga cccccgccca
[0311] ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt ccattgacgt
[0312] caatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagt gtatcatatg
[0313] ccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag
[0314] tacatgacct tatgggactt tcctacttgg cagtacatct actcgaggcc acgttctgct
[0315] tcactctccc catctccccc ccctccccac ccccaatttt gtatttattt attttttaat
[0316] tattttgtgc agcgatgggg gcgggggggg ggggggggcg cgcgccaggc ggggcggggc
[0317] ggggcgaggg gcggggcggg gcgaggcgga gaggtgcggc ggcagccaat cagagcggcg
[0318] cgctccgaaa gtttcctttt atggcgaggc ggcggcggcg gcggccctat aaaaagcgaa
[0319] gcgcgcggcg ggcg
[0320] (SEQ ID NO:136)
[0321] In one embodiment, the AAV vector plasmid comprises a ubiquitous promoter. Non-limiting examples of ubiquitous promoters include CMV, CBA (including derivatives CAG, CBh, etc.), EF-1a, PGK, UBC, GUSB (hGBp) and UCOE (promoter of HNRPA2B1-CBX3). In one embodiment, any promoter taught by Yu, Soderblom, Gill, Husain, Passini, Xu, Drews or Raymond can be used in the present invention. Yu et al. (Molecular Pain 2011, 7: 63; the contents of which are incorporated herein by reference in their entirety) evaluated the expression of eGFP under CAG, EF-1a, PGK and UBC promoters in rat DRG cells and primary DRG cells using lentiviral vectors and found that UBC showed weaker expression than the other three promoters, and only 10%-12% of glial expression was observed for all promoters.
[0322] Soderblom et al. (E. Neuro 2015; the contents of which are incorporated herein by reference in their entirety) evaluated the expression of eGFP in AAV8 with CMV and UBC promoters and in AAV2 with CMV promoter after injection in the motor cortex. Intranasal administration of plasmids containing UBC or EF-1a promoters showed sustained airway expression greater than expression with CMV promoter (see, e.g., Gill et al., Gene Therapy 2001, Vol. 8, 1539-1546; the contents of which are incorporated herein by reference in their entirety). Husain et al. (Gene Therapy 2009; the contents of which are incorporated herein by reference in their entirety) evaluated HβH constructs with hGUSB promoter, HSV-1LAT promoter, and NSE promoter, and found that the HβH construct showed weaker expression than NSE in mouse brain. Passini and Wolfe (J. Virol. 2001, 12382-12392, the contents of which are incorporated herein by reference in their entirety) evaluated the long-term effects of HβH vectors after intracerebroventricular injection in neonatal mice and found that expression persisted for at least 1 year. Xu et al. found low expression in all large regions when using NF-Land NF-H compared to CMV-lacZ, CMV-luc, EF, GFAP, hENK, nAChR, PPE, PPE+wpre, NSE (0.3 kb), NSE (1.8 kb) and NSE (1.8 kb+wpre) (Gene Therapy 2001, 8, 1323-1332; the contents of which are incorporated herein by reference in their entirety). Xu et al. found that the promoter activity was NSE (1.8 kb), EF, NSE (0.3 kb), GFAP, CMV, hENK, PPE, NFL and NFH in descending order. NFL is a 650 nucleotide promoter and NFH is a 920 nucleotide promoter, neither of which is present in the liver, but NFH is abundant in sensory proprioceptive neurons, brain and spinal cord, and NFH is present in the heart.SCN8A is a 470 nucleotide promoter that is expressed throughout the DRG, spinal cord, and brain, with particularly high expression in hippocampal neurons and cerebellar Purkinje cells, cortex, thalamus, and hypothalamus (see, e.g., Drews et al., Identification of evolutionary conserved, functional noncoding elements in the promoter region of the sodium channel gene SCN8A, Mamm Genome (2007) 18:723-731; and Raymond et al., Expression of Alternatively Spliced Sodium Channel a-subunit genes, Journal of Biological Chemistry (2004) 279(44)46234-4624; the contents of each of which are incorporated herein by reference in their entirety).
[0323] In one embodiment, the AAV vector plasmid comprises a non-cell-specific promoter. In one embodiment, the promoter is a weak promoter (classified by its affinity and other promoter affinities for RNA polymerase and / or sigma factor) for sustained expression of hTREM2 antibodies or antigen-binding fragments thereof (e.g., as described herein) in neural tissue. In one embodiment, the promoter is a weak promoter for sustained expression of frataxin in nervous system tissues (e.g., but not limited to, neuronal tissue and glial tissue).
[0324] In one embodiment, the AAV vector plasmid comprises a Friedreich's ataxia (FRDA) promoter.
[0325] In one embodiment, the AAV vector plasmid comprises a ubiquitin c (UBC) promoter. The UBC promoter may have a size of 300-350 nucleotides. As a non-limiting example, the UBC promoter is 332 nucleotides.
[0326] In one embodiment, the AAV vector plasmid comprises a β-glucuronidase (GUSB) promoter. The GUSB promoter may have a size of 350-400 nucleotides. As a non-limiting example, the GUSB promoter is 378 nucleotides. As a non-limiting example, the AAV vector plasmid may be 5'-promoter-CMV / globin intron-hFXN-RBG-3', wherein the AAV vector plasmid may be self-complementary, and the capsid may be a DJ serotype.
[0327] In one embodiment, the AAV vector plasmid comprises a neurofilament (NFL) promoter. The NFL promoter may have a size of 600-700 nucleotides. As a non-limiting example, the NFL promoter is 650 nucleotides. As a non-limiting example, the AAV vector plasmid may be 5'-promoter-CMV / globin intron-hFXN-RBG-3, wherein the AAV vector plasmid may be self-complementary and the capsid may be a DJ serotype.
[0328] In one embodiment, the AAV vector plasmid comprises a neurofilament heavy (NFH) promoter. The NFH promoter may have a size of 900-950 nucleotides. As a non-limiting example, the NFH promoter is 920 nucleotides. As a non-limiting example, the AAV vector plasmid may be 5'-promoter-CMV / globin intron-hFXN-RBG-3', wherein the AAV vector plasmid may be self-complementary and the capsid may be a DJ serotype.
[0329] In one embodiment, the AAV vector plasmid comprises a SCN8A promoter. The SCN8A promoter may have a size of 450-500 nucleotides. As a non-limiting example, the SCN8A promoter is 470 nucleotides. As a non-limiting example, the AAV vector plasmid may be d'-promoter-CMV / globin intron-hFXN-RBG-3, wherein the AAV vector plasmid may be self-complementary, and the capsid may be a DJ serotype.
[0330] In one embodiment, the AAV vector plasmid comprises a frataxin (FXN) promoter.
[0331] In one embodiment, the AAV vector plasmid comprises a phosphoglycerate kinase 1 (PGK) promoter.
[0332] In one embodiment, the AAV vector plasmid comprises a chicken β-actin (CBA) promoter.
[0333] In one embodiment, the AAV vector plasmid comprises an immediate early cytomegalovirus (CMV) promoter.
[0334] In one embodiment, the AAV vector plasmid comprises an H1 promoter.
[0335] In one embodiment, the AAV vector plasmid comprises a U6 promoter.
[0336] In one embodiment, the AAV vector plasmid comprises a liver or skeletal muscle promoter. Non-limiting examples of liver promoters include hAAT and TBG. Non-limiting examples of skeletal muscle promoters include Desmin, MCK, and C5-12.
[0337] In one embodiment, the AAV vector plasmid comprises an engineered promoter, eg, a promoter derived from but not identical to the promoters described herein.
[0338] Reinforcement components
[0339] In one embodiment, the AAV vector plasmid may include at least one enhancer and / or expression element. The enhancer or expression element may be used in combination with a regulatory sequence (e.g., a promoter). In one embodiment, the AAV vector plasmid includes a transgenic enhancer, a promoter, and / or a 5'UTR intron. The transgenic enhancer, also referred to herein as an "enhancer," may be, but is not limited to, a CMV enhancer (or a fragment thereof, e.g., as described herein). The promoter may be, but is not limited to, CMV, CBA, UBC, GUSB, NSE, synaptic protein, MeCP2, and GFAP promoters. The 5'UTR / intron may be, but is not limited to, SV40 and CBA-MVM.
[0340] In one embodiment, the AAV vector comprises an intron, optionally placed between a promoter element and a polynucleotide encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein). Without being bound by theory, inclusion of a 5' intron has been shown to enhance the level and homeostasis of mRNA encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein). In an embodiment, the enhancer is a 5' intron derived from SV40. In one embodiment, the SV40 intron comprises, for example, consists of, the following sequence:
[0341] gtaagtt tagtcttttt gtcttttatt tcaggtcccg gatccggtgg tggtgcaaatcaaagaactg ctcctcagtg gatgttgcct ttacttctag
[0342] (SEQ ID NO:137)
[0343] In one embodiment, the AAV vector plasmid (e.g., an AAV vector plasmid of an AAV vector) comprises an enhancer, promoter and / or intron combination, such as, but not limited to (1) CMV enhancer, CMV promoter, SV40 5'UTR intron (e.g., as described herein); (2) CMV enhancer, CBA promoter, SV40 5'UTR intron (e.g., as described herein); (3) CMV enhancer, CBA promoter, CBA-MVM 5'UTR intron (e.g., as described herein).
[0344] Transgenic enhancement
[0345] In one embodiment, the AAV vector plasmid comprises at least one transgene enhancer element that can enhance transgene target specificity and expression (see, e.g., Powell et al. Viral Expression Cassette Elements to Enhance Transgene Target Specificity and Expression in Gene Therapy, 2015; the contents of which are incorporated herein by reference in their entirety). Non-limiting examples of transgene enhancer elements for enhancing transgene target specificity and expression include promoters, endogenous miRNAs, post-transcriptional regulatory elements (PREs), polyadenylation (poly A) signal sequences and upstream enhancers (USEs), CMV enhancers, and introns.
[0346] In one embodiment, the AAV vector plasmid comprises at least one transgene enhancer element that is a CMV enhancer. In one embodiment, the AAV vector plasmid comprises at least one transgene enhancer element that is a promoter.
[0347] In one embodiment, the AAV vector plasmid comprises at least one transgene enhancer element that is an intron.
[0348] In one embodiment, the AAV vector plasmid comprises at least one transgene enhancer element which is an endogenous miRNA.
[0349] In one embodiment, the AAV vector plasmid comprises at least one transgene enhancer element that is a post-transcriptional regulatory element (PRE).
[0350] In one embodiment, the AAV vector plasmid comprises at least one transgenic enhancer element, which is a polyadenylation (poly A) signal sequence. In an embodiment, the AAV vector plasmid of the AAV vector comprises a growth hormone poly A signal. In one embodiment, the growth hormone poly A signal is derived from a bovine growth hormone (BGH) poly A signal. An example of a BGH poly A signal sequence is: ctagagct cgctgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttgcccctcccccgtgccttcct tgaccctgga aggtgccact cccactgtcc tttcctaataaaatgaggaa attgcatcgcattgtctgag taggtgtcat tctattctgg ggggtggggtggggcaggac agcaaggggg aggattgggaagacaatagc aggcatgctg ggga
[0351] (SEQ ID NO:138)
[0352] In embodiments, the AAV vector plasmid comprises a poly A signal (e.g., a BGH poly A signal) downstream (e.g., 3') of a polynucleotide encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein).
[0353] In one embodiment, the AAV vector plasmid comprises at least one transgene enhancer element that is an upstream enhancer (USE).
[0354] Tissue-specific expression
[0355] In one embodiment, the vector genome may comprise a tissue-specific expression element to promote expression of the hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein) in tissues and / or cells. As a non-limiting example, the promoter may be a tissue-specific expression element, which includes, but is not limited to, human elongation factor 1a subunit (EF-1a), immediate-early cytomegalovirus (CMV), chicken β-actin (CBA) and its derivative CAG, β-glucuronidase (GUSB), and ubiquitin C (UBC).
[0356] In one embodiment, the vector genome may comprise tissue-specific expression elements that can be used to restrict expression to certain cell types, such as, but not limited to, neural promoters that can be used to restrict expression to neurons, astrocytes, or oligodendrocytes.
[0357] In one embodiment, the vector genome may comprise neuronal tissue-specific expression elements, such as, but not limited to, neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B chain (PDGF-β), synaptobrevin (Syn), methyl-CpG binding protein 2 (MeCP2), Ca<2+> / calmodulin-dependent protein kinase II (CaMKII), metabotropic glutamate receptor 2 (mGluR2), NFL, NFH, ηβ2, PPE, Enk, and EAAT2 promoters.
[0358] In one embodiment, the vector genome may contain tissue-specific expression elements for astrocytes, such as, but not limited to, the glial fibrillary acidic protein (GFAP) and EAAT2 promoters.
[0359] In one embodiment, the vector genome may comprise a tissue-specific expression element for oligodendrocytes, such as, but not limited to, the myelin basic protein (MBP) promoter.
[0360] Intron
[0361] In one embodiment, the AAV vector plasmid comprises at least one element that enhances transgene expression, such as one or more introns or portions thereof.
[0362] In one embodiment, the payload construct comprises at least one element that enhances transgene expression, such as one or more introns or portions thereof.
[0363] Non-limiting examples of introns include MVM (67 bp-97 bp), FIX truncated intron 1 (300 bp), β-globin SD / immunoglobulin heavy chain splice acceptor (250 bp), adenovirus splice donor / immunoglobulin splice acceptor (500 bp), SV40 late splice donor / splice acceptor (19S / 16S) (180 bp), and hybrid adenovirus splice donor / IgG splice acceptor (230 bp).
[0364] In one embodiment, the length of the intron or intron portion can be 100-500 nucleotides. The promoter can have a length of 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490 or 500. An intron may have a length of between 80-100, 80-120, 80-140, 80-160, 80-180, 80-200, 80-250, 80-300, 80-350, 80-400, 80-450, 80-500, 200-300, 200-400, 200-500, 300-400, 300-500, or 400-500.
[0365] In one embodiment, the AAV vector comprises an intron, optionally placed between a promoter element and a polynucleotide encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein). Without being bound by theory, inclusion of a 5' intron has been shown to enhance the level and homeostasis of mRNA encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein). In an embodiment, the enhancer is a 5' intron derived from SV40. In one embodiment, the SV40 intron comprises, for example, consists of, the following sequence:
[0366] gtaagtt tagtcttttt gtcttttatt tcaggtcccg gatccggtgg tggtgcaaatcaaagaactg ctcctcagtg gatgttgcct ttacttctag
[0367] (SEQ ID NO:137)
[0368] In one embodiment, the AAV vector plasmid of the AAV vector comprises (1) a CMV enhancer (e.g., SEQ ID NO: 134), (2) a CBA promoter (e.g., SEQ ID NO: 135), (3) an SV40 intron (e.g., SEQ ID NO: 137), (4) a polynucleotide encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein), and (5) a BGH poly A signal (e.g., SEQ ID NO): 138). In one embodiment, elements (1) to (5) are arranged from 5' to 3' on the AAV vector plasmid. In an embodiment, elements (1) to (5) are arranged on an AAV vector plasmid that further comprises ITRs (e.g., 5' ITRs and 3' ITRs). In an embodiment, the ITRs are derived from AAV2 ITRs.
[0369] In one embodiment, the AAV vector plasmid is a self-complementary AAV vector plasmid. "Self-complementary" or the abbreviation "sc" refers to self-complementarity. "Self-complementary AAV" or "scAAV" refers to a construct in which the coding region carried by the recombinant AAV nucleic acid sequence has been designed to form an intramolecular double-stranded DNA template. Not bound by theory, during infection, the second strand of cell-mediated synthesis is not waited for, but two complementary half-scAAVs will associate to form a double-stranded DNA (dsDNA) that is easy to replicate and transcribe immediately. See, for example, DM McCarty et al., "Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis" Gene Therapy, (August 2001), Vol. 8, No. 16, pp. 1248-1254 (incorporated by reference as a whole). Self-complementary AAVs are described in, for example, U.S. Patent Nos. 6,596,535; 7,125,717; and 7,456,683, each of which is incorporated herein by reference in its entirety. For example, the 5' ITR can be mutated, for example, by deleting the terminal splitting site to allow for hairpin formation of the genome.
[0370] Capsid and capsid serotypes
[0371] In some embodiments, the AAV particles of the invention may be encapsidated in a capsid structure or may be capsid-free. Such capsid-free viral vector donor and / or acceptor sequences such as AAV are described in, for example, U.S. Publication No. 2014 / 0107186, the contents of which are incorporated by reference in their entirety.
[0372] In some embodiments, the AAV particles produced according to the present invention may comprise hybrid serotypes having enhanced transduction, prolonged transgene expression, and / or safety profiles for specific cell types of interest in the central nervous system. Hybrid serotypes may be produced by trans-encapsulation, adsorption of bispecific antibodies to the capsid surface, mosaic capsids and chimeric capsids, and / or other capsid protein modifications.
[0373] In some embodiments, the AAV particles of the invention can be further modified for specific therapeutic applications by rational mutagenesis of capsid proteins (see, e.g., Pulicherla et al., Mol Ther, 201 1, 19: 1070-1078), incorporation of peptide ligands (e.g., peptides derived from NMDA receptor agonists for enhancing retrograde transport) into the capsid (Xu et al., Virology, 2005, 341: 203-214), and directed evolution to generate new AAV variants, e.g., for increased CNS transduction.
[0374] In some embodiments, the AAV particles produced according to the present invention may comprise naturally occurring and / or recombinant different capsid proteins, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV 8, AAV9, AAV 10, and AAV11, AAV 12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ / 8 capsid serotypes or variants thereof (e.g., AAV3A and AAV3B). Nucleic acid sequences encoding one or more AAV capsid proteins useful in the present invention are disclosed in International Publication No. WO2015191508, the contents of which are incorporated herein by reference in their entirety.
[0375] In some embodiments, the AAV particles of the present invention may comprise or be derived from any natural or recombinant AAV serotype. According to the present invention, the AAV particles may utilize or be based on any serotype selected from the group consisting of AAV1, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV5, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8, AAV9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV 12. AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42-lb, AAV42-2, AAV42-3a, AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, A AV42-8, AAV42-10, AAV42-11, AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12, AAV43-20, AAV43-21, AAV43-23, AA V43-25, AAV43-5, AAV44.1, AAV44.2, AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7, AAVl-7 / rh.48, A AVl-8 / rh.49, AAV2-15 / rh.62, AAV2-3 / rh.61, AAV2-4 / rh.50, AAV2-5 / rh.51, AAV3.1 / hu.6, AAV3.1 / hu.9, AAV3-9 / rh.52, AAV3-l l / rh.53, AAV4-8 / r 11.64, AAV4-9 / rh.54, AAV4-19 / rh.55, AAV5-3 / rh.57, AAV5-22 / rh.58, AAV7.3 / h u.7, AAV16.8 / hu.10, AAV16.12 / hu.11, AAV29.3 / bb.1, AAV29.5 / bb.2, AAV106.1 / h u.37, AAV114.3 / hu.40, AAV127.2 / hu.41, AAV127.5 / hu.42, AAV128.3 / hu.44, AAV1 30.4 / hu.48, AAV145.1 / hu.53, AAV145.5 / hu.54, AAV145.6 / hu.55, AAV161.10 / hu.60、AAV161.6 / hu.61、AAV33.12 / hu.17、AAV33.4 / hu.15、AAV33.8 / hu.16、AAV52 / hu.19、AAV52.1 / hu.20、AAV58.2 / hu.25、AAVA3.3、AAV A3.4、AAV A3.5、AAV A3.7、AAVC1、AAVC2、AAVC5、AAV-DJ、AAV-DJ8、AAVF3、AAVF5、AAVH2、AAVrh.72、AAVhu.8、AAVrh.68、AAVrh.70、AAVpi.1、AAVpi.3、 AAVpi.2、AAVrh.60、AAVrh.44、AAVrh.65、AAVrh.55、AAVrh.47、AAVrh.69、AAVrh.45、AAVrh.59、AAVhu.12、AAVH6、AAVLK03、AAVH- 1 / hu.1、AAVH-5 / hu.3、AAVLG-10 / rh.40、AAVLG-4 / rh.38、AAVLG-9 / hu.39、AAVN721-8 / rh.43、AAVCh.5、AAVCh.5Rl、AAVcy.2、AAVcy.3、AAVcy.4、AAVcy.5、AAVCy.5Rl、AAVCy.5R2、AAVCy.5R3、AAVCy.5R4、AAVcy.6、AAVhu.1、AAVhu.2、AAVhu.3、AAVhu.4、AAVhu.5、 AAVhu.6、AAVhu.7、AAVhu.9、AAVhu.10、AAVhu.11、AAVhu.13、AAVhu.15、AAVhu.16、AAVhu.17、AAVhu.18、AAVhu.20、AAVhu.21、AAVhu. hu.22、AAVhu.23.2、AAVhu.24、AAVhu.25、AAVhu.27、AAVhu.28、AAVhu.29、AAVhu.29R、AAVhu.31、AAVhu.32、AAVhu.34、AAVhu.35、 AAVhu.37、AAVhu.39、AAVhu.40、AAVhu.41、AAVhu.42、AAVhu.43、AAVhu.44、AAVhu.44Rl、AAVhu.44R2、AAVhu.44R3、AAVhu.45、AAV hu.46、AAVhu.47、AAVhu.48、AAVhu.48Rl、AAVhu.48R2、AAVhu.48R3、AAVhu.49、AAVhu.51、AAVhu.52、AAVhu.54、AAVhu.55、AAVhu.56, AAVhu.57, AAVhu.58, AAVhu.60, AAVhu.61, AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14 / 9, AAVhu.t19, AAVrh.2, AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.12, AAVrh.13, AAVrh.13R, AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.20, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54, AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64Rl, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74, AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, goat AAV, bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhER1.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, A AV-LK08, AAV-LK09, AAV-LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-L K16, AAV-LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-miRNA-lOl, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2, AAV reorganized 100-1, AAV reorganized 100-3, AAV reorganized 100-7, AAV reorganized 10-2, AAV reorganized 10-6, AAV reorganized 10-8, AAV reorganized 100-2, AAVSM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.1, AAVhu.53, AAV4-8 / rh.64, AAVLG-9 / hu.39, AAV54.5 / hu.23, AAV54.2 / hu.22, AAV54.7 / hu.24, AAV54.1 / hu.21, AAV54.4R / hu.27, AAV46.2 / hu.28, AAV46.6 / hu.29, AAV128.1 / hu.43, authentic AAV (ttAAV), UPEN AAV 10 and / or Japanese AAV 10 serotypes, and variants thereof.
[0376] As a non-limiting example, the capsid of the recombinant AAV virus is AAV2. As a non-limiting example, the capsid of the recombinant AAV virus is AAVrh10. As a non-limiting example, the capsid of the recombinant AAV virus is AAV9(hul4). As a non-limiting example, the capsid of the recombinant AAV virus is AAV-DJ. As a non-limiting example, the capsid of the recombinant AAV virus is AAV9.47. As a non-limiting example, the capsid of the recombinant AAV virus is AAV-DJ8.
[0377] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a serotype as described in U.S. Publication No. US20030138772 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV1 (SEQ ID NOs: 6 and 64 of US20030138772), AAV2 (SEQ ID NOs: 7 and 70 of US20030138772), AAV3 (SEQ ID NOs: 8 and 71 of US20030138772), AAV4 (SEQ ID NO: 63 of US 20030138772), AAV5 (SEQ ID NO: 114 of US20030138772), AAV6 (SEQ ID NO: 65 of US20030138772), AAV7 (SEQ ID NOs: 1-3 of US20030138772), AAV 8 (SEQ ID NOs: 4 and 95 of US20030138772), AAV9 (SEQ ID NOs: 5 and 100 of US20030138772), AAV10 (SEQ ID NO: 117 of US20030138772), AAV11 (SEQ ID NO: 118 of US20030138772), AAV12 (SEQ ID NO: 119 of US20030138772), AAVrhlO (amino acids 1 to 738 of SEQ ID NO: 81 of US20030138772), AAV16.3 (US20030138772 SEQ ID NO: 10), AAV29.3 / bb.1 (US 20030138772 SEQ ID NO: 11), AAV29.4 (US20030138772 SEQ ID NO: 12). NO:12), AAV29.5 / bb.2 (US20030138772 SEQ ID NO:13), AAV1.3 (US 20030138772 SEQ ID NO:14), AAV13.3 (US20030138772 SEQ ID NO:15), AAV24.1 (US20030138772 SEQ ID NO:16), AAV27.3 (US 20030138772SEQ ID NO:17), AAV7.2 (US20030138772 SEQ ID NO:18), AAVC1 (US20030138772 SEQ ID NO:19), AAVC3 (US 20030138772SEQ ID NO:20), AAVC5(US20030138772 SEQ IDNO:21)、AAVF1(US20030138772 SEQ ID NO:22)、AAVF3(US20030138772SEQ ID NO:23)、AAVF5(US20030138772 SEQ ID NO:24)、AAVH6(US20030138772 SEQ ID NO:25)、AAVH2(US 20030138772SEQ ID NO:26)、AAV42-8(US20030138772 SEQ ID NO:27)、AAV42-15(US20030138772 SEQ ID NO:28)、AAV42-5b(US20030138772SEQ ID NO:29)、AAV42-lb(US20030138772 SEQ ID NO:30)、AAV42-13(US20030138772 SEQ ID NO:31)、AAV42-3a(US 20030138772SEQ ID NO:32)、AAV42-4(US20030138772 SEQ ID NO:33)、AAV42-5a(US20030138772 SEQ ID NO:34)、AAV42-10(US20030138772SEQ ID NO:35)、AAV42-3b(US20030138772 SEQ ID NO:36)、AAV42-11(US20030138772 SEQ ID NO:37)、AAV42-6b(US 20030138772SEQ ID NO:38)、AAV43-1(US20030138772 SEQ ID NO:39)、AAV43-5(US20030138772 SEQ ID NO:40)、AAV43-12(US20030138772SEQ ID NO:41)、AAV43-20(US20030138772 SEQ ID NO:42)、AAV43-21(US20030138772 SEQ ID NO:43)、AAV43-23(US 20030138772SEQ ID NO:44)、AAV43-25(US20030138772 SEQ ID NO:45)、AAV44.1(US20030138772 SEQ ID NO:46)、AAV44.5(US20030138772SEQ ID NO:47)、AAV223.1(US20030138772 SEQ IDNO: 48), AAV223.2 (US20030138772 SEQ ID NO: 49), AAV223.4 (US 20030138772 SEQ ID NO: 50), AAV223.5 (US20030138772 SEQ ID NO: 51), AAV223.6 (US20030138772 SEQ ID NO: 52), AAV223.7 (US20030138772 SEQ ID NO: 53), AAV A3.4 (US20030138772 SEQ ID NO: 54), AAV A3.5 (US20030138772 SEQ ID NO: 55), AAV A3.7 (US 20030138772 SEQ ID NO: 56), AAV A3.3 (US20030138772 SEQ ID NO: 57), AAV42.12 (US20030138772 SEQ ID NO: 58), AAV44.2 (US20030138772 SEQ ID NO: 59), AAV42-2 (US20030138772 SEQ ID NO: 9), or variants thereof.
[0378] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype that may be or may have a sequence as described in U.S. Publication No. US20150159173 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV2 (SEQ ID NOs: 7 and 23 of US 20150159173), rh20 (SEQ ID NO: 1 of US20150159173), rh32 / 33 (SEQ ID NO: 2 of US20150159173), rh39 (SEQ ID NOs: 3, 20, and 36 of US 20150159173), rh46 (SEQ ID NOs: 4 and 22 of US20150159173), rh73 (SEQ ID NO: 5 of US20150159173), rh74 (SEQ ID NO: 6 of US20150159173), NO:6), AAV6.1 (SEQ ID NO:29 of US20150159173), rh.8 (SEQ ID NO:41 of US20150159173), rh.48.1 (SEQ ID NO:44 of US20150159173), hu.44 (SEQ ID NO:45 of US20150159173), hu.29 (SEQ ID NO:42 of US20150159173), hu.48 (SEQ ID NO:38 of US20150159173), rh54 (SEQ ID NO:49 of US20150159173), AAV2 (SEQ ID NO:7 of US20150159173), cy.5 (SEQ ID NO:8 of US20150159173), NO: 8 and 24), rh.10 (SEQ ID NO: 9 and 25 of US20150159173), rh.13 (SEQ ID NO: 10 and 26 of US20150159173), AAV1 (SEQ ID NO: 11 and 27 of US20150159173), AAV3 (SEQ ID NO: 12 and 28 of US20150159173), AAV6 (SEQ ID NO: 13 and 29 of US20150159173), AAV7 (SEQ ID NO: 14 and 30 of US 20150159173), AAV8 (SEQ ID NO: 15 and 31 of US20150159173), hu.13 (SEQ ID NO: 16 and 17 of US20150159173), NO: 16 and 32), hu.26 (SEQ ID NO: 17 and 33 of US20150159173), hu.37 (SEQ ID NOs: 18 and 34 of US20150159173), hu.53 (SEQ ID NOs: 19 and 35 of US20150159173), rh.43 (SEQ ID NOs: 21 and 37 of US20150159173), rh2 (SEQ ID NO: 39 of US 20150159173), rh.37 (SEQ ID NO: 40 of US20150159173), rh.64 (SEQ ID NO: 43 of US20150159173), rh.48 (SEQ ID NO: 44 of US20150159173), ch.5 (SEQ ID NO 46 of US20150159173), rh.67 (SEQ ID NO: 48 of US20150159173), NO:47), rh.58 (SEQ ID NO:48 of US20150159173), or variants thereof, including but not limited to Cy5R1, Cy5R2, Cy5R3, Cy5R4, rh.13R, rh.37R2, rh.2R, rh.8R, rh.48.1, rh.48.2, rh.48.1.2, hu.44R1, hu.44R2, hu.44R3, hu.29R, ch.5R1, rh64R1, rh64R2, AAV6.2, AAV6.1, AAV6.12, hu.48R1, hu.48R2, and hu.48R3. .
[0379] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in U.S. Pat. No. 7,198,951 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV9 (SEQ ID NOs: 1-3 of US 7,198,951), AAV2 (SEQ ID NO: 4 of US 7,198,951), AAV1 (SEQ ID NO: 5 of US 7,198,951), AAV3 (SEQ ID NO: 6 of US 7,198,951), and AAV 8 (SEQ ID NO: 7 of US 7,198,951).
[0380] In some embodiments, the AAV vector comprises or is derived from an AAV serotype that may be or may have a mutation in the AAV9 sequence described in N Pulicherla et al. (Molecular Therapy 19(6):1070-1078 (2011), the contents of which are incorporated herein by reference in their entirety), such as but not limited to AAV9.9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84. In some embodiments, the AAV capsid comprises one or more sequences engineered to deliver the vector across the blood-brain barrier (see, e.g., BEDeverman et al., Nature Biotech, Vol. 34, No. 2, pp. 204-211 (published online Feb. 1, 2016) and Caltech press release, A. Wetherston, www.neurology-cenfrd.com / 2016 / 02 / 10 / successfd / brain-barrier; see also WO 2016 / 0492301 and US 8,734,809 (the contents of each of which are incorporated by reference in their entirety).
[0381] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in U.S. Pat. No. 6,156,303 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV3B (SEQ ID NOs: 1 and 10 of US 6156,303), AAV6 (SEQ ID NOs: 2, 7, and 11 of US 6156,303), AAV2 (SEQ ID Nos: 3 and 8 of US 6156,303), AAV3A (SEQ ID NOs: 4 and 9 of US 6156,303), or derivatives thereof.
[0382] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in U.S. Publication No. US20140359799 (the contents of which are incorporated herein by reference in their entirety), such as but not limited to AAV 8 (SEQ ID NO: 1 of US20140359799), AAVDJ (SEQ ID NO: 2 and 3 of US20140359799), or variants thereof.
[0383] In some embodiments, the AAV particle may comprise a capsid from a serotype such as, but not limited to, AAVDJ or a variant thereof, such as AAVDJ8 (or AAV-DJ8), as described by Grimm et al. (Journal of Virology 82(12):5887-5911 (2008), which is incorporated herein by reference in its entirety). The amino acid sequence of AAVDJ8 may comprise two or more mutations to remove the heparin binding domain (HBD). As a non-limiting example, the AAV-DJ sequence described as SEQ ID NO: 1 in U.S. Pat. No. 7,588,772 (the contents of which are incorporated herein by reference in their entirety) may comprise two mutations: (1) R587Q, wherein the arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gln) and (2) R590T, wherein the arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr). As another non-limiting example, three mutations may be included: (1) K406R, wherein the lysine (K; Lys) at amino acid 406 is changed to arginine (R; Arg), (2) R587Q, wherein the arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gln), and (3) R590T, wherein the arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr).
[0384] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype, which may be or may have the sequence of AAV4 as described in International Publication No. WO 1998011244 (the contents of which are incorporated herein by reference in their entirety), such as but not limited to AAV4 (SEQ ID NOs: 1-20 of WO 1998011244).
[0385] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype that may be or may have a mutation in the AAV2 sequence to produce AAV2G9 as described in International Publication No. WO 2014144229, the contents of which are incorporated herein by reference in their entirety.
[0386] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype that may be or may have a sequence described in International Publication No. WO 2005033321 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV3-3 (SEQ ID NO: 217 of WO 2005033321), AAV1 (SEQ ID NO: 219 and 202 of WO 2005033321), AAV106.1 / hu.37 (SEQ ID NO: 10 of WO 2005033321), AAV114.3 / hu.40 (SEQ ID NO: 11 of WO 2005033321), AAV127.2 / hu.41 (SEQ ID NO: 6 and 8 of WO 2005033321), AAV128.3 / hu.44 (SEQ ID NO: 129 of WO 2005033321), AAV129.4 / hu.50 (SEQ ID NO: 13 of WO 2005033321), AAV130.5 / hu.51 (SEQ ID NO: 14 of WO 2005033321), AAV131.6 / hu.52 (SEQ ID NO: 15 of WO 2005033321), AAV132.7 / hu.53 (SEQ ID NO: 16 of WO 2005033321), AAV133.8 / hu.54 (SEQ ID NO: 17 of WO 2005033321), AAV134.9 / hu.55 (SEQ ID NO: 18 of WO 2005033321), AAV135.1 / hu.56 (SEQ ID NO: 19 of 81), AAV130.4 / hu.48 (SEQ ID NO: 78 of WO 2005033321), AAV145.1 / hu.53 (SEQ ID NO: 176 and 177 of WO 2005033321), AAV145.6 / hu.56 (SEQ ID NO: 168 and 192 of WO2005033321), AAV16.12 / hu.11 (SEQ ID NO: 153 and 57 of WO 2005033321), AAV16.8 / hu.10 (SEQ ID NO: 156 and 56 of WO 2005033321), AAV161.10 / hu.60 (SEQ ID NO: 170 of WO2005033321), AAV161.6 / hu.61 (SEQ ID NO: 192 of WO 2005033321). 2005033321), AAV1-7 / rh.48 (SEQ ID NO: 32 of WO 2005033321), AAV1-8 / rh.49 (SEQ ID NOs: 103 and 25 of WO 2005033321), AAV2 (SEQ ID NOs: 211 and 221 of WO 2005033321), AAV2-15 / rh.62 (SEQ ID NOs: 33 and 114 of WO 2005033321), AAV2-3 / rh.61 (SEQ ID NO: 21 of WO 2005033321), AAV2-4 / rh.50 (SEQ ID NOs: 23 and 108 of WO 2005033321), AAV2-5 / rh.51 (SEQ ID NOs: 211 and 221 of WO 2005033321), 2005033321, SEQ ID NO: 104 and 22), AAV3.1 / hu.6 (SEQ ID NOs: 5 and 84 of WO 2005033321), AAV3.1 / hu.9 (SEQ ID NOs: 155 and 58 of WO 2005033321), AAV3-1 l / rh.53 (SEQ ID NOs: 186 and 176 of WO 2005033321), AAV3-3 (SEQ ID NO: 200 of WO 2005033321), AAV33.12 / hu.17 (SEQ ID NO: 4 of WO 2005033321), AAV33.4 / hu.15 (SEQ ID NO: 50 of WO 2005033321), AAV33.8 / hu.16 (SEQ ID NO: 51 of WO 2005033321), AAV3-9 / rh.52 (SEQ ID NOs: 186 and 176 of WO 2005033321), AAV3-3 (SEQ ID NO: 200 of WO 2005033321), AAV33.12 / hu.17 (SEQ ID NO: 4 of WO 2005033321), AAV33.4 / hu.15 (SEQ ID NO: 50 of WO 2005033321), 2005033321 SEQ ID NO: 96 and 18), AAV4-19 / rh.55 (SEQ ID NO: 117 of WO 2005033321), AAV4-4 (SEQ ID NO: 201 and 218 of WO 2005033321), AAV4-9 / rh.54 (SEQ ID NO: 116 of WO 2005033321), AAV5 (SEQ ID NO: 199 and 216 of WO 2005033321), AAV52.1 / hu.20 (SEQ ID NO: 63 of WO 2005033321), AAV52 / hu.19 (SEQ ID NO: 133 of WO 2005033321), AAV5-22 / rh.58 (SEQ ID NO: 27 of WO 2005033321), AAV5-3 / rh.57 (SEQ ID NO: 197 of WO 2005033321). 2005033321), AAV5-3 / rh.57 (SEQ ID NO: 26 of WO 2005033321), AAV58.2 / hu.25 (SEQ ID NO: 49 of WO 2005033321), AAV6 (SEQ ID NOs: 203 and 220 of WO 2005033321), AAV7 (SEQ ID NOs: 222 and 213 of WO 2005033321), AAV7.3 / hu.7 (SEQ ID NO: 55 of WO 2005033321), AAV8 (SEQ ID NOs: 223 and 214 of WO 2005033321), AAVH-1 / hu.1 (SEQ ID NO: 46 of WO 2005033321), AAVH-5 / hu.3 (SEQ ID NO: 57 of WO 2005033321), AAVH-6 / hu.7 (SEQ ID NO: 61 of WO 2005033321), AAVH-7 / hu.8 (SEQ ID NO: 62 of WO 2005033321), AAVH-8 / hu.9 (SEQ ID NO: 63 of WO 2005033321), AAVH-9 / hu.10 (SEQ ID NO: 64 of WO 2005033321), AAVH-10 / hu.11 (SEQ ID NO: 65 of WO 2005033321), AAVH-11 / hu.9 (SEQ ID NO: 66 of WO 2005033321), AAVH 2005033321 of SEQ ID NO:44), AAVhu.1 (SEQ ID NO: 144 of WO 2005033321), AAVhu.10 (SEQ ID NO: 156 of WO 2005033321), AAVhu.11 (SEQ ID NO: 153 of WO 2005033321), AAVhu.12 (SEQ ID NO: 59 of WO 2005033321), AAVhu.13 (SEQ ID NO: 129 of WO 2005033321), AAVhu.14 / AAV9 (SEQ ID NO: 123 and 3 of WO 2005033321), AAVhu.15 (SEQ ID NO: 147 of WO 2005033321), AAVhu.16 (SEQ ID NO: 148 of WO 2005033321), AAVhu.17 (SEQ ID NO: 83 of WO 2005033321), AAVhu.18 (SEQ ID NO: 149 of WO 2005033321), AAVhu.19 (SEQ ID NO: 133 of WO 2005033321), AAVhu.2 (SEQ ID NO: 143 of WO 2005033321), AAVhu.20 (SEQ ID NO: 134 of WO 2005033321), AAVhu.21 (SEQ ID NO: 135 of WO 2005033321), AAVhu.22 (SEQ ID NO: 138 of WO 2005033321), AAVhu.23.2 (SEQ ID NO: 137 of WO 2005033321), AAVhu.24 (SEQ ID NO: 136 of WO 2005033321), AAVhu.25 (SEQ ID NO: 146 of WO 2005033321), AAVhu.27 (SEQ ID NO: 140 of WO 2005033321), AAVhu.29 (SEQ ID NO: 132 of WO 2005033321), AAVhu.3 (SEQ ID NO: 145 of WO 2005033321), AAVhu.31 (SEQ ID NO: 121 of WO 2005033321), AAVhu.32 (SEQ ID NO: 122 of WO 2005033321), AAVhu.34 (SEQ ID NO: 125 of WO 2005033321), AAVhu.35 (SEQ ID NO: 164 of WO 2005033321), AAVhu.37 (SEQ ID NO: 88 of WO 2005033321), AAVhu.39 (SEQ ID NO:102 of WO 2005033321), AAVhu.4 (SEQ ID NO:141 of WO 2005033321), AAVhu.40 (SEQ ID NO:87 of WO 2005033321), AAVhu.41 (SEQ ID NO:91 of WO 2005033321), AAVhu.42 (SEQ ID NO:85 of WO 2005033321), AAVhu.43 (SEQ ID NO:160 of WO 2005033321), AAVhu.44 (SEQ ID NO:144 of WO 2005033321), AAVhu.45 (SEQ ID NO:127 of WO 2005033321), AAVhu.46 (SEQ ID NO:159 of WO 2005033321), AAVhu.47 (SEQ ID NO:128 of WO 2005033321), AAVhu.48 (SEQ ID NO:157 of WO 2005033321), AAVhu.49 (SEQ ID NO:189 of WO 2005033321), AAVhu.51 (SEQ ID NO:190 of WO 2005033321), AAVhu.52 (SEQ ID NO:191 of WO 2005033321), AAVhu.53 (SEQ ID NO:186 of WO 2005033321), AAVhu.54 (SEQ ID NO:188 of WO 2005033321), AAVhu.55 (SEQ ID NO:187 of WO 2005033321), AAVhu.56 (SEQ ID NO:192 of WO 2005033321), AAVhu.57 (SEQ ID NO:193 of WO 2005033321), AAVhu.58 (SEQ ID NO:194 of WO 2005033321), AAVhu.6 (SEQ ID NO:84 of WO 2005033321), AAVhu.60 (SEQ ID NO:184 of WO 2005033321), AAVhu.61 (SEQ ID NO:185 of WO 2005033321), AAVhu.63 (SEQ ID NO:195 of WO 2005033321), AAVhu.64 (SEQ ID NO:196 of WO 2005033321), AAVhu.66 (SEQ ID NO:197 of WO 2005033321), AAVhu.67 (SEQ ID NO:198 of WO 2005033321), AAVhu.7 (SEQ ID NO:150 of WO 2005033321), AAVhu.8 (SEQ ID NO:12 of WO 2005033321), AAVhu.9 (SEQ ID NO:155 of WO 2005033321), AAVLG-10 / rh.40 (SEQ ID NO:14 of WO 2005033321), AAVLG-4 / rh.38 (SEQ ID NO:86 of WO 2005033321), AAVLG-4 / rh.38 (SEQ ID NO:7 of WO 2005033321), AAVN721-8 / rh.43 (SEQ ID NO:163 of WO 2005033321), AAVN721-8 / rh.43 (SEQ ID NO:43 of WO 2005033321), AAVpi.l (SEQ ID NO:28 of WO 2005033321), AAVpi.2 (SEQ ID NO:30 of WO 2005033321), AAVpi.3 (SEQ ID NO:29 of WO 2005033321), AAVrh.38 (SEQ ID NO:86 of WO 2005033321), AAVrh.40 (SEQ ID NO:92 of WO 2005033321), AAVrh.43 (SEQ ID NO:163 of WO 2005033321), AAVrh.44 (SEQ ID NO:34 of WO 2005033321), AAVrh.45 (SEQ ID NO:41 of WO 2005033321), AAVrh.47 (SEQ ID NO:38 of WO 2005033321), AAVrh.48 (SEQ ID NO:115 of WO 2005033321), AAVrh.49 (SEQ ID NO:103 of WO 2005033321), AAVrh.50 (SEQ ID NO:108 of WO 2005033321), AAVrh.51 (SEQ ID NO:104 of WO 2005033321), AAVrh.52 (SEQ ID NO:96 of WO 2005033321), AAVrh.53 (SEQ ID NO:97 of WO 2005033321), AAVrh.55 (SEQ ID NO:37 of WO 2005033321), AAVrh.56 (SEQ ID NO:152 of WO 2005033321), AAVrh.57 (SEQ ID NO: 105 of WO 2005033321), AAVrh.58 (SEQ ID NO: 106 of WO 2005033321), AAVrh.59 (SEQ ID NO: 42 of WO2005033321), AAVrh.60 (SEQ ID NO. WO 2005033321 NO: 31), AAVrh.61 (SEQ ID NO: 107 of WO 2005033321), AAVrh.62 (SEQ ID NO: 114 of WO 2005033321), AAVrh.64 (SEQ ID NO: 99 of WO 2005033321), AAVrh.65 (SEQ ID NO: 99 of WO 2005033321) SEQ ID NO:35), AAVrh.68 (WO 2005033321SEQ ID NO:16), AAVrh.69 (WO 2005033321 SEQ ID NO:39), AAVrh.70 (WO 2005033321 SEQ ID NO:20), AAVrh.72 (WO 2005033321 SEQ ID NO:9), or variants thereof, including but not limited to AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVcy.6, AAVrh.12, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.25 / 42 15. AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrhl4. Non-limiting examples of variants are SEQ ID NOs: 13, 15, 17, 19, 24, 36, 40, 45, 47, 48, 51-54, 60-62, 64-77, 79, 80, 82, 89, 90, 93-95, 98, 100, 101, 109-113, 118-120, 124, 126, 131, 139, 142, 151, 154, 158, 161, 162, 165-183, 202, 204-212, 215, 219, 224-236 of WO2005033321 (the contents of which are incorporated herein by reference in their entirety).
[0387] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in International Publication No. WO 2015168666 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAVrh8R (SEQ ID NO: 9 of WO 2015168666), AAVrh8R A586R mutant (SEQ ID NO: 10 of WO 2015168666), AAVrh8R R533A mutant (SEQ ID NO: 11 of WO 2015168666), or variants thereof.
[0388] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in International Publication No. WO2018 / 160582 (the contents of which are incorporated herein by reference in their entirety), such as but not limited to AAVhu68 (SEQ ID NO: 2 of WO 2018160582), or a variant thereof.
[0389] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype that may be or may have a sequence described in U.S. Pat. No. 9,233,131 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAVhE1.1 (SEQ ID NO: 44 of U.S. Pat. No. 9,233,131), AAVhErl.5 (SEQ ID NO: 45 of U.S. Pat. No. 9,233,131), AAVhER1.14 (SEQ ID NO: 46 of U.S. Pat. No. 9,233,131), AAVhErl.8 (SEQ ID NO: 47 of U.S. Pat. No. 9,233,131), AAVhEr1.16 (SEQ ID NO: 48 of U.S. Pat. No. 9,233,131), AAVhEr1.18 (SEQ ID NO: 49 of U.S. Pat. No. 9,233,131), AAVhEr1.35 (SEQ ID NO: 50 of U.S. Pat. No. 9,233,131), AAVhEr1.7 (SEQ ID NO: 51 of U.S. Pat. No. 9,233,131), 9233131 SEQ ID NO: 51), AAVhEr1.36 (US 9233131 SEQ ID NO: 52), AAVhEr2.29 (US 9233131 SEQ ID NO: 53), AAVhEr2.4 (US 9233131 SEQ ID NO: 54), AAVhEr2.16 (US 9233131 SEQ ID NO: 55), AAVhEr2.30 (US 9233131 SEQ ID NO: 56), AAVhEr2.31 (US 9233131 SEQ ID NO: 58), AAVhEr2.36 (US 9233131 SEQ ID NO: 57), AAVhER1.23 (US SEQ ID NO:53 of 9233131, AAVhEr3.1 (US 9233131), AAV2.5T (SEQ ID NO: 42 of US 9233131), or variants thereof.
[0390] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence described in U.S. Patent Publication No. US20150376607 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV-PAEC (SEQ ID NO: 1 of US20150376607), AAV-LKO1 (SEQ ID NO: 2 of US20150376607), AAV-LK02 (SEQ ID NO: 3 of US20150376607), AAV-LK03 (SEQ ID NO: 4 of US20150376607), AAV-LK04 (SEQ ID NO: 5 of US20150376607), AAV-LK05 (SEQ ID NO: 6 of US20150376607), AAV-LK06 (SEQ ID NO: 7 of US20150376607), NO:7), AAV-LK07 (SEQ ID NO:8 of US20150376607), AAV-LK08 (SEQ ID NO:9 of US20150376607), AAV-LK09 (SEQ ID NO:10 of US20150376607), AAV-LK10 (SEQ ID of US20150376607 NO: l), AAV-LK11 (SEQ ID NO: 12 of US20150376607), AAV-LK12 (SEQ ID NO: 13 of US20150376607), AAV-LK13 (SEQ ID NO: 14 of US20150376607), AAV-LK14 (SEQ ID NO: US20150376607 NO:15), AAV-LK15(US 20150376607's SEQ ID NO: 16), AAV-LK16 (US20150376607's SEQ ID NO: 17), AAV-LK17 (US20150376607's SEQ ID NO: 18), AAV-LK18 (US20150376607's SEQ ID NO: 19), AAV-LK19 (US 20150376607's SEQ ID NO: 20), AAV-PAEC2 (US20150376607's SEQ ID NO: 21), AAV-PAEC 4 (US20150376607's SEQ ID NO: 22), AAV-PAEC6 (US20150376607's SEQ ID NO: 23), AAV-PAEC7 (US SEQ ID of 20150376607 NO:24) and AAV-PAEC8 (SEQ ID NO: 25 of US20150376607), AAV-PAEC11 (SEQ ID NO: 26 of US20150376607), AAV-PAEC 12 (SEQ ID No: 27 of US20150376607), or variants thereof.
[0391] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype that may be or may have a sequence as described in U.S. Pat. No. 9,163,261 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV-2-pre-miRNA-101 (SEQ ID NO: 1 of US 9,163,261), or a variant thereof.
[0392] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in U.S. Patent Publication No. US20150376240 (the contents of which are incorporated herein by reference in their entirety), such as but not limited to AAV-8h (SEQ ID NO: 6 of US20150376240), AAV-8b (SEQ ID NO: 5 of US20150376240), AAV-h (SEQ ID NO: 2 of US20150376240), AAV-b (SEQ ID NO: 1 of US20150376240), or variants thereof.
[0393] In some embodiments, the AAV particles of the invention may comprise or be derived from an AAV serotype that may be or may have a sequence described in U.S. Patent Publication No. US20160017295 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV SM 10-2 (SEQ ID NO: 22 of US20160017295), AAV shuffled 100-1 (SEQ ID NO: 23 of US20160017295), AAV shuffled 100-3 (SEQ ID NO: 24 of US20160017295), AAV shuffled 100-7 (SEQ ID NO: 25 of US20160017295), AAV shuffled 10-2 (SEQ ID NO: 34 of US20160017295), AAV shuffled 10-6 (SEQ ID NO: 35 of US20160017295), AAV shuffled 10-7 (SEQ ID NO: 36 of US20160017295), AAV shuffled 10-8 (SEQ ID NO: 37 of US20160017295), AAV shuffled 10-9 (SEQ ID NO: 40 of US20160017295), AAV shuffled 10-10 (SEQ ID NO: 41 of US20160017295), AAV shuffled 10-20 (SEQ ID NO: 42 of US20160017295), AAV shuffled 10-30 (SEQ ID NO: 43 of US20160017295), AAV shuffled 10-11 (SEQ ID NO: 44 of US20160017295 NO:35), AAV shuffled 10-8 (SEQ ID NO:36 of US 20160017295), AAV shuffled 100-2 (SEQ ID NO:37 of US20160017295), AAV SM 10-1 (SEQ ID NO:38 of US20160017295), AAV SM 10-8 (SEQ ID NO:39 of US20160017295), AAV SM 100-3 (SEQ ID NO:40 of US20160017295), AAV SM 100-10 (SEQ ID NO:41 of US 20160017295), or variants thereof.
[0394] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in U.S. Patent Publication No. US20150238550 (the contents of which are incorporated herein by reference in their entirety), such as but not limited to BNP61 AAV (SEQ ID NO: 1 of US20150238550), BNP62 AAV (SEQ ID NO: 3 of US20150238550), BNP63 AAV (SEQ ID NO: 4 of US20150238550), or variants thereof.
[0395] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence described in U.S. Patent Publication No. US20150315612 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAVrh.50 (SEQ ID NO: 108 of US20150315612), AAVrh.43 (SEQ ID NO: 163 of US20150315612), AAVrh.62 (SEQ ID NO: 114 of US20150315612), AAVrh.48 (SEQ ID NO: 115 of US20150315612), AAVhu.19 (SEQ ID NO: 133 of US 20150315612), AAVhu.ll (SEQ ID NO: 137 of US20150315612), or AAVrh.51 (SEQ ID NO: 139 of US20150315612). NO: 153), AAVhu.53 (SEQ ID NO: 186 of US20150315612), AAV4-8 / rh.64 (SEQ ID NO: 15 of US20150315612), AAVLG-9 / hu.39 (SEQ ID of US20150315612 NO: 24), AAV54.5 / hu.23 (SEQ ID NO: 60 of US20150315612), AAV54.2 / hu.22 (SEQ ID NO: 67 of US20150315612), AAV54.7 / hu.24 (SEQ ID of US20150315612 NO:66), AAV54.1 / hu.21 (SEQ ID of US20150315612 NO:65), AAV54.4R / hu.27 (SEQ ID NO:64 of US20150315612), AAV46.2 / hu.28 (SEQ ID NO:68 of US20150315612), AAV46.6 / hu.29 (SEQ ID NO:69 of US20150315612), AAV128.1 / hu.43 (SEQ ID NO:80 of US20150315612), or variants thereof.
[0396] In some embodiments, the AAV particles of the present invention may comprise or be derived from an AAV serotype, which AAV serotype may be or may have a sequence as described in International Publication No. WO 2015121501 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, authentic AAV (ttAAV) (SEQ ID NO: 2 of WO 2015121501), "UPenn AAV10" (SEQ ID NO: 8 of WO2015121501), "Japanese AAV10" (SEQ ID NO: 9 of WO 2015121501), or variants thereof.
[0397] According to the present invention, the AAV particles may comprise an AAV capsid serotype that may be selected from or derived from a variety of species. In one embodiment, the AAV may be an avian AAV (AAAV). The AAAV serotype may be or may have a sequence as described in U.S. Pat. No. US9238800 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAAV (SEQ ID NOs: 1, 2, 4, 6, 8, 10, 12, and 14 of US 9,238,800), or a variant thereof.
[0398] In one embodiment, the AAV particles may comprise an AAV capsid serotype, which may be or be derived from bovine AAV (BAAV). The BAAV serotype may be or may have a sequence as described in U.S. Pat. No. US 9,193,769 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, BAAV (SEQ ID NOs: 1 and 6 of US 9193769), or a variant thereof. The BAAV serotype may be or may have a sequence as described in U.S. Pat. No. US 7427396 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, BAAV (SEQ ID NOs: 5 and 6 of US 7427396), or a variant thereof.
[0399] In one embodiment, the AAV particle may comprise an AAV capsid serotype, which may be or be derived from goat AAV. The goat AAV serotype may be or may have a sequence as described in U.S. Pat. No. US 7427396 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, goat AAV (SEQ ID NO: 3 of US 7427396), or a variant thereof.
[0400] In other embodiments, the AAV particles may comprise an AAV capsid serotype that may be engineered as a hybrid AAV from two or more parental serotypes. In one embodiment, the AAV may be AAV2G9, which comprises sequences from AAV2 and AAV9. The AAV2G9 AAV serotype may be or may have a sequence as described in U.S. Patent Publication No. US20160017005 (the contents of which are incorporated herein by reference in their entirety).
[0401] In one embodiment, the AAV particle may comprise an AAV capsid serotype that can be generated from an AAV9 capsid library, which has mutations in amino acids 390-627 (VP1 numbering) as described by Pulicherla et al. (Molecular Therapy 19(6):1070-1078 (2011), the contents of which are incorporated herein by reference in their entirety). The serotypes and corresponding nucleotide and amino acid substitutions may be, but are not limited to, AAV9.1 (G1594C; D532H), AAV6.2 (T1418A and T1436X; V473D and I479K), AAV9.3 (T1238A; F413Y), AAV9.4 (T1250C and A1617T; F417S), AAV9.5 (A1235G, A1314T, A1642G, C1760T; Q412R, T548A, A587V), AAV9.6 (T1231A; F411I), AAV9. .9 (G1203A, G1785T; W595C), AAV9.10 (A1500G, T1676C; M559T), AAV9.11 (A1425T, A1702C, A1769T; T568P, Q590L), AAV9.13 (A 1369C, A1720T; N457H, T574S), AAV9.14 (T1340A, T1362C, T1560C, G1713A; L447H), AAV9.16 (A1775T; Q592L), AAV9.24 (T1507 A AV9.35 (A1289T, T1450A, C1494T, A1515T, C1794A, G1816A; Q430L, Y484N, N98K, V606I), AAV9.40 (A1694T, E565V), AAV9.41 (A 1348T, T1362C; T450S), AAV9.44 (A1684C, A1701T, A1737G; N562H, K567N), AAV9.45 (A1492T, C1804T; N498Y, L602F), AAV9.46 (G1441C, T1525C, T1549G; G481R, W509R, L517V), 9.47 (G1241A, G1358A, A1669G, C1745T; S414N, G453D, K557E, T582I), AAV9.48 (C1445T, A1736T; P482L, Q579L), AAV9.50 (A1638T, C1683T, T1805A; Q546H, L602H), AAV9.53 (G1 301A, A1405C, C1664T, G1811T; R134Q, S469R, A555V, G604V), AAV9.54 (C1531A, T1609A; L511I, L53 7M), AAV9.55 (T1605A; F535L), AAV9.58 (C1475T, C1579A; T492I, H527N), AAV.59 (T1336C; Y446H), AAV9.61 (A1493T; N498I), AAV9.64 (C1531A, A1617T; L511I), AAV9.65 (C1335T, T1530C, C1568A; A5 23D), AAV9.68 (C1510A; P504T), AAV9.80 (G1441A,; G481R), AAV9.83 (C1402A, A1500T; P468T, E500 D), AAV9.87 (T1464C, T1468C; S490P), AAV9.90 (A1196T; Y399F), AAV9.91 (T1316G, A1583T, C1782G , T1806C; L439R, K528I), AAV9.93 (A1273G, A1421G, A1638C, C1712T, G1732A, A1744T, A1832T; S425G, Q474R, Q546H, P571L, G578R, T582S, D611V), AAV9.94 (A1675T; M559L) and AAV9.95 (T1605A; F535L). .
[0402] In one embodiment, the AAV particle of the present invention may comprise a capsid protein having the sequence of SEQ ID NO: 1 and 3 of International Publication No. WO 2014160092 (the contents of which are incorporated herein by reference in their entirety), which has increased tropism for the brain.
[0403] In one embodiment, the AAV particles of the present invention may include a capsid protein that can target oligodendrocytes in the central nervous system. The capsid protein may include an AAV capsid coding sequence of SEQ ID NO: 1 of International Publication No. WO 2014052789 (the contents of which are incorporated herein by reference in their entirety) or an AAV capsid protein containing an amino acid sequence of SEQ ID NO: 2 to 4.
[0404] In one embodiment, the AAV particles of the invention may comprise a capsid protein having an increased ability to cross the blood-brain barrier in the CNS as disclosed in U.S. Pat. No. 8,927,514 (the contents of which are incorporated herein by reference in their entirety). The amino acid sequence and nucleic acid sequence of such a capsid protein may include, but are not limited to, SEQ ID NO: 2-17 and SEQ ID NO: 25-33 of U.S. Pat. No. 8,927,514, respectively.
[0405] In some embodiments, the AAV particles of the present invention may include AAV2 capsid protein or a variant thereof. AAV particles with AAV2 capsid protein have been shown to effectively deliver genes to neurons in the brain, retina, and spinal cord. In one embodiment, the AAV2 capsid protein can be further modified, for example, by adding a targeting peptide to the capsid protein that targets the AAV particles to the cerebral vascular endothelium (as disclosed in U.S. Patent Nos. 6,691,948 and 8,299,215, the contents of each of which are incorporated herein by reference in their entirety). Such AAV particles can be used to deliver functional hTREM2 antibodies or antigen-binding fragments thereof (e.g., as described herein).
[0406] In some embodiments, the AAV particles of the present invention may comprise an AAV5 capsid protein or a variant thereof. AAV particles with an AAV5 capsid protein can transduce neurons in various regions of the CNS, including the cortex, hippocampus (HPC), cerebellum, substantia nigra (SN), striatum, globus pallidus, and spinal cord (Burger C et al., Mol Ther. [Molecular Therapy], 2004, 10 (2): 302-317; Liu G et al., Mol Ther. [Molecular Therapy] 2007, 15 (2): 242-247; and Colle M et al., Hum, Mol. Genet. [Human Molecular Genetics] 2010, 19 (1): 147-158). In one embodiment, AAV particles with an AAV 5 capsid protein (which has increased transduction of cells in the CNS) can be those particles from U.S. Pat. No. 7,056,502 (the contents of which are incorporated herein by reference in their entirety).
[0407] In some embodiments, the AAV particles of the present invention may comprise an AAV6 capsid protein or a variant thereof. Recombinant AAV6 serotypes can be targeted to motor neurons in the spinal cord by intracerebroventricular injection (ICV) (Dirren E et al., Hum Gene Ther. [Human Gene Therapy], 2014, 25 (2): 109-120). In addition, studies by San Sebastian et al. have shown that AAV6 serotypes can be retrogradely transported from the terminal to the neuronal cell body in the rat brain (San Sebastian et al., Gen Ther. [Gene Therapy], 2014, 20 (12): 1178-1183).
[0408] In some embodiments, the AAV particles of the present invention may include an AAV8 capsid protein or a variant thereof. AAV particles with an AAV8 capsid protein can transduce neurons, such as neurons in the hippocampus (Klein RL et al., Mol Ther. [Molecular Therapy], 2006, 13 (3): 517-527). In one embodiment, the AAV8 capsid protein may include the amino acid sequence of SEQ ID NO: 2 of U.S. Patent No. 8,318,480 (the contents of which are incorporated herein by reference in their entirety).
[0409] In some embodiments, the AAV particles of the present invention may include AAV9 capsid protein or variants thereof. AAV9 capsid serotype-mediated gene delivery has been observed in the brain, which effectively and long-term expresses transgenes after intraparenchymal injection into the CNS (Klein RL et al., Eur J Neurosci. [European Journal of Neuroscience], 2008, 27: 1615-1625). After peripheral, systemic (e.g., intravenous) administration in neonatal subjects, AAV9 serotypes can produce robust and extensive neuronal transduction throughout the CNS (Foust KD et al., Nat. Biotechnol [Natural Biotechnology], 2009, 27: 59-65; and Duque S et al., Mol Ther. [Molecular Therapy], 2009, 17: 1187-1196). Intrathecal (cerebellomedullary cisterna magna route) administration of AAV9 serotypes can also produce extensive spinal expression. In one embodiment, the AAV9 serotype may include an AAV capsid protein having an amino acid sequence of SEQ ID NO: 2 of U.S. Patent No. 7,198,951 (the contents of which are incorporated herein by reference in their entirety). On the other hand, the AAV9 serotype may include a VP1 capsid protein of SEQ ID NO: 2, 4, or 6, wherein at least one of the surface-exposed tyrosine residues in the amino acid sequence is substituted with another amino acid residue, as disclosed in U.S. Patent Publication No. US20130224836, the contents of which are incorporated herein by reference in their entirety. In an embodiment, an AAV vector comprising an AAV9 capsid is administered systemically, for example, intravenously. In an embodiment, an AAV vector comprising an AAV9 capsid is administered to the brain, spine, or cerebrospinal fluid (CSF), for example, intrathecally.
[0410] In certain embodiments, AAV vectors include variant capsid proteins engineered to obtain specific characteristics. These methods for obtaining engineered capsids are described in, for example, patent disclosure WO 2011038187, the contents of which are incorporated herein by reference in their entirety. Such methods and vectors are also described in, for example, patent disclosure WO 2012112832 and patent application disclosure WO2015054653, the contents of which are incorporated herein by reference in their entirety. Such variant capsids include, for example, WO 2015054653 SEQ ID NO:23, or variants thereof. Other variant capsids include, for example, those capsid sequences described in patent disclosure WO2017 / 019994 (its contents are incorporated herein by reference in their entirety). In an embodiment, the AAV vector comprises a capsid having an Anc80 AAV capsid sequence (e.g., SEQ ID NO: 1 of WO 2017019994), e.g., Anc80L65 (e.g., SEQ ID NO: 23 of WO 2017019994), or e.g., Anc110 (e.g., SEQ ID NO: 42 of WO 2017019994).
[0411] In some embodiments, the AAV particles of the present invention may comprise an AAVrh10 capsid protein or a variant thereof. AAV particles comprising an AAVrh10 capsid protein can target neurons and other cells in the spinal cord after intrathecal (IT) administration. In one embodiment, the AAVrh10 capsid protein may comprise the amino acid sequence of SEQ ID NO:81 of European Patent No. 2341068.
[00188] In some embodiments, the AAV of the present invention may comprise an AAVDJ capsid protein, an AAVDJ / 8 capsid protein or a variant thereof. Holehonnur et al. showed that the AAVDJ / 8 serotype can target neurons within the basal and lateral amygdala (BLA) (Holehonnur R et al., BMC Neurosci [BMC Neuroscience], 2014, February 18: 15:28). In one embodiment, the AAVDJ capsid protein and / or AAVDJ / 8 capsid protein may comprise an amino acid sequence comprising a first region derived from a first AAV serotype (e.g., AAV2), a second region derived from a second AAV serotype (e.g., AAV8), and a third region derived from a third AAV serotype (e.g., AAV 9), wherein the first, second, and third regions may comprise any amino acid sequence disclosed in the present specification.
[0412] In one embodiment, an AAV particle of the invention may comprise a capsid protein that has been shown or known to transduce dorsal root ganglia (DRG).
[0413] In one embodiment, an AAV particle of the invention may comprise a capsid protein that has been shown or known to transduce motor neurons.
[0414] In one embodiment, the AAV particle comprises a self-complementary (SC) vector genome.
[0415] In one embodiment, the AAV particle comprises a single-stranded (SS) genome.
[0416] In one embodiment, AAV particles comprising a self-complementary (sc) vector can be used to produce higher expression than AAV particles comprising the corresponding single-stranded vector genome.
[0417] In one embodiment, the serotype of the AAV particles described herein may depend on the desired distribution, transduction efficiency, and desired cell targeting. As described in Sorrentino et al. (comprehensive map of CNS transduction by eight adeno-associated virus serotypes upon cerebrospinal fluid administration in pigs, Molecular Therapy [Molecular Therapy] received an article online preview on December 7, 2015; doi: 10.1038 / mt.2015.212; the contents of which are incorporated herein by reference in their entirety), AAV serotypes provide different distributions, transduction efficiencies, and cell targeting. In order to provide the desired efficacy, it is necessary to select an AAV serotype that not only best matches the cells to be targeted, but also matches the desired transduction efficiency and distribution.
[0418] In one embodiment, the AAV vector comprises an AAV9 capsid (as described herein) and an AAV vector plasmid comprising (1) ITRs derived from AAV2, (2) a CMV enhancer (e.g., SEQ ID NO: 134), (3) a CBA promoter (e.g., SEQ ID NO: 135), (4) an SV40 intron (e.g., SEQ ID NO: 137), (5) a polynucleotide encoding an hTREM2 antibody or antigen-binding fragment thereof (e.g., as described herein), and (6) a BGH poly A signal (e.g., SEQ ID NO: 138). In one embodiment, elements (2) to (6) are arranged from 5' to 3' on the AAV vector plasmid. In an embodiment, elements (2) to (6) are arranged between the 5' ITR and the 3' ITR on the AAV vector plasmid. In one embodiment, the AAV vector is a scAAV vector.
[0419] Production of monoclonal antibodies
[0420] Monoclonal antibodies (mAbs) can be produced by a variety of techniques, including conventional monoclonal antibody methods, such as the standard somatic cell hybridization technique of Kohler and Milstein, 1975 Nature 256: 495. A number of techniques for producing monoclonal antibodies are available, such as viral or oncogenic transformation of B lymphocytes.
[0421] The animal system used to prepare hybridomas is the murine system. Hybridoma production in mice is a well-established procedure. Immunization protocols and techniques for isolating immune spleen cells for fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.
[0422] In some embodiments, these antibodies of the present invention are humanized monoclonal antibodies. Chimeric or humanized antibodies of the present invention and antigen-binding fragments thereof can be prepared based on the sequence of the mouse monoclonal antibody prepared as described above. DNA encoding heavy and light chain immunoglobulins can be obtained from mouse hybridomas of interest and engineered to contain non-mouse (e.g., human) immunoglobulin sequences using standard molecular biology techniques. For example, in order to produce chimeric antibodies, mouse variable regions can be connected to human constant regions using methods known in the art (see, e.g., U.S. Pat. No. 4,816,567 by Cabilly et al.). To produce humanized antibodies, murine CDR regions can be inserted into human frameworks using methods known in the art. See, e.g., U.S. Pat. No. 5,225,539 (belonging to Winter) and U.S. Pat. No. 5,530,101; 5,585,089; 5,693,762 and 6180370 (belonging to Queen et al.).
[0423] In some embodiments, the antibodies of the present invention are human monoclonal antibodies. Transgenic or transchromosomal mice carrying part of the human immune system rather than the mouse system can be used to generate such human monoclonal antibodies against TREM2. These transgenic and transchromosomal mice include mice referred to herein as HuMAb mice and KM mice, respectively, and are collectively referred to herein as "human Ig mice".
[0424] HuMAb (Medarex, Inc.) contains human immunoglobulin gene miniloci encoding unrearranged human heavy chain (μ and γ) and κ light chain immunoglobulin sequences, as well as targeted mutations that inactivate the endogenous μ and κ chain loci (see, e.g., Lonberg, et al., 1994 Nature 368(6474):856-859). Thus, the mice exhibit reduced expression of mouse IgM or K, and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation to generate a high affinity human IgG-κ monoclonal (Lonberg, N. et al., 1994 supra; reviewed in Lonberg, N., 1994 Handbook of Experimental Pharmacology 113:49-101; Lonberg, N. and Huszar, D., 1995 Intern. Rev. Immunol. 13:65-93, and Harding, F. and Lonberg, N., 1995 Ann. NY Acad. Sci. 764:536-546). Preparation and use of HuMAb mice and genomic modifications made by such mice are further described in the following literature: Taylor, L. et al., 1992 Nucleic Acids Research 20:6287-6295; Chen, J. et al., 1993 International Immunology 5:647-656; Tuaillon et al., 1993 Proc. Natl. Acad. Sci. USA 94:3720-3724; Choi et al., 1993 Nature Genetics 4:117-123; Chen, J. et al., 1993 EMBO J. 12:821-830; Tuaillon et al., 1994 J. Immunol. 152:2912-2920; Taylor, L. et al., 1994 International Immunology 579-591; and Fishwild, D. et al., 1996 Nature Biotechnology 14:845-851, the contents of all of which are specifically incorporated by reference in their entirety.See also U.S. Patent Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; and 5,770,429; all to Lonberg and Kay; U.S. Patent No. 5,545,807 (to Surani et al.); PCT Publication Nos. WO 92103918, WO 93 / 12227, WO 94 / 25585, WO 97113852, WO 98 / 24884, and WO 99 / 45962 (all to Lonberg and Kay); and PCT Publication No. WO 01 / 14424 (to Korman et al.).
[0425] In certain embodiments, human antibodies can be produced using mice carrying human immunoglobulin sequences on transgenic and transchromosomes, such as mice carrying human heavy chain transgenics and human light chain transchromosomes. Such mice (referred to herein as "KM mice") are described in detail in PCT Publication WO 02 / 43478 (belonging to Ishida et al.).
[0426] Still further, alternative transgenic animal systems expressing human immunoglobulin genes are available in the art and can be used to produce TREM2 binding antibodies and antigen-binding fragments thereof. For example, an alternative transgenic system known as Xenomouse (Abgenix, Inc.) can be used. Such mice are described in, for example, U.S. Patent Nos. 5,939,598; 6,075,181; 6,114,598; 6,150,584 and 6,162,963 (to Kucherlapati et al.).
[0427] In addition, alternative transgenic animal systems expressing human immunoglobulin genes are available in the art and can be used to produce the TREM2 binding antibodies of the present invention. For example, mice called "TC mice" carrying human heavy chain transchromosomes and human light chain transchromosomes can be used; such mice are described in Tomizuka et al., 2000 Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 97: 722-727. In addition, cattle carrying human heavy and light chain transchromosomes have been described in the art (Kuroiwa et al., 2002 Nature Biotechnology [Natural Biotechnology] 20: 889-894) and can be used to produce the TREM2 binding antibodies of the present invention.
[0428] Human monoclonal antibodies can also be prepared using phage display methods for screening human immunoglobulin gene libraries. Such phage display methods for isolating human antibodies are established in the art or described in the following examples. See, for example, U.S. Patent Nos. 5,223,409; 5,403,484; and 5,571,698 (Ladner et al.); U.S. Patent Nos. 5,427,908 and 5,580,717 (Dower et al.); U.S. Patent Nos. 5,969,108 and 6,172,197 (McCafferty et al.); and U.S. Patent Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 (Griffiths et al.).
[0429] Human monoclonal antibodies of the invention can also be prepared using SCID mice into which human immune cells have been reconstituted so that a human antibody response can be generated upon immunization. Such mice are described in U.S. Pat. Nos. 5,476,996 and 5,698,767 to Wilson et al.
[0430] Framework or Fc engineering
[0431] The engineered antibodies and antigen-binding fragments thereof of the present invention include those in which the framework residues in VH and / or VL have been modified, for example, to improve the properties of the antibody. Such framework modifications are generally performed to reduce the immunogenicity of the antibody. For example, one method is to "revert" one or more framework residues to the corresponding germline sequence. More specifically, an antibody that has undergone somatic mutations may contain framework residues that are different from the germline sequence of the derived antibody. Such residues can be identified by comparing the antibody framework sequence with the germline sequence of the derived antibody. In order to restore the framework region sequence to its germline configuration, the somatic mutation can be "reverted" to the germline sequence by, for example, site-directed mutagenesis. Such "reverted" antibodies are also intended to be encompassed by the present invention.
[0432] Another type of framework modification includes mutating one or more residues in the framework region or even in one or more CDR regions to remove T cell epitopes, thereby reducing the potential immunogenicity of the antibody. This approach is also referred to as "deimmunization" and is described in further detail in U.S. Patent Publication No. 20030153043 by Carr et al.
[0433] In addition to the modification carried out in the framework or CDR region or as an alternative to the modification carried out in the framework or CDR region, the antibody of the present invention can be engineered to include the modification in the Fc region, generally to change one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or antigen-dependent cellular toxicity. In addition, the antibody of the present invention can be chemically modified (for example, one or more chemical moieties can be attached to the antibody) or modified to change its glycosylation, thereby again changing one or more functional properties of the antibody. Each of these embodiments is described in more detail below. The numbering of residues in the Fc region is the numbering of the EU index of Kabat.
[0434] In one embodiment, the hinge region of CH1 is modified so that the number of cysteine residues in the hinge region is changed, for example, increased or decreased. This method is further described in U.S. Patent No. 5,677,425 to Bodmer et al. The number of cysteine residues in the hinge region of CH1 is changed, for example, to facilitate the assembly of light and heavy chains or to increase or decrease the stability of the antibody.
[0435] In another embodiment, the Fc hinge region of the antibody is mutated to reduce the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc hinge fragment so that the antibody has impaired staphylococcal protein A (SpA) binding relative to native Fc hinge domain SpA binding. This method is further described in detail in U.S. Pat. No. 6,165,745 to Ward et al.
[0436] In another embodiment, the antibody is modified to increase its biological half-life. Various methods can be used. For example, one or more of the following mutations can be introduced: T252L, T254S, T256F, as described in Ward's U.S. Patent No. 6,277,375. Alternatively, to increase the biological half-life, the antibody can be changed in the CH1 or CL region to contain a salvage receptor binding epitope collected from two loops of the CH2 domain of the Fc region of IgG, as described in Presta et al. U.S. Patent Nos. 5,869,046 and 6,121,022.
[0437] In one embodiment, the Fc region is changed by replacing at least one amino acid residue with a different amino acid residue to change the effector function of the antibody. For example, one or more amino acids can be replaced with different amino acid residues so that the antibody has a changed affinity for the effector ligand, but retains the antigen binding ability of the parent antibody. The effector ligand that changes affinity can be, for example, an Fc receptor or the C1 component of complement. This method is further described in detail in U.S. Patent Nos. 5,624,821 and 5,648,260 by Winter et al.
[0438] In another embodiment, one or more amino acids selected from the amino acid residues can be replaced with a different amino acid residue such that the antibody has altered C1q binding and / or reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Patent No. 6,194,551 to Idusogie et al.
[0439] In another embodiment, one or more amino acid residues are altered to thereby alter the ability of the antibody to fix complement. This approach is further described in PCT Publication WO 94 / 29351 by Bodmer et al.
[0440] In some embodiments, the TREM2 binding molecule contains a human IgG1 constant region. In some embodiments, the human IgG1 constant region includes an Fc region.
[0441] In some embodiments, the Fc region of the TREM2 binding molecule includes one or more mutations that mediate reduced or no antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). In some embodiments, amino acid residues L234 and L235 of the IgG1 constant region are substituted with A234 and A235. In some embodiments, amino acid residue N267 of the IgG1 constant region is substituted with A267. In some embodiments, amino acid residues D265 and P329 of the IgG1 constant region are substituted with A265 and A329. In certain embodiments, the Fc region optionally includes a mutation or a combination of mutations that confer reduced effector function, selected from any one of D265A, P329A, P329G, N297A, D265A / P329A, D265A / N297A, L234 / L235A, P329A / L234A / L235A, and P329G / L234A / L235A. In some embodiments, the Fc region comprises a mutation or a combination of mutations that confer reduced effector function selected from any one of D265A, P329A, P329G, N297A, D265A / P329A, D265A / N297A, L234 / L235A, P329A / L234A / L235A, and P329G / L234A / L235A (all positions according to EU numbering).
[0442] In another embodiment, the Fc region is modified to increase the ability of the antibody to mediate antibody-dependent cellular cytotoxicity (ADCC) and / or to increase the affinity of the antibody for the Fc-γ receptor by modifying one or more amino acids. This method is further described by Presta in PCT Publication WO 00 / 42072. In addition, the binding sites for Fc-γRI, Fc-γRII, Fc-γRIII and FcRn on human IgG1 have been mapped, and variants with improved binding have been described (see Shields, RL et al., 2001 J. Biol. Chen. [Journal of Biological Chemistry] 276: 6591-6604). For example, the Fc region may comprise a mutation or a combination of mutations that confer increased effector function selected from any one of S239D, I332E, A330L, S298A, E333A, E333S, K334A, K236A, K236W, F243L, P247I, D280H, K290S, R292P, S298D, S298V, Y300L, V305I, A339D, A339Q, A339T, P396L (all positions according to EU numbering).
[0443] In yet another embodiment, the glycosylation of the modified antibody. For example, a non-glycosylated antibody (i.e., the antibody lacks glycosylation) can be prepared. Glycosylation can be changed, for example, to increase the affinity of the antibody for the antigen. Such carbohydrate modifications can be achieved by, for example, changing one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions can be made, which leads to the elimination of one or more variable region framework glycosylation sites, thereby eliminating the glycosylation of the site. This aglycosylation can increase the affinity of the antibody for the antigen. Such methods are further described in detail in U.S. Patent Nos. 5,714,350 and 6,350,861 of Co et al.
[0444] Additionally or alternatively, antibodies with altered glycosylation types can be prepared, such as low-fucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisecting GlcNac structures. Such altered glycosylation patterns have been shown to increase the ADCC ability of antibodies. Such carbohydrate modifications can be achieved, for example, by expressing antibodies in host cells with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which recombinant antibodies of the present invention are expressed, thereby producing antibodies with altered glycosylation. For example, EP 1,176,195 by Hang et al. describes a cell line with a functionally disrupted FUT8 gene that encodes a fucosyltransferase, such that antibodies expressed in such a cell line exhibit low fucosylation. PCT Publication WO 03 / 035835 by Presta describes a variant CHO cell line, LecI3 cells, which have a reduced ability to attach fucose to Asn(297)-linked carbohydrates, also resulting in hypofucosylation of antibodies expressed in the host cells (see also Shields, RL et al., 2002 J. Biol. Chem. 277:26733-26740). PCT Publication WO 99 / 54342 by Umana et al. describes a cell line engineered to express a glycoprotein modifying glycosyltransferase (e.g., β(1,4)-N-acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell line exhibit increased bisecting GlcNac structures, which result in increased ADCC activity of the antibodies (see also Umana et al., 1999 Nat. Biotech. 17:176-180).
[0445] In some embodiments, the TREM2 binding molecule is an antibody. In some embodiments, the antibody has an IgG1 isotype having one or more mutations (e.g., relative to a wild-type Fc region of the same isotype). In some embodiments, the one or more mutations are selected from N297A, N297Q (BoltS et al. (1993) Eur J Immunol [European Journal of Immunology] 23:403-411), D265A, L234A, L235A (McEarchern et al., (2007) Blood [Blood], 109:1185-1192), C226S, C229S (McEarchern et al., (2007) Blood [Blood], 109:1185-1192), P238S (Davis et al., (2007) J Rheumatol [Rheumatol], 34:2204-2210), E233P, L234V (McEarchern et al., (2007) Blood [Blood], 109:1185-1192), P238A, A327Q, A327G, P329A (Shields et al., (2001) J Biol Chem. 276(9):6591-604), K322A, L234F, L235E (Hezareh et al., (2001) J Viral [Journal of Virology] 75, 12161-12168; Oganesyan et al., (2008). Acta Crystallographica [Acta Crystallographica] 64, 700-704), P331S (Oganesyan et al., (2008) Acta Crystallographica [Acta Crystallographica] 64, 700-704), T394D (Wilkinson et al. (2013) MAbs 5(3):406-417), A330L, M252Y, S254T, and / or T256E, wherein the amino acid positions are according to the EU or Kabat numbering convention. In certain embodiments, the Fc region further comprises an amino acid deletion at the position corresponding to glycine 236 according to the EU or Kabat numbering convention.
[0446] In some embodiments, the antibody is of an IgG1 isotype according to the EU or Kabat numbering convention, having a heavy chain constant region containing a C220S mutation.
[0447] In some embodiments, the Fc region further contains one or more additional mutations selected from the group consisting of: A330L, L234F, L235E, and / or P331S (according to EU or Kabat numbering conventions).
[0448] In certain embodiments, the antibody has an IgG2 isotype. In certain embodiments, the antibody contains a human IgG2 constant region. In certain embodiments, the human IgG2 constant region includes an Fc region. In certain embodiments, the Fc region includes one or more modifications. For example, in certain embodiments, the Fc region includes one or more mutations (e.g., relative to a wild-type Fc region of the same isotype). In certain embodiments, the one or more mutations are selected from V234A, G237A, H268E, V309L, N297A, N297Q, A330S, P331S, C232S, C233S, M252Y, S254T, and / or T256E, wherein the amino acid position is according to EU or Kabat numbering conventions.
[0449] In certain embodiments, the antibody has an IgG4 isotype. In certain embodiments, the antibody contains a human IgG4 constant region. In certain embodiments, the human IgG4 constant region includes an Fc region. In certain embodiments, the Fc region includes one or more modifications. For example, in certain embodiments, the Fc region includes one or more mutations (e.g., relative to a wild-type Fc region of the same isotype). In some embodiments, the one or more mutations are selected from E233P, F234V, L235A, G237A, E318A (Hutchins et al. (1995) Proc Nat / A cad Sci USA, 92: 11980-11984), S228P, L236E, S241P, L248E (Reddy et al., (2000) J Immuno / , 164: 1925-1933; Angal et al., (1993) Mol Immunol. 30(1): 105-8; US 8614299 B2), T394D, M252Y, S254T, T256E, N297A, and / or N297Q, wherein amino acid positions are according to the EU or Kabat numbering convention.
[0450] In some embodiments, the Fc region further contains one or more additional mutations selected from M252Y, S254T and / or T256E, wherein the amino acid positions are according to the EU or Kabat numbering convention.
[0451] In some embodiments, one or more IgG1 variants described herein may be combined with an A330L mutation (Lazar et al., (2006) Proc Natl Acad Sci USA, 103:4005-4010), or with one or more of the L234F, L235E, and / or P331S mutations (Sazinsky et al., (2008) Proc Natl Acad Sci USA, 105:20167-20172) to eliminate complement activation, where amino acid positions are according to the EU or Kabat numbering convention. In some embodiments, the IgG variants described herein may be combined with one or more mutations (e.g., M252Y, S254T, T256E mutations according to the EU or Kabat numbering convention) to enhance antibody half-life in human serum (Dall'Acqua et al., (2006) J Biol Chem, 281:23514-23524; and Strohl et al., (2009) Current Opinion in Biotechnology, 20:685-691).
[0452] In some embodiments, the IgG4 variants of the present disclosure may be combined with the S228P mutation (according to the EU or Kabat numbering convention) (Angal et al., (1993) Mol Immunol, 30: 105-108), and / or with one or more mutations described in Peters et al. ((2012) J Biol Chem. 13; 287(29): 24525-33) to enhance antibody stability.
[0453] In some embodiments, the antibody has an Fc region selected from an IgG2 Fc region, an IgG4 Fc region, or an IgG2 / IgG4 hybrid Fc region.
[0454] Methods of engineering altered antibodies
[0455] As described above, the TREM2 binding antibodies having VH and VL sequences or full-length heavy and light chain sequences described herein can be used to generate new TREM2 binding antibodies by modifying the full-length heavy and / or light chain sequences, VH and / or VL sequences, or one or more constant regions attached thereto. Thus, in another aspect of the invention, the structural features of the TREM2 binding antibodies of the invention are used to generate structurally related TREM2 binding antibodies that retain at least one functional property of the antibodies and antigen-binding fragments thereof of the invention, such as binding to human TREM2 and stabilizing the functional properties of human TREM2.
[0456] For example, one or more CDR regions or mutations thereof of an antibody or antigen-binding fragment thereof of the invention can be recombined with known framework regions and / or other CDRs to produce additional recombinantly engineered TREM2 binding antibodies or antigen-binding fragments thereof of the invention, as discussed above. Other types of modifications include those described in the previous section. The starting material for the engineering method is one or more VH and / or VL sequences provided herein, or one or more CDR regions thereof. In order to produce an engineered antibody, it is not necessary to actually prepare (i.e., express as a protein) an antibody having one or more VH and / or VL sequences provided herein, or one or more CDR regions thereof. Instead, the information contained in the one or more sequences is used as a starting material to produce one or more "second generation" sequences derived from the one or more original sequences, which are then prepared and expressed as proteins.
[0457] The antibody sequence of change can also be prepared by screening an antibody library with a diversity of fixed CDR3 sequences or minimally necessary binding determinants and CDR1 and CDR2 sequences as described in US20050255552. The screening can be carried out according to any screening technique suitable for screening antibodies from antibody libraries, such as phage display technology.
[0458] Standard molecular biology techniques can be used to prepare and express the altered antibody sequences.Antibodies encoded by one or more altered antibody sequences are antibodies that retain one, some, or all of the functional properties of the TREM2 binding antibodies described herein, including but not limited to specific binding to and stabilizing human TREM2 proteins.
[0459] The functional properties of the altered antibodies can be assessed using standard assays available in the art and / or described herein, such as those described in the Examples (eg, ELISA).
[0460] In some embodiments, in methods of engineering antibodies and antigen-binding fragments thereof of the invention, mutations can be introduced randomly or selectively along all or part of a TREM2 binding antibody coding sequence, and the resulting modified TREM2 binding antibody can be screened for binding activity and / or other functional properties as described herein. Mutation methods have been described in the art. For example, PCT Publication WO 02 / 092780 by Short describes methods for generating and screening antibody mutations using saturation mutagenesis, synthetic ligation assembly, or a combination thereof. Alternatively, PCT Publication WO 03 / 074679 by Lazar et al. describes methods for using computational screening methods to optimize the physiochemical properties of antibodies.
[0461] Characterization of the Antibodies of the Invention
[0462] The antibodies and antigen-binding fragments thereof of the invention can be characterized by various functional assays. For example, they are characterized by their ability to bind to and stabilize TREM2.
[0463] The ability of an antibody to bind TREM2 can be detected by directly labeling the antibody of interest, or the antibody can be unlabeled and binding detected indirectly using various sandwich assay formats known in the art.
[0464] In some embodiments, the TREM2 binding antibodies and antigen-binding fragments thereof of the present invention block a reference TREM2 binding antibody or compete with a reference TREM2 binding antibody for binding to a TREM2 polypeptide. These may be fully human or humanized TREM2 binding antibodies as described above. They may also be other human, mouse, chimeric or humanized TREM2 binding antibodies that bind to the same epitope as the reference antibody. The ability to block binding of a reference antibody or to compete with a reference antibody for binding indicates that the TREM2 binding antibody in the test binds to an epitope that is identical or similar to that defined by the reference antibody, or binds to an epitope that is sufficiently close to that bound by the reference TREM2 binding antibody. Such antibodies may particularly have favorable properties for identification against a reference antibody. The ability to block or compete with a reference antibody can be determined, for example, by a competitive binding assay. Using a competitive binding assay, the ability of the test antibody in the test to inhibit specific binding of a reference antibody to a common antigen (such as a TREM2 polypeptide) is examined. If an excess of the test antibody substantially inhibits binding of the reference antibody, the test antibody competes with the reference antibody for specific binding to the antigen. Substantial inhibition means that the test antibody typically reduces specific binding of the reference antibody by at least 10%, 25%, 50%, 75% or 90%.
[0465] Many known competitive binding assays can be used to assess whether an antibody competes with a reference antibody for binding to a specific protein, in this case TREM2. These assays include, for example, solid phase direct or indirect radioimmunoassays (RIAs), solid phase direct or indirect enzyme immunoassays (EIAs), sandwich competition assays (see Stahli et al., Methods in Enzymology 9:242-253, 1983); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614-3619, 1986); solid phase direct label assay, solid phase direct label sandwich assay (see Harlow and Lane, supra); solid phase direct label RIA using 1-125 labeling (see Morel et al., Mol. Immunol. 25:7-15, 1988); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546-552, 1990); and directly labeled RIA (Moldenhauer et al., Scand. J. Immunol. 32:77-82, 1990). Typically, such assays involve the use of purified antigen bound to a solid surface or cell carrying any of these unlabeled test TREM2 binding antibodies and labeled reference antibodies. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cell in the presence of the test antibody. Typically, the test antibody is present in excess. Antibodies identified by competition assays (i.e., competing antibodies) include antibodies that bind to the same epitope as the reference antibody and antibodies that bind to an adjacent epitope that is sufficiently close to the epitope bound by the reference antibody to cause steric hindrance.
[0466] To determine whether the selected TREM2 binding monoclonal antibody binds to a unique epitope, each antibody can be biotinylated using commercially available reagents (e.g., reagents from Pierce, Rockford, Ill., Rockford, Illinois). Competition studies using unlabeled monoclonal antibodies and biotinylated monoclonal antibodies can be performed using TREM2 polypeptide-coated ELISA plates. Biotinylated MAb binding can be detected with a streptavidin-alkaline phosphatase probe. To determine the isotype of the purified TREM2 binding antibody, an isotype ELISA can be performed. For example, wells of a microtiter plate can be coated with 1 μg / ml anti-human IgG overnight at 4°C. After blocking with 1% BSA, the plates are reacted with 1 μg / ml or less monoclonal TREM2 binding antibodies or purified isotype controls at ambient temperature for 1 to 2 hours. The wells can then be reacted with probes conjugated to human IgG1 or human IgM-specific alkaline phosphatase. The plates are then developed and analyzed to determine the isotype of the purified antibodies.
[0467] To demonstrate the binding of monoclonal TREM2 binding antibodies to hepatocytes expressing TREM2 polypeptides, flow cytometry can be used. In short, cell lines expressing TREM2 (grown under standard growth conditions) can be mixed with various concentrations of TREM2 binding antibodies in PBS containing 0.1% BSA and 10% fetal bovine serum and incubated at 37°C for 1 hour. After washing, the cells are reacted with fluorescein-labeled anti-human IgG antibodies under the same conditions as the primary antibody staining. The samples can be analyzed by gating single cells using light and side scatter properties by a FACScan instrument. (In addition to or in lieu of) flow cytometry, an alternative assay using fluorescence microscopy can also be used. Cells can be stained as described above and examined by fluorescence microscopy. This method allows visualization of single cells, but can have reduced sensitivity depending on the density of the antigen.
[0468] The reactivity of the TREM2 binding antibodies and antigen-binding fragments thereof of the present invention with TREM2 polypeptides or antigen fragments can be further tested by Western blotting. In short, purified TREM2 polypeptides or fusion proteins, or cell extracts from cells expressing TREM2, can be prepared and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis. After electrophoresis, the separated antigens are transferred to nitrocellulose membranes, blocked with 10% fetal bovine serum, and probed with the monoclonal antibodies to be tested. Human IgG binding can be detected using anti-human IgG alkaline phosphatase, and developed with BCIP / NBT substrate tablets (Sigma Chem. Co., St. Louis, Mo., St. Louis, Mo.).
[0469] Examples of functional assays are also described in the Examples section below.
[0470] Treatment
[0471] Provided herein are methods of treating diseases associated with loss of TREM2 function by using the TREM2 binding molecules disclosed herein. In some embodiments, the disease associated with loss of TREM2 function is a neuroinflammatory or neurodegenerative disease, such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakora disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage diseases, such as Niemann-Pick disease (Niemann-Pick C) and mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, neurobehcet's disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen's encephalitis (Rasmussen's In some preferred embodiments, the disease associated with loss of TREM2 function is selected from the list consisting of Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, or Nasu-Hakkara disease.
[0472] Also provided herein are methods for treating TREM2-related disorders directly or indirectly associated with abnormal TREM2 activity and / or expression by using the TREM2 binding molecules disclosed herein. Trem2-related disorders include CNS-related diseases, PNS-related diseases, systemic inflammation and other inflammation-related diseases, pain and withdrawal symptoms caused by abuse of chemical substances, and CNS-related diseases or disorders include generalized anxiety disorder, cognitive impairment, learning and memory deficits and dysfunctions, Alzheimer's disease (mild, moderate and severe), attention deficit and hyperactivity disorder, Parkinson's disease, Parkinson's disease dementia, Huntington's disease, ALS, chronic neurodegenerative disorders, such as Creutzfeld-Jacob disease and kuru disease, Tourette syndrome, psychosis, depression and depressive disorders, mania, manic depression, schizophrenia, cognitive deficits in schizophrenia, obsessive-compulsive disorder, panic disorder, eating disorders, narcolepsy, nociception, AIDS-dementia, Alzheimer's disease, age-related mild cognitive impairment (MCI), age-related memory impairment, autism, dyslexia, tardive dyskinesia, epilepsy, and convulsive disorders, post-traumatic stress disorder, transient hypoxia, pseudodementia, premenstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome and jet lag. In some preferred embodiments, Trem2-related disorders are selected from the following list, which consists of: Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis or Nasu-Hakola disease.
[0473] Trem2-related diseases also include: immune disorders, especially inflammatory disorders (such as bacterial infections, fungal infections, viral infections, protozoan or other parasitic infections, psoriasis, sepsis, cerebral malaria, inflammatory bowel disease, arthritis (such as rheumatoid arthritis), folliculitis, impetigo, granuloma, lipoid pneumonia, vasculitis, and osteoarthritis), autoimmune disorders (such as rheumatoid arthritis, thyroiditis (such as Hashimoto's thyroiditis and Graves' disease), insulin-resistant diabetes, pernicious anemia, Addison's disease, pemphigus, vitiligo, ulcerative colitis, enteritis, systemic lupus erythematosus (SLE), Sjögren's syndrome, multiple sclerosis, dermatomyositis, mixed connective tissue disease, scleroderma, polymyositis, transplant rejection (such as allogeneic transplant rejection), T-cell disorders (such as AIDS), allergic inflammatory disorders (such as skin and / or mucosal allergies, such as allergic rhinitis, asthma, psoriasis), nervous system disorders, eye disorders, embryonic disorders, or any other disorder directly or indirectly related to aberrant activity and / or expression of TREM2 (such as tumors, cancer, leukemia, myeloid diseases, and trauma).
[0474] In some embodiments, a TREM2-associated disorder is an autoimmune disorder, inflammatory disorder, or malignant disorder mediated by or associated with extensive proteolytic cleavage of TREM2 or cells expressing an abnormal or mutant variant of the TREM2 receptor. Examples of autoimmune diseases include, but are not limited to, arthritis (e.g., rheumatoid arthritis, chronic arthritis, and deforming arthritis) and rheumatic diseases, including inflammatory conditions and rheumatic diseases involving bone loss, inflammatory pain, spondylitis (including ankylosing spondylitis), Reiter's syndrome, reactive arthritis, psoriatic arthritis, and enterophathic arthritis, hypersensitivity reactions (including airway hypersensitivity reactions and skin hypersensitivity reactions), and allergies. Autoimmune diseases include autoimmune blood disorders (including, for example, hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), systemic lupus erythematosus, inflammatory muscle disorders, polychondritis, scleroma, Wegener's granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven Johnson syndrome, idiopathic sprue, endocrine eye diseases, Graves' disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis chondroitinib, leukemia, leukoderma, leukoplakia, chondroitinib, leukoderma lucidum, leukoderma necrosis, leukoderma sclerosing ...necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma sclerosing, leukoderma necrosis, leukoderma necrosis, leukoderma necrosis, leukoderma necrosis
[0475] In some embodiments, the TREM2-associated disorder is selected from asthma, bronchitis, pneumoconiosis, emphysema, other obstructive or inflammatory diseases of the airways including idiopathic pulmonary fibrosis, or COPD.
[0476] In some embodiments, the TREM2-associated disorder is a hematopoietic or hepatocellular malignancy, such as acute myeloid leukemia, chronic myeloid leukemia, a myeloproliferative disorder, myelodysplastic syndrome, multi...
Claims
1. An antibody or an antigen-binding fragment thereof that binds to the immunoglobulin superfamily (IgSF) domain of human myeloid cell triggering receptor 2 (hTREM2) protein and stabilizes the hTREM2 protein (e.g., SEQ ID NO: 1, 2 or 3).
2. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to one or more residues selected from the group consisting of: D39, S40, M41, K42, W44, G45, R46, R47, H67, N68, L69, W70, L71, L72, F74, L75, R77, D87, T88, L89 and G90 of hTREM2.
3. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to one or more residues of hTREM2 selected from the group consisting of: D39, S40, M41, K42, W44, G45, R46 and R47, one or more residues selected from the group consisting of: H67, N68, L69, W70, L71, L72, F74, L75 and R77, and one or more residues selected from the group consisting of: D87, T88, L89 and G90.
4. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to five or more residues selected from the group consisting of: D39, S40, M41, K42, W44, G45, R46 and R47, four or more residues selected from the group consisting of: H67, N68, L69, W70, L71, L72, F74, L75 and R77, and three or more residues selected from the group consisting of: D87, T88, L89 and G90 of hTREM2.
5. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to seven or more residues of hTREM2 selected from the group consisting of: D39, S40, M41, K42, W44, G45, R46 and R47, four or more residues selected from the group consisting of: H67, N68, L69, W70, L71, L72, F74, L75 and R77, and three or more residues selected from the group consisting of: D87, T88, L89 and G90.
6. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to five or more residues of hTREM2 selected from the group consisting of: D39, S40, M41, K42, W44, G45, R46 and R47, all residues H67, N68, L69, W70, L71, L72, F74, L75 and R77, and three or more residues selected from the group consisting of: D87, T88, L89 and G90.
7. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to one or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
8. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to two or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
9. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to three or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
10. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to four or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
11. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds five or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
12. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds six or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
13. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds seven or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
14. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds eight or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
15. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds nine or more residues selected from the group consisting of: S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
16. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to all residues S40, M41, W44, G45, W70, L71, L72, F74, T88 and L89 of hTREM2.
17. The antibody or antigen-binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen-binding fragment thereof binds to one or more residues selected from the group consisting of: D39, K42, R46 and G90 of hTREM2.
18. The antibody or antigen-binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen-binding fragment thereof binds to two or more residues selected from the group consisting of: D39, K42, R46 and G90 of hTREM2.
19. The antibody or antigen-binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen-binding fragment thereof binds to three or more residues selected from the group consisting of: D39, K42, R46 and G90 of hTREM2.
20. The antibody or antigen-binding fragment thereof of any one of claims 7 to 15, wherein the antibody or antigen-binding fragment thereof binds to all of residues D39, K42, R46 and G90 of hTREM2.
21. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to all residues S40, M41, W44, G45, W70, L71, L72, F74, T88, L89, D39, K42, R46 and G90 of hTREM2.
22. The antibody or antigen-binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen-binding fragment thereof binds to one or more residues selected from the group consisting of: R47, H67, N68, L69, L75, R77 and D87 of hTREM2.
23. The antibody or antigen-binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen-binding fragment thereof binds to two or more residues selected from the group consisting of: R47, H67, N68, L69, L75, R77 and D87 of hTREM2.
24. The antibody or antigen-binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen-binding fragment thereof binds to three or more residues selected from the group consisting of: R47, H67, N68, L69, L75, R77 and D87 of hTREM2.
25. The antibody or antigen binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen binding fragment thereof binds to four or more residues selected from the group consisting of: R47, H67, N68, L69, L75, R77 and D87 of hTREM2.
26. The antibody or antigen-binding fragment thereof of any one of claims 7 to 16, wherein the antibody or antigen-binding fragment thereof binds five or more residues selected from the group consisting of: R47, H67, N68, L69, L75, R77 and D87 of hTREM2.
27. The antibody or antigen-binding fragment thereof of any one of claims 7 to 15, wherein the antibody or antigen-binding fragment thereof binds six or more residues selected from the group consisting of: R47, H67, N68, L69, L75, R77 and D87 of hTREM2.
28. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds to all of residues S40, M41, W44, G45, W70, L71, L72, F74, T88, L89, R47, H67, N68, L69, L75, R77 and D87 of hTREM2.
29. The antibody or antigen-binding fragment thereof of any one of claims 1 to 28, wherein the antibody or antigen-binding fragment thereof activates hTREM2.
30. The antibody or antigen-binding fragment thereof of any one of claims 1 to 29, wherein the antibody or antigen-binding fragment thereof promotes one or more hTREM2-dependent physiological activities in cells expressing TREM2.
31. The antibody or antigen-binding fragment thereof of any one of claims 1 to 30, wherein the antibody or antigen-binding fragment thereof: a) increasing phagocytosis, e.g., increasing phagocytosis in a cell expressing hTREM2, e.g., wherein the TREM2-expressing cell is a hM2A macrophage or a human iPS-derived microglia-like cell, b) increasing chemotaxis, e.g., increasing chemotaxis in a cell expressing hTREM2, e.g., wherein the TREM2-expressing cell is a hM2a macrophage or a human iPS-derived microglia-like cell, c) increase NFAT-driven reporter gene activity in a human monocytic cell line, d) increasing Syk phosphorylation, e.g., increasing Syk phosphorylation in a cell expressing hTREM2, e.g., wherein the cell expressing TREM2 is a hM2A macrophage, or e) any combination of two or more of a) to d) added.
32. The antibody or antigen-binding fragment thereof of any one of claims 1 to 31, wherein the antibody or antigen-binding fragment thereof has a half-maximal effective concentration (EC) of 1 nM or less, as measured, for example, by FACS analysis on hM2a macrophages. 50 ) binds to hTREM2, for example, binds to hTREM2 on the surface of a cell.
33. The antibody or antigen-binding fragment thereof of any one of claims 1 to 32, wherein the antibody or antigen-binding fragment thereof has a half-maximal effective concentration (EC) of 0.59 nM or less, for example as measured by FACS analysis on hM2a macrophages. 50 ) binds to hTREM2, for example, binds to hTREM2 on the surface of a cell.
34. The antibody or antigen-binding fragment thereof of any one of claims 1 to 33, wherein the antibody or antigen-binding fragment thereof has a dissociation constant (K) of 150 pM or less, as measured, for example, by surface plasmon resonance (SPR). D ) binds to hTREM2.
35. The antibody or antigen-binding fragment thereof of any one of claims 1 to 34, wherein the antibody or antigen-binding fragment thereof has a dissociation constant (K) of 50 pM or less, as measured, for example, by surface plasmon resonance (SPR). D ) binds to hTREM2.
36. The antibody or antigen-binding fragment thereof of any one of claims 1 to 35, wherein the antibody or antigen-binding fragment thereof stabilizes the hTREM2 protein on the cell surface of a cell expressing hTREM2.
37. The antibody or antigen-binding fragment thereof of claim 36, wherein the cell expressing hTREM2 is a macrophage, such as an M2a macrophage, a dendritic cell, an osteoclast, a microglia, a mast cell, a monocyte, a lung epithelial cell, a Langerhans cell of the skin, a Kupffer cell, a neutrophil or a hepatoma cell.
38. The antibody or antigen-binding fragment thereof of any one of claims 1 to 37, wherein the antibody or antigen-binding fragment thereof reduces shedding of the extracellular domain of the hTREM2 protein in hM2A macrophages at a concentration of 100 nM or less.
39. The antibody or antigen-binding fragment thereof of any one of claims 1 to 38, wherein TREM2 cell surface expression is increased 3-fold or more.
40. The antibody or antigen-binding fragment thereof of any one of claims 1 to 39, wherein the IgSF domain of hTREM2 comprises amino acid residues 19 to 132 of any one of SEQ ID NOs 1, 2 and 3.
41. The antibody or antigen-binding fragment thereof of any one of claims 1 to 40, wherein the antibody or antigen-binding fragment thereof comprises: a) a heavy chain variable region CDR1 comprising, for example consisting of: SEQ ID NO:41 or SEQ ID NO:44 or SEQ ID NO:45 or SEQ ID NO:47; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 42 or SEQ ID NO: 46, or SEQ ID NO: 48; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 43 or SEQ ID NO: 49; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 54 or SEQ ID NO: 57 or SEQ ID NO: 60; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 55 or SEQ ID NO: 58; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 56 or SEQ ID NO: 59; b) a heavy chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 4 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 10; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 5 or SEQ ID NO: 9 or SEQ ID NO: 11; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 6 or SEQ ID NO: 12; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 17 or SEQ ID NO: 20 or SEQ ID NO: 23; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 18 or SEQ ID NO: 21; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 19 or SEQ ID NO: 22; c) a heavy chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 4 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 10; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 5 or SEQ ID NO: 9 or SEQ ID NO: 11; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 6 or SEQ ID NO: 12; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 17 or SEQ ID NO: 20 or SEQ ID NO: 23; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 18 or SEQ ID NO: 21; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 78 or SEQ ID NO: 79; or d) a heavy chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO:84 or SEQ ID NO:87 or SEQ ID NO:88 or SEQ ID NO:90; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO:85 or SEQ ID NO:89 or SEQ ID NO:91; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO:86 or SEQ ID NO:92; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO:97 or SEQ ID NO:100 or SEQ ID NO:103; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO:98 or SEQ ID NO:101; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO:99 or SEQ ID NO:
102.
42. An antibody or antigen-binding fragment thereof that binds to the IgSF domain of hTREM2 protein, wherein the antibody or antigen-binding fragment thereof comprises: a) a heavy chain variable region CDR1 comprising, for example consisting of: SEQ ID NO:41 or SEQ ID NO:44 or SEQ ID NO:45 or SEQ ID NO:47; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 42 or SEQ ID NO: 46, or SEQ ID NO: 48; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 43 or SEQ ID NO: 49; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 54 or SEQ ID NO: 57 or SEQ ID NO: 60; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 55 or SEQ ID NO: 58; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 56 or SEQ ID NO: 59; b) a heavy chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 4 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 10; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 5 or SEQ ID NO: 9 or SEQ ID NO: 11; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 6 or SEQ ID NO: 12; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 17 or SEQ ID NO: 20 or SEQ ID NO: 23; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 18 or SEQ ID NO: 21; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 19 or SEQ ID NO: 22; c) a heavy chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 4 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 10; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 5 or SEQ ID NO: 9 or SEQ ID NO: 11; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 6 or SEQ ID NO: 12; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO: 17 or SEQ ID NO: 20 or SEQ ID NO: 23; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO: 18 or SEQ ID NO: 21; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO: 78 or SEQ ID NO: 79; or d) a heavy chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO:84 or SEQ ID NO:87 or SEQ ID NO:88 or SEQ ID NO:90; a heavy chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO:85 or SEQ ID NO:89 or SEQ ID NO:91; a heavy chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO:86 or SEQ ID NO:92; a light chain variable region CDR1 comprising, for example, consisting of: SEQ ID NO:97 or SEQ ID NO:100 or SEQ ID NO:103; a light chain variable region CDR2 comprising, for example, consisting of: SEQ ID NO:98 or SEQ ID NO:101; and a light chain variable region CDR3 comprising, for example, consisting of: SEQ ID NO:99 or SEQ ID NO:
102.
43. The antibody or antigen-binding fragment thereof of any one of claims 1 to 42, wherein the antibody or antigen-binding fragment thereof comprises a) a VH polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 13 or SEQ ID NO: 50, and a VL polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 61; or b) a VH polypeptide sequence having at least 95% sequence identity to SEQ ID NO:13 or SEQ ID NO:93, and a VL polypeptide sequence having at least 95% sequence identity to SEQ ID NO:80 or SEQ ID NO:
104.
44. The antibody or antigen-binding fragment thereof of any one of claims 1 to 43, comprising: a) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:7; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:5; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:6; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:17; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:18; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:19; b) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:44; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:42; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:43; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:54; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:55; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:56; c) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:7; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:5; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:6; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:17; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:18; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:78; or d) a heavy chain variable region CDR1 comprising, for example, consisting of SEQ ID NO:87; a heavy chain variable region CDR2 comprising, for example, consisting of SEQ ID NO:85; a heavy chain variable region CDR3 comprising, for example, consisting of SEQ ID NO:86; a light chain variable region CDR1 comprising, for example, consisting of SEQ ID NO:97; a light chain variable region CDR2 comprising, for example, consisting of SEQ ID NO:98; and a light chain variable region CDR3 comprising, for example, consisting of SEQ ID NO:
99.
45. The antibody or antigen-binding fragment thereof of any one of claims 1 to 43, comprising: a) a heavy chain variable region CDR1 of SEQ ID NO: 8; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 9; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 6; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO: 20; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 21; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 22; b) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:45; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:46; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:43; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:57; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:58; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:59; c) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO: 8; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 9; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 6; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO: 20; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 21; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 79; or d) a heavy chain variable region CDR1 comprising, for example, consisting of SEQ ID NO:88; a heavy chain variable region CDR2 comprising, for example, consisting of SEQ ID NO:89; a heavy chain variable region CDR3 comprising, for example, consisting of SEQ ID NO:86; a light chain variable region CDR1 comprising, for example, consisting of SEQ ID NO:100; a light chain variable region CDR2 comprising, for example, consisting of SEQ ID NO:101; and a light chain variable region CDR3 comprising, for example, consisting of SEQ ID NO:
102.
46. The antibody or antigen-binding fragment thereof of any one of claims 1 to 43, comprising: a) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO: 10; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 11; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 12; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO: 23; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 21; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 19; b) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:47; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:48; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:49; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:60; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:58; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:56; c) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO: 10; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 11; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 12; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO: 23; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO: 21; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO: 78; or d) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:90; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:91; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:92; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:103; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:101; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:
99.
47. The antibody or antigen-binding fragment thereof of any one of claims 1 to 43, comprising: a) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:4; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:5; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:6; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:17; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:18; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:19; b) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:41; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:42; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:43; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:54; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:55; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:56; c) a heavy chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:4; a heavy chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:5; a heavy chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:6; a light chain variable region CDR1 comprising, e.g., consisting of, SEQ ID NO:17; a light chain variable region CDR2 comprising, e.g., consisting of, SEQ ID NO:18; and a light chain variable region CDR3 comprising, e.g., consisting of, SEQ ID NO:78; or d) a heavy chain variable region CDR1 comprising, for example, consisting of SEQ ID NO:84; a heavy chain variable region CDR2 comprising, for example, consisting of SEQ ID NO:85; a heavy chain variable region CDR3 comprising, for example, consisting of SEQ ID NO:86; a light chain variable region CDR1 comprising, for example, consisting of SEQ ID NO:97; a light chain variable region CDR2 comprising, for example, consisting of SEQ ID NO:98; and a light chain variable region CDR3 comprising, for example, consisting of SEQ ID NO:
99.
48. The antibody or antigen-binding fragment thereof of any one of claims 1-47, wherein the antibody or antigen-binding fragment thereof comprises: a) VH and VL, the VH comprising, for example, consisting of SEQ ID NO: 13, and the VL comprising, for example, consisting of SEQ ID NO: 24; or b) VH and VL, the VH comprising, for example, consisting of SEQ ID NO: 50, and the VL comprising, for example, consisting of SEQ ID NO: 61; or c) a VH and a VL, the VH comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 13, and the VL comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 24; or d) a VH comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 50, and a VL comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 61; or e) a VH comprising, e.g., consisting of, a sequence that differs from SEQ ID NO: 13 by at least 1, 2, 3, 4, 5, 6 amino acids, and a VL comprising, e.g., consisting of, a sequence that differs from SEQ ID NO: 24 by at least 1, 2, 3, 4, 5, 6 amino acids; or f) VH and VL, the VH comprising, for example, consisting of, a sequence that differs from SEQ ID NO: 50 by at least 1, 2, 3, 4, 5, 6 amino acids, and the VL comprising, for example, consisting of, a sequence that differs from SEQ ID NO: 61 by at least 1, 2, 3, 4, 5, 6 amino acids; g) a VH and a VL, the VH comprising, for example, consisting of SEQ ID NO: 13, and the VL comprising, for example, consisting of SEQ ID NO: 80; or h) a VH and a VL, the VH comprising, for example, consisting of SEQ ID NO: 93, and the VL comprising, for example, consisting of SEQ ID NO: 104; or i) a VH and a VL, the VH comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 13, and the VL comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 80; or j) a VH and a VL, the VH comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 93, and the VL comprising, e.g., consisting of, a sequence having at least 95% homology to SEQ ID NO: 104; or k) a VH and a VL, the VH comprising, for example, consisting of, a sequence that differs from SEQ ID NO: 13 by at least 1, 2, 3, 4, 5, 6 amino acids, and the VL comprising, for example, consisting of, a sequence that differs from SEQ ID NO: 80 by at least 1, 2, 3, 4, 5, 6 amino acids; or l) VH and VL, wherein VH comprises, for example, consists of, a sequence that differs from SEQ ID NO:93 by at least 1, 2, 3, 4, 5, or 6 amino acids, and VL comprises, for example, consists of, a sequence that differs from SEQ ID NO:104 by at least 1, 2, 3, 4, 5, or 6 amino acids.
49. The antibody or antigen-binding fragment thereof of any one of claims 1-48, wherein the antibody or antigen-binding fragment thereof comprises: a) a heavy chain amino acid sequence comprising, for example, consisting of, SEQ ID NO: 15, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, or SEQ ID NO: 39, and a light chain amino acid sequence comprising, for example, consisting of, SEQ ID NO: 26; b) a heavy chain amino acid sequence comprising, for example, consisting of, SEQ ID NO: 52, SEQ ID NO: 66, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, or SEQ ID NO: 76, and a light chain amino acid sequence comprising, for example, consisting of, SEQ ID NO: 63; c) a heavy chain amino acid sequence and a light chain amino acid sequence, wherein the heavy chain amino acid sequence has at least 95% sequence identity to SEQ ID NO:15, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 or SEQ ID NO:39, and the light chain amino acid sequence has at least 95% sequence identity to SEQ ID NO:26; d) a heavy chain amino acid sequence and a light chain amino acid sequence, wherein the heavy chain amino acid sequence has at least 95% sequence identity to SEQ ID NO:52, SEQ ID NO:66, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76, and the light chain amino acid sequence has at least 95% sequence identity to SEQ ID NO:63; e) a heavy chain amino acid sequence comprising, for example, consisting of SEQ ID NO: 15, and a light chain amino acid sequence comprising, for example, consisting of SEQ ID NO: 82; f) a heavy chain amino acid sequence comprising, for example, consisting of SEQ ID NO: 95, and a light chain amino acid sequence comprising, for example, consisting of SEQ ID NO: 106; g) a heavy chain amino acid sequence that has at least 95% sequence identity to SEQ ID NO: 15 and a light chain amino acid sequence that has at least 95% sequence identity to SEQ ID NO: 82; or h) a heavy chain amino acid sequence and a light chain amino acid sequence, wherein the heavy chain amino acid sequence has at least 95% sequence identity to SEQ ID NO:95 and the light chain amino acid sequence has at least 95% sequence identity to SEQ ID NO:
106.
50. An antibody or antigen-binding fragment thereof, which binds to the immunoglobulin superfamily (IgSF) domain of human triggering receptor 2 on myeloid cells (hTREM2), the antibody or antigen-binding fragment thereof comprising: a) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 15, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 26; b) a heavy chain sequence and a light chain sequence, the heavy chain sequence comprising, for example consisting of, SEQ ID NO: 29, The light chain sequence comprises, for example, consists of, SEQ ID NO: 26; c) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 33, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 26; d) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 35, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 26; e) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 37, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 26; f) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 39, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 26; g) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 52, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 63; h) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 66, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 63; i) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 70, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 63; j) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 72, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 63; k) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 74, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 63; 1) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 76, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 63; m) a heavy chain sequence comprising, for example, consisting of SEQ ID NO: 15, and a light chain sequence comprising, for example, consisting of SEQ ID NO: 82; or n) a heavy chain sequence comprising, for example, consisting of, SEQ ID NO: 95, and a light chain sequence comprising, for example, consisting of, SEQ ID NO:
106.
51. An antibody or antigen-binding fragment thereof that competes with any antibody or antigen-binding fragment thereof as described in any one of claims 1-50 for binding to hTREM2 protein.
52. An antibody or antigen-binding fragment thereof that binds to an epitope overlapping with the epitope of any of the antibodies or antigen-binding fragments thereof as described in any one of claims 1-51.
53. The antibody or antigen-binding fragment thereof of any one of claims 1-52, wherein the antibody has an IgG1, IgG2, IgG3 or IgG4 isotype.
54. The antibody or antigen-binding fragment thereof of any one of claims 1-52, wherein the antibody or antigen-binding fragment thereof comprises an Fc region selected from an IgG1 Fc region, an IgG2 Fc region, an IgG4 Fc region, or an IgG2 / IgG4 hybrid Fc region.
55. The antibody or antigen-binding fragment thereof of any one of claims 1-49 or 51-54, wherein the antibody or antigen-binding fragment thereof comprises a modified Fc region having reduced antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity compared to the parent antibody.
56. The antibody or antigen-binding fragment thereof of any one of claims 1-55, wherein the antibody or antigen-binding fragment thereof is a human or humanized antibody or fragment thereof.
57. The antibody or antigen-binding fragment thereof of any one of claims 1-56, wherein the antibody or antigen-binding fragment thereof is conjugated to another moiety.
58. The antibody of any one of claims 1-57, wherein the antibody is of the IgG1 isotype.
59. The antibody of any one of claims 1-56, wherein the antibody is a human or humanized antibody.
60. An antigen-binding fragment of the antibody of any one of claims 1-57, wherein the antigen-binding fragment is selected from Fab, F(ab')2, Fv fragment, scFv, minibody or diabody.
61. The antibody or antigen-binding fragment thereof of any one of claims 1-60, wherein the antibody or antigen-binding fragment thereof is monoclonal.
62. The antibody of any one of claims 1-61, wherein the antibody is a multispecific antibody, such as a bispecific antibody.
63. The antibody of claim 62, wherein the multispecific antibody, e.g., a bispecific antibody, specifically binds to hTREM2 and human DAP12 (DNAX activating protein of 12 kDa).
64. The antibody of any one of claims 1-63, wherein the antibody has altered effector function by mutation of the Fc region.
65. A nucleic acid molecule or a group of nucleic acid molecules encoding any one of the antibodies or antigen-binding fragments thereof according to any one of claims 1 to 64.
66. The nucleic acid molecule of claim 65, wherein the nucleic acid is DNA.
67. A nucleic acid molecule or a group of nucleic acid molecules as described in claim 65 or 66, which comprises one or more of SEQ ID NO: 14, 28, 51, 65, 16, 30, 34, 36, 38, 40, 53, 67, 71, 73, 75, 77, 25, 31, 62, 68, 27, 32, 64, 69, 13, 93, 15, 95, 80, 104, 82 or 106.
68. A vector comprising the nucleic acid molecule of any one of claims 65-67.
69. The vector of claim 68, wherein the vector is a cloning vector or an expression vector.
70. The vector of claim 68 or 69, wherein the vector comprises one or more of SEQ ID NO: 14, 28, 51, 65, 16, 30, 34, 36, 38, 40, 53, 67, 71, 73, 75, 77, 25, 31, 62, 68, 27, 32, 64, 69, 13, 93, 15, 95, 80, 104, 82, or 106, or a fragment thereof encoding at least one CDR region.
71. The vector of any one of claims 68-70, wherein the vector is capable of replicating in prokaryotic cells and / or eukaryotic cells.
72. The vector of any one of claims 68-71, wherein the vector is selected from a DNA vector, an RNA vector, a plasmid, a cosmid or a viral vector.
73. A vector as described in any one of claims 68-72, further comprising a detectable and / or selectable marker.
74. A set of two expression vectors according to any one of claims 68 to 73, one vector encoding a) at least one VH domain comprising SEQ ID NO: 13 or 50, and the other vector encoding at least one VL domain comprising SEQ ID NO: 24 or 61; or b) comprises at least one VH domain of SEQ ID NO: 13 or 93, and the other vector encodes at least one VL domain of SEQ ID NO: 80 or 104.
75. The vector of any one of claims 68-74, wherein the vector is a viral vector, optionally wherein the viral vector is a lentivirus, an adenovirus, an adeno-associated virus (AAV), herpes simplex virus (HSV), a parvovirus, a retrovirus, vaccinia virus, Sindbis virus, influenza virus, reovirus, Newcastle disease virus (NDV), measles virus, vesicular stomatitis virus (VSV), poliovirus, poxvirus, Seneca Valley virus, coxsackievirus, enterovirus, myxoma virus, or Maraba virus.
76. The vector of claim 75, wherein the vector is an AAV vector.
77. The vector of any one of claims 68-76, wherein the vector further comprises a promoter.
78. The vector of any one of claims 68-77, wherein the vector comprises an AAV9 capsid and an AAV vector plasmid comprising (1) ITRs derived from AAV2, (2) a CMV enhancer (e.g., comprising SEQ ID NO: 134), (3) a CBA promoter (e.g., comprising SEQ ID NO: 135), (4) an SV40 intron (e.g., comprising SEQ ID NO: 137), (5) a polynucleotide encoding an hTREM2 antibody or an antigen-binding fragment thereof (e.g., as described herein), and (6) a BGH poly A signal (e.g., comprising SEQ ID NO: 138).
79. A vector as described in claim 78, wherein elements (2) to (6) are arranged from 5' to 3' on the AAV vector plasmid.
80. The vector of claim 78 or 79, wherein any one of elements (2) to (6) is arranged between the 5'ITR and the 3'ITR on the AAV vector plasmid.
81. The vector of any one of claims 78-80, wherein the AAV vector is a scAAV vector.
82. The vector of any one of claims 68-75, wherein the vector is a lentiviral vector.
83. A cell comprising a nucleic acid molecule or a group of nucleic acid molecules as described in any one of claims 64-66 or a vector as described in any one of claims 68-82.
84. A method of producing an hTREM2 antibody or an antigen-binding fragment thereof, the method comprising: (i) culturing the cell of claim 83 and (ii) isolating the hTREM2 antibody or antigen-binding fragment thereof from the culture.
85. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof as described in any one of claims 1-64, a nucleic acid molecule or a group of nucleic acid molecules as described in any one of claims 65-67, a vector as described in any one of claims 68-82 or a cell as described in claim 83, and a pharmaceutically acceptable carrier.
86. The antibody or antigen-binding fragment thereof as described in any one of claims 1 to 64, the nucleic acid molecule or group of nucleic acid molecules as described in any one of claims 65 to 67, the vector as described in any one of claims 68 to 82, the cell as described in claim 83 or the pharmaceutical composition as described in claim 85 for use as a medicament.
87. The antibody or antigen-binding fragment thereof of any one of claims 1-64, the nucleic acid molecule or group of nucleic acid molecules of any one of claims 65-67, the vector of any one of claims 68-82, the cell of claim 83 or the pharmaceutical composition of claim 85, for treating a disease associated with loss of hTREM2 function.
88. Use of the antibody or antigen-binding fragment thereof as described in any one of claims 1-64, the nucleic acid molecule or group of nucleic acid molecules as described in any one of claims 65-67, the vector as described in any one of claims 68-82, the cell as described in claim 83, or the pharmaceutical composition as described in claim 85 for preparing a medicament for treating a disease associated with loss of hTREM2 function.
89. The antibody or antigen-binding fragment thereof, nucleic acid molecule or nucleic acid molecule group, vector, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the disease is a neuroinflammation or a neurodegenerative disease, optionally wherein the neuroinflammation or neurodegenerative disease is Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakora disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy ( CIPN), postherpetic neuralgia, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage disease, Niemann-Pick disease, mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, Neuro-Behcet disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen encephalitis, Rett syndrome, stroke, transverse myelitis, traumatic brain injury, spinal cord injury, viral encephalitis, or bacterial meningitis.
90. The antibody or antigen-binding fragment thereof, nucleic acid molecule or group of nucleic acid molecules, vector, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the disease is Alzheimer's disease.
91. The antibody or antigen-binding fragment thereof, nucleic acid molecule or group of nucleic acid molecules, vector, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the disease is Parkinson's disease.
92. The antibody or antigen-binding fragment thereof, nucleic acid molecule or set of nucleic acid molecules, vector, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the disease is multiple sclerosis.
93. The antibody or antigen-binding fragment thereof, nucleic acid molecule or group of nucleic acid molecules, vector, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the disease is frontotemporal dementia.
94. The antibody or Fab thereof, nucleic acid molecule or group of nucleic acid molecules, carrier, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the antibody or Fab thereof, nucleic acid molecule or group of nucleic acid molecules, carrier, cell or pharmaceutical composition is administered to a subject orally, intravenously, intracranially, intrathecally, subcutaneously or intranasally.
95. The antibody or Fab thereof, nucleic acid molecule or group of nucleic acid molecules, carrier, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the antibody or Fab thereof, nucleic acid molecule or group of nucleic acid molecules, carrier, cell or pharmaceutical composition is administered to a subject in combination with at least one other therapeutic agent or treatment procedure.
96. The antibody or antigen-binding fragment thereof, nucleic acid molecule or group of nucleic acid molecules, vector, cell or pharmaceutical composition of claim 87, or the use of claim 88, wherein the antibody or antigen-binding fragment thereof, the nucleic acid molecule or group of nucleic acid molecules, the vector, the cell or the pharmaceutical composition is administered to a subject in combination with at least one additional therapeutic agent, wherein the therapeutic agent comprises one or more of the following: a BACE inhibitor, an anti-Tau antibody, a Tau antisense oligonucleotide, an anti-amyloid β antibody, fingolimod, BG12 or dimethyl fumarate, interferon β or natalizumab.
97. A method for treating a disease associated with loss of hTREM2 function in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof as described in any of claims 1-64, a nucleic acid molecule or group of nucleic acid molecules as described in any of claims 65-67, a vector as described in any of claims 68-82, a cell as described in claim 83, or a pharmaceutical composition as described in claim 85.
98. The method of claim 97, wherein the method comprises: a) determining the level of cell surface hTREM2 in a sample obtained from a subject; b) selecting a subject whose cell surface hTREM2 level is lower than a reference level, wherein the reference level is the cell surface hTREM2 level in a sample obtained from a healthy subject; and c) administering to the selected subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 64, the nucleic acid molecule or group of nucleic acid molecules according to any one of claims 65 to 67, the vector according to any one of claims 68 to 82, the cell according to claim 83, or the pharmaceutical composition according to claim 85.
99. The method of claim 98, wherein the sample comprises cerebrospinal fluid.
100. The method of claim 98 or 99, wherein the cell surface TREM2 level in the sample is determined by an assay selected from the group consisting of flow cytometry, immunohistochemistry, western blot, immunofluorescence assay, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), homogeneous time-resolved fluorescence (HTRF), or positron emission tomography (PET).
101. The method of any one of claims 97-100, wherein the disease associated with loss of TREM2 function is a neuroinflammatory or neurodegenerative disease, optionally wherein the neuroinflammatory or neurodegenerative disease is Alzheimer's disease, frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, Nasu-Hakkara disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), anti-NMDA receptor encephalitis, autism, cerebral lupus (NP-SLE), chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuropathy (HEP), Dysmenorrhea, chronic inflammatory demyelinating polyneuropathy (CIDP), epilepsy, Guillain-Barré syndrome (GBS), inclusion body myositis, lysosomal storage disease, Niemann-Pick disease, mucopolysaccharidosis II / IIIB, metachromatic leukodystrophy, multifocal motor neuropathy, myasthenia gravis, Neuro-Behcet disease, neuromyelitis optica (NMO), optic neuritis, polymyositis, dermatomyositis, Rasmussen encephalitis, Rett syndrome, stroke, transverse myelitis, traumatic brain injury, spinal cord injury, viral encephalitis, or bacterial meningitis.
102. The method of any one of claims 97-101, wherein the disease is Alzheimer's disease.
103. The method of any one of claims 97-101, wherein the disease is Parkinson's disease.
104. The method of any one of claims 97-101, wherein the disease is multiple sclerosis.
105. The method of any one of claims 97-101, wherein the disease is frontotemporal dementia.
106. The method of any one of claims 97-105, wherein the antibody or antigen-binding fragment thereof, the nucleic acid molecule or group of nucleic acid molecules, the vector, the cell or the pharmaceutical composition is administered to the subject orally, intravenously, intracranial, intrathecally, subcutaneously or intranasally.
107. A method for stabilizing hTREM2 protein in a subject, the method comprising administering to the subject an antibody or antigen-binding fragment thereof as described in any one of claims 1-64, a nucleic acid molecule or group of nucleic acid molecules as described in any one of claims 65-67, a vector as described in any one of claims 68-82, a cell as described in claim 83, or a pharmaceutical composition as described in claim 85, in an amount effective to stabilize hTREM2.
108. The method of any one of claims 97-107, further comprising administering to the subject at least one additional therapeutic agent or performing at least one additional therapeutic procedure.
109. The method of claim 108, wherein the additional therapeutic agent comprises one or more of the following: a BACE inhibitor, an anti-Tau antibody, a Tau antisense oligonucleotide, an anti-amyloid beta antibody, fingolimod, BG12 or dimethyl fumarate, interferon beta, or natalizumab.
110. The method of claim 108 or 109, wherein the antibody or antigen-binding fragment thereof of any one of claims 1-64, the nucleic acid molecule or group of nucleic acid molecules of any one of claims 65-67, the vector of any one of claims 68-82, the cell of claim 83, or the pharmaceutical composition of claim 85 is administered simultaneously with, before, or after the additional therapeutic agent.
111. The method of any one of claims 97-110, wherein administration of the antibody or antigen-binding fragment thereof, the nucleic acid molecule or group of nucleic acid molecules, the vector, the cell, or the pharmaceutical composition has one or more of the following effects ad: a) increase TREM2-dependent cellular activities such as phagocytosis and chemotaxis, b) triggering TREM2-dependent gene transcription, c) increase TREM2-dependent intracellular signaling pathways via Syk-phosphorylation, d) Increased clearance of cellular debris.
